WO2007013673A1 - Fused heterocycles as lck inhibitors - Google Patents

Fused heterocycles as lck inhibitors Download PDF

Info

Publication number
WO2007013673A1
WO2007013673A1 PCT/JP2006/315346 JP2006315346W WO2007013673A1 WO 2007013673 A1 WO2007013673 A1 WO 2007013673A1 JP 2006315346 W JP2006315346 W JP 2006315346W WO 2007013673 A1 WO2007013673 A1 WO 2007013673A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridazin
imidazo
pyridinyl
amino
trans
Prior art date
Application number
PCT/JP2006/315346
Other languages
French (fr)
Inventor
Kazuo Nakai
Fumie Takahashi
Kazuya Fujita
Yoshihiro Kozuki
Koichiro Mukoyoshi
Masamichi Inami
Norio Asai
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Priority to US11/993,229 priority Critical patent/US20100216798A1/en
Priority to EP06768412A priority patent/EP1910369A1/en
Priority to JP2008503311A priority patent/JP2009502734A/en
Publication of WO2007013673A1 publication Critical patent/WO2007013673A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Definitions

  • the present invention relates to a novel imidazopyridazine or pyrazolopyrimidine derivative and a pharmaceutically acceptable salt thereof, which is useful as a medicament particularly as an Lck inhibitor, and a pharmaceutical composition comprising the compound as an active ingredient.
  • TCR T-cell receptor
  • Lymphocyte protein tyrosine kinase is one of members of Src kinase family, which is non-receptor type protein tyrosine kinase. Lck is located in initial step of the TCR signal transduction pathway, it phosphorylates and activates ZAP-70, elevates intracellular Ca 2+ concentration, and ultimately induces production of interleukin-2 and proliferation of T-cell. Additionally it is well known that Lck is essential for transduction of the TCR signal, which was showed by analysis of Lck knock-out mouse. Therefore Lck inhibitor is anticipated to have a strong immunosuppressive activity as well as calcineulin inhibitors.
  • Lck inhibitor since Lck is expressed only on T-cell, the effect of Lck inhibitor is limited to lymphocytic organ. Therefore there is low concern on side-effect like as renal toxicity by calcineulin inhibition, and it is hoped that Lck inhibitor may become immunosuppressive agent with less side-effect.
  • Lck inhibitors are useful for medicine for disorder that participates in T-cell, for example, autoimmune disease like as psoriasis, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, nephrotic syndrome and the like, suppression of immunological rejection of graft-versus-host disease, organ transplant or the like.
  • pyrazolo [3, 4-d] pyrimidine derivatives are disclosed in International Publication WO 02/76986 and WO 02/80926, imidazo[l, 5-a]pyrazine derivative in Japanese laid-open patent publication No.
  • pyrazolo [1, 5-a] pyrimidine derivatives represented by the formula (A) as Src inhibitor and Lck inhibitor are disclosed in Japanese laid-open patent publication No. 2005-8581.
  • imidazo [1, 2-b] p'yridazine and pyrazolo [1, 5-a] pyrimidine derivatives represented by the formula (B) as human protooncogene proviral insertion site in moloney murine leukemia virus kinase are disclosed in "J. Med. Chem. 48, pp7604-7614, 2005".
  • the present inventors made extensive and intensive investigations with respect to compounds having Lck inhibitory activity/ which are expected to be a safe immunosuppressive agent. As a result, it has been found that a novel imidazopyridazine or pyrazolopyrimidine derivative or a salt thereof of the present invention has an excellent Lck inhibitory activity, leading to accomplishment of the invention. '
  • the present invention provides a fused heterocyclic compound of the following general formula (I) or a pharmaceutically acceptable salt thereof that is useful as an immunosuppressive agent.
  • Y or Z is C atom, and the other is N atom.
  • -R 1 is hydrogen or lower alkyl;
  • -R 11 and -R 12 are the same or different, each being hydrogen or lower alkyl;
  • -R 2 is hydrogen, cycloalkyl, aryl, 5- or 6-me ⁇ nbered non-aromatic heterocycle or 5- or ⁇ -membered aromatic heterocycle, each of which may be substituted, or alternatively -R 1 and "-A-R 2 " taken with the adjacent nitrogen atom may form 5-, 6- or 7- membered cyclic amino, which may be substituted;
  • -E- represents bond, lower alkylene, lower alkenylene or lower alkynylene, wherein a methylene unit of -E- is optionally replaced by -0-, -(CO)O-, -NH-, -NHCO-,
  • -R 3 is cycloalkyl, aryl, 5- or 6-membered non-aromatic heterocycle or 5- or 6-membered aromatic heterocycle, each of which may be substituted and may be fused with benzene; and -R 4 , -R 5 and -R 6 are the same or different, each being hydrogen, halogen, lower alkyl, -0-lower alkyl or aryl.
  • Y is C atom and Z is N atom; (ii) when X is NH, -R 2 is cyclopropyl, 2-pyridyl, 3-pyridyl, 2-thienyl or 4-fluorophenyl and -R 3 is 3-acetylphenyl, 3-chlorophenyl, 4-chlorophenyl, phenyl, 2-furyl or 2-thienyl, then A is bond. or a pharmaceutically acceptable salt thereof.
  • -R 11 and -R 12 are the same or different, each being hydrogen or lower alkyl;
  • -R 2 is hydrogen, C 5 - 10 cycloalkyl, aryl, 5- or 6-membered non-aromatic heterocycle which contains one to three heteroatom ( s) or 5- or 6-membered aromatic heterocycle which contains one heteroatom; each of which may be substituted with one to three substituent (s) selected from the group consisting of hydrogen, halogen, hydroxy, nitro, lower alkyl, -0-lower alkyl, -0- ( ⁇ -membered cyclic amino), -CONH-lower alkyl, -C (0) NH-aryl, -S(0) 2 -aryl, -C (O)O-lower alkyl, -C(O)OH, -C (0) NH-0-lower alkyl, -NR 11 R 12 , 6-membered non-aromatic heterocycle, and
  • -0- 6-membered aromatic heterocycle
  • -R 1 and "-A-R 2 " taken with the adjacent nitrogen atom may form 5-, 6- or 7- membered cyclic amino, which may be substituted
  • -E- is bond, lower alkylene, lower alkenylene or lower alkynylene, wherein a methylene unit of -E- is optionally replaced by -NHSO 2 - or -NH(CO)NH-;
  • -R 3 is 5- or 6-membered non-aromatic heterocycle or 5- or
  • 6-membered aromatic heterocycle which contains one to two nitrogen atom, which may be fused-with benzene; each of which may be substituted with one to three substituent (s) selected from the group consisting of halogen, lower alkyl, lower alkyl having halogen, lower alkyl having hydroxyl, -OH, cyano, -0-lower alkyl, phenyl, -0-phenyl, -S-phenyl, -O-cycloalkyl, -C(0)0-lower alkyl, -C(O)NH 2 , -NHCO-aryl, -NHC(0)0-lower alkyl and -NR 11 R 12 ; and
  • -R 4 , -R 5 and -R 6 are the same or different, each being hydrogen, halogen, lower alkyl, -0- lower alkyl or aryl .
  • Another one of the more preferred embodiments of the present invention can be represented by the formula (I) , wherein -X- in the compound represented by the formula (I) is preferably -NH- or -O- ; -A- in the compound represented by the formula (I) is preferably bond or lower alkylene; -R 2 in the compound represented by the formula (I) is preferably hydrogen, cyclohexyl, phenyl, adamantyl, pyridinyl, piperidinyl or tetrahydropyranyl; each of which may be substituted with one or two substituent (s) selected from the group consisting of hydroxy, halogen, methyl and lower alkyloxy optionally substituted with halogen; -E- in the compound represented by the formula (I) is preferably bond; -R 3 in the compound represented by the formula (I) is preferably pyridinyl which may be substituted with halogen; -R 4 in the compound represented by the formula (I) is
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising one or more compounds represented by the formula (I) as an active ingredient, which is useful as an Lck inhibitor, especially as a medicament for disorder that participates in T-cell, for example, autoimmune disease like as psoriasis, atopic dermatitis,' rheumatoid arthritis, systemic lupus erythematosus, nephrotic syndrome and the like, suppression of immunological rejection of graft-versus-host. disease, organ transplant or the like.
  • lower alkyl means a monovalent group of a straight or branched carbon chain such as methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, tert-butyl and the like.
  • the "lower alkylene” means a divalent group of alkane such as methylene, ethylene, trimethylene, tetramethylene, dimethylmethylene, dimethylethylene and the like.
  • the "lower alkenylene” means a divalent group of alkene such as ethen-1, 1-diyl, vinylene, propendiyl, butendiyl and the like.
  • the "lower alkynylene” means a divalent group of alkyne such as ethyndiyl, propyndiyl, butyndiyl and the like.
  • cycloalkyl means a non-aromatic carbon ring having 3 to 10 carbon atoms, which may have partial unsaturation and may be fused or bridged. Its examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohepyl, cyclooctyl, cyclohexenyl, cyclooctadienyl, bornyl, norbornyl, adamantyl, 1, 2, 3, 4-tetrahydronaphthyl and the like, of which preferred ones are ones having 5 to 10 carbon atoms.
  • the "aryl” means a mono- to tri-cyclic aromatic carbon ring having 6 to 14 carbon atoms, of which ones 6 to 10 carbon atoms, e.g. phenyl and naphthyl are preferred, and phenyl is more preferred.
  • the "5- or ⁇ -membered non-aromatic heterocycle” means a monovalent group of a non-aromatic heterocycle having one or more hetero atoms selected from the group consisting of a nitrogen, an oxygen and a sulfur atom, which may be fused or bridged.
  • azetidinyl pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dihydropyridinyl, piperidinyl, azepinyl, piperazinyl, homopiperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, thiopyranyl, indolinyl, isoindolinyl, 8-azabicyo [3.2.1] octanyl, quinuclidinyl and the like.
  • the NV 5- or 6-membered aromatic heterocycle means a monovalent group of an aromatic heterocycle having one or more hetero atoms selected from the group consisting of a nitrogen, an oxygen and a sulfur atom, which may be fused. Its examples include pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, thiadiazolyl, oxadiazolyl, triasolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyridinonyl, indolyl, benzothiazolyl, quinolyl, isoquinolyl, lH-isoindolyl- ' 1, 3 (2H) -dione, 2-methyl-l, 2 , 3, 4-tetrahydroisoquinolyl and the like.
  • halogen means chloro, bromo, iodo and fluoro.
  • substituent groups that can be used for the term “optionally substituted” or “which may be substituted” those commonly used as substituent groups for each group can be used, and each group may have one or more substituent groups.
  • substituent groups that can be used for "cycloalkyl, aryl, 5- or ⁇ -membered non-aromatic heterocycle or 5- or 6-membered aromatic heterocycle, each of which may be substituted" in the definition of -R 2 and -R 3 , which may be one or more, preferably one to three and may be the same or different, the following groups (a) to (h) can be exemplified.
  • the compound of the present invention represented by the general formula (I) may comprise asymmetric carbon atoms depending on the kinds of substituent groups, and optical isomers based on the asymmetric carbon atom may exist.
  • the compound of the present invention includes a mixture of these optical isomers or isolated ones.
  • tautomers may exist in the compound of the present invention, and the compound of the present invention includes these isomers as a mixture or an isolated one.
  • labeled compound i.e., compounds wherein one or more atoms are labeled with radioisotopes or non-radioisotopes, are also included in the present invention.
  • the compound of the present invention may form a salt, which is included in the present invention as long as pharmaceutically acceptable.
  • the salt include addition salts with a mineral acid such as hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesufonic acid, a'spartic acid, glutamic acid, and the like; or an organic base such as methylamine, ethylamine, ethanolamine, lysine, ornithine, and the like; and ammonium salts, and the like.
  • the compound of the invention also includes a compound which is metabolized in a living body to be converted into the compound of the general formula (I) or its salt, >> a so ⁇ called prodrug.
  • prodrug those described in Prog, Med., 5, pp.2157-2161, 1985; and Hirokawa-Shoten, 1990, "Development of medicine” VoI . 7, Molecular Design, pp. 163-198 can be exemplified.
  • the compounds and its pharmaceutically acceptable salt of the present invention can be prepared by various known synthesis methods, using characteristics based on its basic backbone or the kinds of substituent groups.
  • a suitable protection group i.e., a group that can be easily converted into the functional group, in the starting material or intermediate step. Then, if necessary, the protection group is removed to obtain a desired compound.
  • the functional group include hydroxyl, carboxyl, amino group and the like
  • examples of the protection group include those described in "Protective Groups in Organic Synthesis", third edition, edited by Greene and Wuts. It is preferable to suitably use them depending on reaction conditions .
  • Lv 1 represents a leaving group
  • X 1 represents -N(R 1 )-, -0- or -S-
  • n represents 1 or 2
  • Hal represents halogen
  • -R 1 , -R 2 , -R 3 , -R 4 , -R 5 , -R 6 , -A-, -E-, 1 -X-, Y and Z are as defined in the foregoing.
  • the compound (I) is prepared by- substitution reaction of Ia with Ib (step 1-1), followed by, if necessary, oxidation step of sulfanyl group into sulfinyl group or sulfonyl group (step 1-2) , followed by halogenation of Ic or Id (step 1-3) , and followed by coupling reaction etc. of the thus-prepared compound Ie (step 1-4) .
  • a leaving group include halogen, alkanesulfonyl optionally substituted by one or more halogen, arylsulfonyl and the like.
  • the compound (I) can be prepared by coupling reaction etc. of Ie.
  • the compound Ie can be reacted with a compound "R 3 -E-H (If)" in a non-protonic polar solvent such as N, N-dimethylformamide (DMF), N-methyl-2-pyrrolidone, dimethylsulfoxide (DMSO) and the like; an inert organic solvent such as halogenated hydrocarbon including dichloromethane, dichloroethane, chloroform and the like; ether including ether, tetrahydrofuran (THF) , dioxane and the like; aromatic hydrocarbon including benzene, toluene, xylene and the like; or water, or a mixture thereof to prepare a compound (I) .
  • the reaction is preferably carried out at ambient temperature to reflux temperature of the used solvent.
  • the compound (I) can be prepared by nitration of Ic or Id followed by reduction of nitro group into amino group, followed by acylation with "R 3 -CO 2 H (Ig) . " A commonly used manner for one skilled in the art can be applied to reduction and acylation.
  • the reactive derivative such as ester, acid halide, acid anhydride and the like of Ig can also be used.
  • a condensing agent such as dicyclohexylcarbodiimide, carbonyldiimidazole, 1-ethyl- 3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI. HCl) and the like.
  • the reaction is, although it varies depending on the reactive derivatives or condensing agent, carried out in an inert solvent such as a halogenated hydrocarbon, aromatic hydrocarbon, ether, DMF, DMSO and the like, under cooling, cooling to ambient temperature, or ambient temperature to heating.
  • an inert solvent such as a halogenated hydrocarbon, aromatic hydrocarbon, ether, DMF, DMSO and the like
  • Ig is reacted in its acid halide form, to progress the reaction smoothly, it is advantageous in some cases to carry out the reaction in the presence of a base.
  • the compound Ie can be prepared by halogenation of Ic or Id.
  • a halogenation agent those commonly used for a halogen substitution reaction of hydrogen on an aromatic ring can be used.
  • a halogen molecule such as chlorine, bromine, iodine and the like, dioxanedihalide, phenyltrimethylammonium trihalide, a pyridine derivative such as pyridinium hydrohalide perhalide, pyrrolidonehydrotrihalide and the like, a perhalide such as a-pyrrolidone, quaternary ammonium, dioxane and the like are appropriate.
  • An imide-type halogenation agent such as N-iodosuccinimide, N-bromosuccinimide and the like, a hydrogen halide such as hydriodic acid, hydrobromic acid and the like, a metal agent such as copper (II) halide including copper (II) iodide and the like can also be used.
  • the compound Ic or Id can be reacted in an inert organic solvent such as halogenated hydrocarbon; ether/ alcohol oncluding methanol (MeOH), ethanol (EtOH), 2-propanol (iPrOH) , ethyleneglycol and the like; aromatic hydrocarbon; acetic acid; ester including ethyl acetate (AcOEt) and the like.
  • an inert organic solvent such as halogenated hydrocarbon; ether/ alcohol oncluding methanol (MeOH), ethanol (EtOH), 2-propanol (iPrOH) , ethyleneglycol and the like; aromatic hydrocarbon; acetic acid; ester including ethyl acetate (AcOEt) and the like.
  • a catalyst such as hydrogen halide. It is preferable to carry out the reaction at -30 0 C to reflux temperature of the used solvent.
  • the compound Ie can be reacted therewith in an acid solution or a base solution such as sodium hydroxide aqueous solution, and the reaction is preferably carried out at -30 0 C to reflux temperature of the used solvent.
  • a metal agent is used as a halogenation agent
  • the compound Ie is generally dissolved in an inert organic solvent such as halogenated hydrocarbon, ether, alcohol, aromatic hydrocarbon, acetic acid, ester and the like, or water, or a mixture thereof to react with the agent, and if necessary, it is advantageous to carry out the reaction in the presence of a small amount of a catalyst such as hydrogen halide, under ambient temperature to heating.
  • oxidation method of sulfur atom of sulfanyl group which is well-known by one skilled in the art is applicable, for example, m-chloroperbenzoic acid, hydrogen peroxide or caboxylic peracid like as acetic peracid or trifluoroacetic peracid can be used for the oxidation.
  • step 1-1 which includes a substituation reaction of Ia with Ib (step 1-1), can be carried out in accordance with the step 1-4.
  • the compound (I) and a salt thereof can be prepared, for example, according to the procedures as illustrated in Examples in the present specification or in a manner similar thereto.
  • the starting compounds can be prepared, for example, according to the procedures- as illustrated in Preparations in the present specification or in a manner similar thereto.
  • the compound (I) and a salt thereof can be prepared according to the methods as shown in Preparations or Examples, or in a manner similar thereto.
  • the thus-obtained compounds can be subjected to a process commonly used in the art such as alkylation, acylation, substitution, oxidation, reduction, hydrolysis, and the like to prepare some of the compounds of the general formula (I) .
  • the thus-prepared compound of the present invention is isolated and purified as its free form or as a salt thereof.
  • a salt of the compound (I) can be prepared by subjecting it to a usual salt formation reaction.
  • the isolation and purification are carried out by usual chemical manipulations such as extraction, concentration, e ⁇ aporation, crystallization, filtration, recrystallization, various types of chromatography and the like.
  • a racemic mixture can be separated by a general racemic mixture resolution method, e.g., a method in which racemic mixture is converted into diastereomer salts with an optically active acid such as tartaric acid and the like and then subjected to optical resolution.
  • diastereomers can be separated by fraction crystallization or various types of chromatography or the like.
  • optically active compounds can be prepared using appropriate optically active starting materials .
  • the Src substrate peptide (Upstate) was coated onto 96-well Maxisorp plates (Nunc) . Plates were sealed and incubated at 4 0 C ' for 16 hours, washed three times with TBST
  • TBST Purified Lck (Upstate) was incubated in 10OmM Tris-HCl pH 7.5, 125 mM MgCl 2 , 25 mM MnCl 2 , 2 mM EGTA, 0.25 mM Sodium Vanadate, 2 mM DTT, 0.05 mM ATP with or without inhibitors at 30 0 C for 60 minuites and washed with TBST three times.
  • HRP conjugate (4GlO, Upstate) for 1 hour at ambient temperature and washed three times with TBST. Detection was carried out using a color reagent, TMB (KPL) . Ten minute after TMB addition the OD at 450 nm was measured.
  • IC 50 values were obtained: 81 nM for Example 127, 97 nM for Example 153, 460 nM for Example 16, 380 nM for Example 44, 350 nM for Example 47, 310 nM for Example 102, 410 nM for Example 106, and 320 nM for Example 249.
  • a pharmaceutical composition comprising the compound of the present invention represented by the formula (I) is useful as a therapeutic or prophylactic agent for diseases or conditions caused by undesirable cytokine signal transduction, such as rejection reaction in organ transplantation, autoimmune diseases, asthma, atopic dermatitis, cancer and leukemia as exemplified below: Rejection reactions by transplantation of organs or tissues such as the heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, islet, small intestine, limb, muscle, nerve, intervertebral disc, trachea, myoblast, cartilage, etc.; and graft-versus-host reactions following bone marrow transplantation; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple s
  • composition comprising Lck inhibitor such as the compound of the present invention represented by the formula (I) is useful for the therapy or prophylaxis of the following diseases:
  • Inflammatory or hyperproliferative skin diseases or cutaneous manifestations of immunologically-mediated diseases e.g., psoriasis, atopic dermatitis, contact dermatitis, eczematoid dermatitis, seborrheic dermatitis, lichen planus, pemphigus, bullous penphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, erythema, dermal eosinophilia, lupus erythematosus, acne, alopecia areata, etc.); autoimmune diseases of the eye (e.g., keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical keratitis, corneal epithelial dystrophy, keratoleukoma, ocular
  • autoimmune diseases and inflammatory conditions e.g., primary mucosal edema, autoimmune atrophic gastritis, premature menopause, male sterility, juvenile diabetes mellitus, pemphigus vulgaris, pemphigoid, sympathetic ophthalmitis, lens-induced uveitis, idiopathic leukopenia, active chronic hepatitis, idiopathic cirrhosis, discoid lupus erythematosus, autoimmune orchitis, arthritis (e.g., arthritis deformans, etc.), polychondritis, etc.); allergic conjunctivitis .
  • autoimmune diseases and inflammatory conditions e.g., primary mucosal edema, autoimmune atrophic gastritis, premature menopause, male sterility, juvenile diabetes mellitus, pemphigus vulgaris, pemphigoid, sympathetic ophthalmitis, lens-induced uveitis, i
  • the pharmaceutical composition of the present invention is useful for the therapy and prophylaxis of liver diseases [e.g., immunogenic diseases (e.g., chronic autoimmune liver diseases such as autoimmune hepatic diseases, primary biliary cirrhosis, sclerosing cholangitis, etc.), partial liver resection, acute liver necrosis (e.g., necrosis caused by toxins, viral hepatitis, shock, anoxia, etc.), hepatitis B, non-A non-B hepatitis, hepatocirrhosis, hepatic failure (e.g., fulminant hepatitis, late-onset hepatitis, "acute-on-chronic" liver failure (acute liver failure on chronic liver diseases, etc.), etc.), etc.].
  • the pharmaceutical composition of the present invention can be used in- the form of pharmaceutical preparation, for example, in a solid, semisolid or liquid form, which contains the compound of the present invention represented by the formula
  • the active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, injections, ointments, linimnts, eyedrops, lotion, ' gel, cream, and any other form suitable for use.
  • the carriers those can be used for the present invention include water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, cornstarch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations in a solid, semisolid, or liquid -form. Furthermore,- auxiliary, stabilizing, thickening, solubilizing and coloring agents and perfumes may be used. For applying the composition to human, it is preferable to apply it by intravenous, intramuscular, topical or oral administration, or by a vascular stent impregnated with the compound (I) .
  • a daily dose is approximately 0.0001-50 mg/kg of body weight, preferably approximately 0.001-10 mg/kg, and more preferably approximately 0.01-1 mg/kg, and the daily dose is administered once a day or by dividing it into 2 to 4 doses per day.
  • a daily dose is approximately 0.0001-1 mg/kg of body weight, preferably approximately 0.0001-0.1 mg/kg, and the daily dose is administered once a day or by dividing it into plural doses per day. The dose is appropriately decided by taking symptoms, age, and sex of the patient to be treated and the like into consideration.
  • the compound (I) or a salt thereof can also be combined together with other immunosuppressive substances, for example rapamycin, mycophenolic acid, cyclosporin A, tacrolimus or brequinar sodium.
  • immunosuppressive substances for example rapamycin, mycophenolic acid, cyclosporin A, tacrolimus or brequinar sodium.
  • compositions of the present invention either from alone or in combination with one of more additional agents which may include but are not limited to cyclosporin A, tacrolimus, sirolimus, everolimus, micophenolate (e.g. Cellcept (R) , etc.), aza'thioprine, brequinar, lefulunomide, fingolimod, anti-IL-2 receptor antibody (e.g. daclizumab, etc.), anti-CD3 antibody (e.g. OKT3, etc.), Anti-T cell immunogloblin (e.g. AtGam, etc.) aspirin, acetaminophen, ibuprofen, naproxen, piroxicam, and anti inflammatory steroid (e.g. prednisolone or dexamethasone) may be administrated as part of the same or separate dosage forms, via the same or different routes of administration, and on the same or different administration schedules according to standard pharmaceutical pracitce .
  • additional agents which may include but are not
  • Preparation 1 The solution of 5-chloropyrazolo [ 1, 5-a] pyrimidine (200 mg) and trans-4-methoxycyclohexanamine (168 mg) in isopropylalcohol
  • the reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (20mL/20mL) .
  • the resulting mixture was acidified with IM HCl aqueous solution to pH 2 and extracted with ethyl acetate.
  • the aqueous phase was then neutralized by the addition of 2M NaOH aqueous solution to pH 8.
  • the resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo.
  • the residue was purified by silica gel column chromatography eluting with chl ⁇ roform/methanol (20 : 1) to give the following compounds .
  • N-iodosuccinimide (161 mg) in N, N-dimethylformamide (ImI) was stirred at ambient temperature for 4 hours.
  • the reaction mixture was poured into a mixture of 10% sodium thiosulfate aqueous solution and chloroform. Then the organic layer was washed with saturated NaHCU 3 aqueous solution, water, brine, dried over magnesium sulfate, and evaporated in vacuo. Resulting precipitates were collected by filtration and washed with diisopropyl ether to give 5-chloro-3-iodopyrazolo [ 1, 5-a] pyrimidine as an brown solid (180 mg) .
  • reaction mixture was poured into saturated NaHCU 3 aqueous solution (10 mL) .
  • the resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo.
  • the residue was purified by silica gel column chromatography eluting with chloroform/methanol (40:1 to 20:1) to give ⁇ -chloro-2, 3-diphenylimidazo [1, 2-b] pyridazine (286.7 mg) .
  • reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (1OmL/1OmL) .
  • the resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo.
  • the residue was purified by silica gel column chromatography eluting with chloroform/methanol (40:1 to 20:1) to give methyl 6- [ (trans-4-hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazine-3-carboxylate ( 175.1 mg) .
  • the mixture was diluted with ice-cooled water, basified with ammonium hydroxide, and extracted with n-butylalcohol .
  • the organic layer was washed with brine, dried over sodium sulfate, filtered, and evaporated in vacuo.
  • the reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (20mL/20mL) .
  • the resulting mixture was acidified with 1 M HCl aqueous solution to pH 2 and extracted with ethyl acetate.
  • the aqueous phase was then neutralized by the addition of 2 M NaOH aqueous solution to pH 8.
  • the resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo.
  • Example 140 The following compounds were obtained in a similar manner to that of Example 140.
  • Example 4 4-Chloro-3- ⁇ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino ⁇ phenol .
  • Example 8 ( ⁇ ) -N- [3- (4-Pyridinyl) imidazo [1 , 2-b] pyridazin-6-yl] -1 , 2- cyclohexanediamine . MS:309(M+H) + .
  • Example 9 N- (2-Fluorobenzyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin- 6-amine.
  • the mixture was stirred at 110 0 C for 1.5 hours under nitrogen atmosphere.
  • the resultant was poured into a mixt re of water and dichloromethane, and acidified with 1 MHCl aqueous solution (pH 3) .
  • the aqueous phase was separated, adjusted to pH 8.5 by IM NaOH aqueous solution, and extracted with dichloromethane.
  • the organic phase was separated, washed with brine, and dried over sodium sulfate.
  • Example 19 3- ⁇ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino ⁇ -l- adamantanol .
  • Example 35 3- (4-Pyridinyl) -N- (3,4, 5-trimethoxyphenyl) imidazo [1, 2-b] pyridazin-6-amine .
  • Example 38 trans-4- ⁇ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino ⁇ cyclohexanol .
  • Example 46 4-Pyridinyl) -N- (2-pyridinylmethyl) imidazo [1, 2-b] pyridazin-6-amine .
  • Example 58 2-(3- ⁇ [3- (4-Pyridinyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino ⁇ benzyl) -lH-isoindole-1, 3 (2H) -dione.
  • Example 76 3- (4-Pyridinyl) -N- (1, 2, 3, 4-tetrahydro-l-naphthalenyl) imidazo [1, 2-b] pyridazin- ⁇ -amine .
  • Example 87 trans-4- ( ⁇ 3- [3- (Trifluoromethoxy) phenyl] imidazo [1, 2-b] pyridazin-6-yl ⁇ amino) cyclohexanol . '
  • Example 94 tra " ns-4- ⁇ [3- ( 3-Pyridinyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino ⁇ cyclohexanol .
  • Example 98 A mixture of 6-chloro-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine (20 mg) and morpholine (1.0 mL) was stirred at 110
  • reaction was stirred at 110 0 C for 3 hours. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (1OmL: 1OmL). The resulting mixture was acidified with 1 M HCl aqueous solution to pH 2 and extracted with ethyl acetate. The aqueous phase was then adjusted to pH 8 with 2M NaOH aqueous solution. The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol
  • Example 120 tert-butyl (3R) -3- ⁇ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin- 6-yl] amino ⁇ -1-pyrrolidinecarboxylate .
  • Example 136 trans-4- [ (3-Iodoimidazo [1, 2-b] pyridazin-6-yl) amino] cyclohexanol (100 mg) , dichlorobis (triphenylphosphine) palladium(II) (PdCl 2 (PPh 3 ) 2 ,9.80 mg) and CuI (5.32 mg) were dissolved in N, N-dimethylformamide (2.5 mL) and triethylamine
  • Example 146 trans-4- ⁇ [3- ( 1, 3-Benzodioxol-5 ⁇ yl) imidazo [ 1, 2-b] pyridazin- 6-yl] amino ⁇ cyclohexanol .
  • Example 148 trans-4- ⁇ [3- ( 6-Methoxy-3-pyridinyl) imidazo [1, 2-b] pyridazin- 6-yl] amino ⁇ cyclohexanol.
  • Example 150 trans-4- ⁇ [3- (4-Chloro-3-fluorophenyl) imidazo [1, 2-b] pyridazin-6-yl] amino ⁇ cyclohexanol . MS:3 ⁇ l (M+H) + .
  • Example 160 trans-4- ( ⁇ 3- [4- (Benzyloxy) -3-chlorophenyl] imidazo [1, 2-b] pyridazin-6-yl ⁇ amino) cyclohexanol .
  • Example 162 4- ⁇ 6- [ (trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl ⁇ -2, ⁇ -dimethylphenol .
  • Example 166 The following compounds were obtained in a similar manner to that of Example 166.
  • Example 167 trans-4- ⁇ [3-(4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino ⁇ cyclohexyl ethylcarbamate . MS:381 (M+H) + .
  • Example 168 trans-4- ⁇ [3-(4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino ⁇ cyclohexyl ethylcarbamate . MS:381 (M+H) + .
  • Example 168 trans-4- ⁇ [3-(4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino ⁇ cyclohexyl ethylcarbamate . MS:381 (M+H) + .
  • Example 168 trans-4- ⁇ [3-(4-Pyridinyl) imidazo [1, 2-b] pyri
  • Example 172 trans-4- ( ⁇ 3- [4- (Dimethylamino) phenyl] imidazo [1, 2-b] pyridazin-6-yl ⁇ amino) cyclohexanol .
  • Example 173 trans-4- ⁇ [3- (4-Biphenylyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino ⁇ cyclohexanol . MS:385(M+H) + .
  • Example 174 trans-4- ⁇ [3- (3-Fluorophenyl) imidazo [1, 2-b] pyridazin-6-yl ] amino ⁇ cyclohexanol .
  • Example 180 5- ⁇ 6- [ ( trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl ⁇ -2-pyridinecarbonitrile .
  • Example 181 trans-4- ⁇ [3- (3-Quinolinyl) imidazo [1, 2-b] pyridazin-6-yl] amino ⁇ cyclohexanol .
  • Example 189 trans-4- ⁇ [3- (2, 3-Dihydro-l-benzofuran-5-yl) imidazo [1, 2-b] pyridazin-6-yl] amino ⁇ cyclohexanol .
  • Example 190 trans-4- ⁇ [3-(3, 5-Dimethoxyphenyl) imida ⁇ o [ 1, 2-b] pyridazin- ⁇ - yl ] amino ⁇ cyclohexanol .
  • Example 196 trans-4- ⁇ [3- (4-Bromophenyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino ⁇ cyclohexanol .
  • Example 197 trans-4- ( ⁇ 3— [ 4 — (Benzyloxy) -3-fluorophenyl] imidazo [1, 2-b] pyridazin-6-yl ⁇ amino) cyclohexanol . MS:360 (M+H) + .
  • Example 198 trans-4- ( ⁇ 3— [ 4 — (Benzyloxy) -3-fluorophenyl] imidazo [1, 2-b] pyridazin-6-yl ⁇ amino) cyclohexanol . MS:360 (M+H) + .
  • Example 198 trans-4- ( ⁇ 3— [ 4 — (Benzyloxy) -3-fluorophenyl] imidazo [1, 2-b] pyridazin-6-yl ⁇ amino) cyclohexanol .
  • N-4-piperidinyl-3- ( 4-pyridinyl) imidazo- [1, 2-b] pyridazin-6-amine trihydrochloride 70 mg
  • methanol 560 ⁇ L
  • acetic anhydride 25 ⁇ L
  • the resultant was quenched by saturated NaHCO 3 aqueous solution, and extracted with dichloromethane .
  • the organic layer was washed with brine, dried over sodium sulfate, filtered, and evaporated in vacuo.
  • the reaction mixture was poured into water and extracted with 10% methanol in dichloromethane .
  • the organic layer was washed with brine, dried over sodium sulfate, and evaporated in vacuo.
  • the residue was purified by column chromatography on silica gel elution with chloroform/methanol (100: 0 to 100:10). The fraction was concentrated, and dissolved into HCO 2 NH 2 (514 ⁇ l) and sodium methoxide ( 117 mg) was added. After stirring at 100 0 C for 2.5 hours, the reaction mixture was poured into water /dichloromethane.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

There is provided fused heterocycles of imidazopyridazine or pyrazolopyrimidine derivative represented by the formula (I), which have excellent Lck inhibitory activity and are useful for a medicament particularly an immunosuppressive agent. [wherein one of Y and Z is C atom, and the other is N atom; -X-10 is -N (R1) - or the like, -R1 is hydrogen or the like, -A- is bond or the like, is cycloalkyl, aryl or the like, -E- is bond or the like, -R3 is aryl, aromatic heterocycle or the like, -R4, -R5 and -R6 are the same or different, each being hydrogen or the like.]

Description

DESCRIPTION FUSED HETEROCYCLES AS LCK INHIBITORS
TECHNICAL FIELD The present invention relates to a novel imidazopyridazine or pyrazolopyrimidine derivative and a pharmaceutically acceptable salt thereof, which is useful as a medicament particularly as an Lck inhibitor, and a pharmaceutical composition comprising the compound as an active ingredient.
BACKGROUND ART
The compound that inhibits a signaling cascade of T-cell receptor (TCR) targeting to calcineulin is used widely in the transplantation area at this moment. Although these compounds show a strong immunosuppressive activity by inhibiting the TCR signal, these might have the problem of the side effect of renal toxicity and the like.
Lymphocyte protein tyrosine kinase (Lck) is one of members of Src kinase family, which is non-receptor type protein tyrosine kinase. Lck is located in initial step of the TCR signal transduction pathway, it phosphorylates and activates ZAP-70, elevates intracellular Ca2+ concentration, and ultimately induces production of interleukin-2 and proliferation of T-cell. Additionally it is well known that Lck is essential for transduction of the TCR signal, which was showed by analysis of Lck knock-out mouse. Therefore Lck inhibitor is anticipated to have a strong immunosuppressive activity as well as calcineulin inhibitors. Furthermore, since Lck is expressed only on T-cell, the effect of Lck inhibitor is limited to lymphocytic organ. Therefore there is low concern on side-effect like as renal toxicity by calcineulin inhibition, and it is hoped that Lck inhibitor may become immunosuppressive agent with less side-effect.
In view of these, it is thought that Lck inhibitors are useful for medicine for disorder that participates in T-cell, for example, autoimmune disease like as psoriasis, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, nephrotic syndrome and the like, suppression of immunological rejection of graft-versus-host disease, organ transplant or the like.
Hitherto, as protein tyrosine kinase inhibitor, Src inhibitor or Lck inhibitor having the chemical structure of fused skeleton of an aromatic 5-membered heterocycle and an aromatic 6-membered heterocycle, pyrazolo [3, 4-d] pyrimidine derivatives are disclosed in International Publication WO 02/76986 and WO 02/80926, imidazo[l, 5-a]pyrazine derivative in Japanese laid-open patent publication No. 2005-89352, Pyrrolo [2, 3-d] pyrimidine derivatives in WO 00/17202, WO 00/17203 and WO 98/41525, pyrrolo [2, 1-f] [1, 2, 4] triazine derivatives in WO 02/79192, WO 2004/009601 and WO 2004/013145. However each of these publication does not mention or give suggestions on imidazo [1, 2-b] pyridazine or pyrazolo [1, 5-a] pyrimidine related to the present invention.
Meanwhile, pyrazolo [1, 5-a] pyrimidine derivatives represented by the formula (A) as Src inhibitor and Lck inhibitor are disclosed in Japanese laid-open patent publication No. 2005-8581.
Figure imgf000004_0001
[wherein symbols are as defined in the above publication]
The compounds disclosed in the above publication are substituted with carboxamide at 3-position of pyrazolopyrimidine . However the compounds of the present invention are not substituted with carboxamide at 3-position at all.
Meanwhile, imidazo [1, 2-b] p'yridazine and pyrazolo [1, 5-a] pyrimidine derivatives represented by the formula (B) as human protooncogene proviral insertion site in moloney murine leukemia virus kinase are disclosed in "J. Med. Chem. 48, pp7604-7614, 2005".
(B)
Figure imgf000004_0002
[wherein symbols are as defined in the above publication] The compounds disclosed in the above publication are
3, 6-disubstituted imidazo [1, 2-b] pyridazine and
3, 5-disubstituted pyrazolo [1, 5-a] pyrimidine . However the compounds of the present invention do not include these compounds at all.
Given that situation, it is greatly desired to develop medicaments that have more excellent Lck inhibitory activity.
DISCLOSURE OF THE INVENTION
The present inventors made extensive and intensive investigations with respect to compounds having Lck inhibitory activity/ which are expected to be a safe immunosuppressive agent. As a result, it has been found that a novel imidazopyridazine or pyrazolopyrimidine derivative or a salt thereof of the present invention has an excellent Lck inhibitory activity, leading to accomplishment of the invention. '
Accordingly, the present invention provides a fused heterocyclic compound of the following general formula (I) or a pharmaceutically acceptable salt thereof that is useful as an immunosuppressive agent.
(I)
Figure imgf000005_0001
wherein one of Y or Z is C atom, and the other is N atom. -X- is bond, -N(R1)-, -0-, -S-, -S(=0)-, -S(=0)2-; -R1 is hydrogen or lower alkyl; -A- is bond, lower alkylene or lower alkenylene, each of which may be substituted by one or more substituents selected from the group consisting of -OH and -NR11R12, wherein a methylene unit of -A- is optionally replaced by -O- or -C (=0) -; -R11 and -R12 are the same or different, each being hydrogen or lower alkyl;
-R2 is hydrogen, cycloalkyl, aryl, 5- or 6-meτnbered non-aromatic heterocycle or 5- or β-membered aromatic heterocycle, each of which may be substituted, or alternatively -R1 and "-A-R2" taken with the adjacent nitrogen atom may form 5-, 6- or 7- membered cyclic amino, which may be substituted;
-E- represents bond, lower alkylene, lower alkenylene or lower alkynylene, wherein a methylene unit of -E- is optionally replaced by -0-, -(CO)O-, -NH-, -NHCO-,
-NHSO2- or -NH(CO)NH-;
-R3 is cycloalkyl, aryl, 5- or 6-membered non-aromatic heterocycle or 5- or 6-membered aromatic heterocycle, each of which may be substituted and may be fused with benzene; and -R4, -R5 and -R6 are the same or different, each being hydrogen, halogen, lower alkyl, -0-lower alkyl or aryl. provided that (i) when -A- is bond, -X- is NH, -R2 is 4-tetrahydropyranyl and -R3 is 3-chlorophenyl, then
Y is C atom and Z is N atom; (ii) when X is NH, -R2 is cyclopropyl, 2-pyridyl, 3-pyridyl, 2-thienyl or 4-fluorophenyl and -R3 is 3-acetylphenyl, 3-chlorophenyl, 4-chlorophenyl, phenyl, 2-furyl or 2-thienyl, then A is bond. or a pharmaceutically acceptable salt thereof. Another one of the preferred embodiments of the present invention can be represented by the formula (I), wherein one of Y and Z is C atom, and the other is N atom; -X- is -N(R1)-, -0-, or -S-; -R1 is hydrogen or lower alkyl; -A- is bond or lower alkylene each of which may be substituted by one or more substituents selected from the group consisting of -OH and -NR11R12, wherein a methylene unit of -A- is optionally replaced by -0- or -C(=0) -;
-R11 and -R12 are the same or different, each being hydrogen or lower alkyl; -R2 is hydrogen, C5-10 cycloalkyl, aryl, 5- or 6-membered non-aromatic heterocycle which contains one to three heteroatom ( s) or 5- or 6-membered aromatic heterocycle which contains one heteroatom; each of which may be substituted with one to three substituent (s) selected from the group consisting of hydrogen, halogen, hydroxy, nitro, lower alkyl, -0-lower alkyl, -0- (β-membered cyclic amino), -CONH-lower alkyl, -C (0) NH-aryl, -S(0)2-aryl, -C (O)O-lower alkyl, -C(O)OH, -C (0) NH-0-lower alkyl, -NR11R12, 6-membered non-aromatic heterocycle, and
-0- ( 6-membered aromatic heterocycle), or alternatively -R1 and "-A-R2" taken with the adjacent nitrogen atom may form 5-, 6- or 7- membered cyclic amino, which may be substituted; -E- is bond, lower alkylene, lower alkenylene or lower alkynylene, wherein a methylene unit of -E- is optionally replaced by -NHSO2- or -NH(CO)NH-;
, -R3 is 5- or 6-membered non-aromatic heterocycle or 5- or
6-membered aromatic heterocycle which contains one to two nitrogen atom, which may be fused-with benzene; each of which may be substituted with one to three substituent (s) selected from the group consisting of halogen, lower alkyl, lower alkyl having halogen, lower alkyl having hydroxyl, -OH, cyano, -0-lower alkyl, phenyl, -0-phenyl, -S-phenyl, -O-cycloalkyl, -C(0)0-lower alkyl, -C(O)NH2, -NHCO-aryl, -NHC(0)0-lower alkyl and -NR11R12; and
-R4, -R5 and -R6 are the same or different, each being hydrogen, halogen, lower alkyl, -0- lower alkyl or aryl .
Another one of the more preferred embodiments of the present invention can be represented by the formula (I) , wherein -X- in the compound represented by the formula (I) is preferably -NH- or -O- ; -A- in the compound represented by the formula (I) is preferably bond or lower alkylene; -R2 in the compound represented by the formula (I) is preferably hydrogen, cyclohexyl, phenyl, adamantyl, pyridinyl, piperidinyl or tetrahydropyranyl; each of which may be substituted with one or two substituent (s) selected from the group consisting of hydroxy, halogen, methyl and lower alkyloxy optionally substituted with halogen; -E- in the compound represented by the formula (I) is preferably bond; -R3 in the compound represented by the formula (I) is preferably pyridinyl which may be substituted with halogen; -R4 in the compound represented by the formula (I) is preferably hydrogen; -R5 in the compound represented by the formula (I) is preferably hydrogen or methyl; and -R6 in the compound represented by the formula (I) is preferably hydrogen.
The present invention also provides a pharmaceutical composition comprising one or more compounds represented by the formula (I) as an active ingredient, which is useful as an Lck inhibitor, especially as a medicament for disorder that participates in T-cell, for example, autoimmune disease like as psoriasis, atopic dermatitis,' rheumatoid arthritis, systemic lupus erythematosus, nephrotic syndrome and the like, suppression of immunological rejection of graft-versus-host. disease, organ transplant or the like.
The present invention will be explained in more detail herein below. In the definition of the general formula .for the compound in the present invention, The term "lower" used in the description is intended to include 1 to 6 carbon atom(s) unless otherwise indicated.
The term "lower alkyl" means a monovalent group of a straight or branched carbon chain such as methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, tert-butyl and the like.
The "lower alkylene" means a divalent group of alkane such as methylene, ethylene, trimethylene, tetramethylene, dimethylmethylene, dimethylethylene and the like. The "lower alkenylene" means a divalent group of alkene such as ethen-1, 1-diyl, vinylene, propendiyl, butendiyl and the like. The "lower alkynylene" means a divalent group of alkyne such as ethyndiyl, propyndiyl, butyndiyl and the like.
. The "cycloalkyl" means a non-aromatic carbon ring having 3 to 10 carbon atoms, which may have partial unsaturation and may be fused or bridged. Its examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohepyl, cyclooctyl, cyclohexenyl, cyclooctadienyl, bornyl, norbornyl, adamantyl, 1, 2, 3, 4-tetrahydronaphthyl and the like, of which preferred ones are ones having 5 to 10 carbon atoms.
The "aryl" means a mono- to tri-cyclic aromatic carbon ring having 6 to 14 carbon atoms, of which ones 6 to 10 carbon atoms, e.g. phenyl and naphthyl are preferred, and phenyl is more preferred. The "5- or β-membered non-aromatic heterocycle" means a monovalent group of a non-aromatic heterocycle having one or more hetero atoms selected from the group consisting of a nitrogen, an oxygen and a sulfur atom, which may be fused or bridged. Its examples include azetidinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dihydropyridinyl, piperidinyl, azepinyl, piperazinyl, homopiperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, thiopyranyl, indolinyl, isoindolinyl, 8-azabicyo [3.2.1] octanyl, quinuclidinyl and the like. The NV5- or 6-membered aromatic heterocycle" means a monovalent group of an aromatic heterocycle having one or more hetero atoms selected from the group consisting of a nitrogen, an oxygen and a sulfur atom, which may be fused. Its examples include pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, thiadiazolyl, oxadiazolyl, triasolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyridinonyl, indolyl, benzothiazolyl, quinolyl, isoquinolyl, lH-isoindolyl- ' 1, 3 (2H) -dione, 2-methyl-l, 2 , 3, 4-tetrahydroisoquinolyl and the like.
The "halogen" means chloro, bromo, iodo and fluoro. As substituent groups that can be used for the term "optionally substituted" or "which may be substituted", those commonly used as substituent groups for each group can be used, and each group may have one or more substituent groups.
As the substituent groups that can be used for "cycloalkyl, aryl, 5- or β-membered non-aromatic heterocycle or 5- or 6-membered aromatic heterocycle, each of which may be substituted" in the definition of -R2 and -R3, which may be one or more, preferably one to three and may be the same or different, the following groups (a) to (h) can be exemplified. Wherein, "R2" is a lower alkyl which may be substituted with one or more groups selected from the group consisting of -OH, -0- ( lower alkyl) , -C (=0) N (Rz) 2/- amino which may be substituted with one or two lower alkyls, aryl, 5- or 6-membered aromatic heterocycle and halogen.
(a) halogen;
(b) -OH, -0Rz, -0-aryl, -0- (protecting group), -0-(5- or 6-membered aromatic heterocycle), -OCO-RZ, oxo(=0); (c) -SH, -SRZ, -S-aryl, -SO-RZ, -SO-aryl, -SO2-RZ, -S02-aryl, sulfamoyl which may be substituted with one or two Rz;
(d) amino which may be substituted with one or two groups selected from the group consisting of Rz and aryl, -NHCO-Rώ, -NHCO-aryl, -NHCO- (5- or 6-membered aromatic heterocycle) , -NHCO2-R2, -NHCO2-aryl, -NHCONH2, -NHSO2-R2, -NHSO2-aryl, -NHSO2NH2, nitro;
(e) -CHO, -CO-R2, -CO2H, -CO2-R2, cyano, carbamoyl which may be substituted with one or two groups selected from the group consisting of Rz and -0-Rz; (f) aryl or cycloalkyl, each of which may be substituted with one or more groups selected from the group consisting of -OH, -0- (lower alkyl), amino which may be substituted with one or two lower alkyl, halogen and Rz . (g) 5- or 6-membered non-aromatic heterocycle or 5- or 6-membered aromatic heterocycle, each of which may be substituted with one or more groups selected from the group consisting of -OH, -0- (lower alkyl), amino which may be ' substituted with one or two lower alkyl, halogen and Rz . (h) lower alkyl which may be substituted with one or more groups selected from the substituent groups described in (a) to (g) . The compound of the present invention represented by the general formula (I) may comprise asymmetric carbon atoms depending on the kinds of substituent groups, and optical isomers based on the asymmetric carbon atom may exist. The compound of the present invention includes a mixture of these optical isomers or isolated ones. And, tautomers may exist in the compound of the present invention, and the compound of the present invention includes these isomers as a mixture or an isolated one. And, labeled compound, i.e., compounds wherein one or more atoms are labeled with radioisotopes or non-radioisotopes, are also included in the present invention.
In addition, the compound of the present invention may form a salt, which is included in the present invention as long as pharmaceutically acceptable. Examples of the salt include addition salts with a mineral acid such as hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesufonic acid, a'spartic acid, glutamic acid, and the like; or an organic base such as methylamine, ethylamine, ethanolamine, lysine, ornithine, and the like; and ammonium salts, and the like. And a hydrate and a solvate of the compound and its pharmaceutically acceptable salt of the present invention, and those having polymorphism are also included in the present invention. In addition, the compound of the invention also includes a compound which is metabolized in a living body to be converted into the compound of the general formula (I) or its salt, >> a soΛcalled prodrug. As groups forming the prodrug, those described in Prog, Med., 5, pp.2157-2161, 1985; and Hirokawa-Shoten, 1990, "Development of medicine" VoI . 7, Molecular Design, pp. 163-198 can be exemplified.
PRODUCTION METHOD
The compounds and its pharmaceutically acceptable salt of the present invention can be prepared by various known synthesis methods, using characteristics based on its basic backbone or the kinds of substituent groups. The following describes representative preparation methods . And, according to the kinds of functional groups, it is advantageous in some cases in terms of preparation technique to substitute a functional group with a suitable protection group, i.e., a group that can be easily converted into the functional group, in the starting material or intermediate step. Then, if necessary, the protection group is removed to obtain a desired compound. Examples of the functional group include hydroxyl, carboxyl, amino group and the like, and examples of the protection group include those described in "Protective Groups in Organic Synthesis", third edition, edited by Greene and Wuts. It is preferable to suitably use them depending on reaction conditions . Process 1
Figure imgf000016_0001
[wherein Lv1 represents a leaving group, X1 represents -N(R1)-, -0- or -S-, n represents 1 or 2, Hal represents halogen, and -R1 , -R2, -R3, -R4, -R5, -R6, -A-, -E-,1 -X-, Y and Z are as defined in the foregoing.]
In this process, the compound (I) is prepared by- substitution reaction of Ia with Ib (step 1-1), followed by, if necessary, oxidation step of sulfanyl group into sulfinyl group or sulfonyl group (step 1-2) , followed by halogenation of Ic or Id (step 1-3) , and followed by coupling reaction etc. of the thus-prepared compound Ie (step 1-4) . Examples of a leaving group include halogen, alkanesulfonyl optionally substituted by one or more halogen, arylsulfonyl and the like. The compound (I) can be prepared by coupling reaction etc. of Ie. For example, Suzuki coupling, Heck reaction and Sonogashira reaction can be applied, each of which is referred in "Chem. Rev.-, 95, pp.2457, 1995", "J. Am. Soc. Chem. , 127, pp.4685, 2005", "Synlett, pp.2329, 2004", "Tetrahedron Lett ., 41, pp.4363, 2000", or Tetrahedron Lett ., 43, pp.2695, 2002." For the step, substitution reaction can also be applied to prepare the compound (I). The compound Ie can be reacted with a compound "R3-E-H (If)" in a non-protonic polar solvent such as N, N-dimethylformamide (DMF), N-methyl-2-pyrrolidone, dimethylsulfoxide (DMSO) and the like; an inert organic solvent such as halogenated hydrocarbon including dichloromethane, dichloroethane, chloroform and the like; ether including ether, tetrahydrofuran (THF) , dioxane and the like; aromatic hydrocarbon including benzene, toluene, xylene and the like; or water, or a mixture thereof to prepare a compound (I) . The reaction is preferably carried out at ambient temperature to reflux temperature of the used solvent.
In order to progress the reaction smoothly, it is advantageous in some cases to employ an excess amount of the compound If or carry out the reaction in the presence of a base such as N-methylmorpholine, triethylamine, diethylisopropylamide, N,N-dimethylaniline, pyridine, 4- (N, N-dimethylamino) pyridine, picoline, lutidine and the like. In another method, when E represents -NHCO-, the compound (I) can be prepared by nitration of Ic or Id followed by reduction of nitro group into amino group, followed by acylation with "R3-CO2H (Ig) . " A commonly used manner for one skilled in the art can be applied to reduction and acylation. In the acylation step, the reactive derivative such as ester, acid halide, acid anhydride and the like of Ig can also be used. In case Ig is reacted in its free acid form, it is preferable to carry out the reaction using a condensing agent such as dicyclohexylcarbodiimide, carbonyldiimidazole, 1-ethyl- 3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI. HCl) and the like. The reaction is, although it varies depending on the reactive derivatives or condensing agent, carried out in an inert solvent such as a halogenated hydrocarbon, aromatic hydrocarbon, ether, DMF, DMSO and the like, under cooling, cooling to ambient temperature, or ambient temperature to heating. In case Ig is reacted in its acid halide form, to progress the reaction smoothly, it is advantageous in some cases to carry out the reaction in the presence of a base. The compound Ie can be prepared by halogenation of Ic or Id. As a halogenation agent, those commonly used for a halogen substitution reaction of hydrogen on an aromatic ring can be used. A halogen molecule such as chlorine, bromine, iodine and the like, dioxanedihalide, phenyltrimethylammonium trihalide, a pyridine derivative such as pyridinium hydrohalide perhalide, pyrrolidonehydrotrihalide and the like, a perhalide such as a-pyrrolidone, quaternary ammonium, dioxane and the like are appropriate. An imide-type halogenation agent such as N-iodosuccinimide, N-bromosuccinimide and the like, a hydrogen halide such as hydriodic acid, hydrobromic acid and the like, a metal agent such as copper (II) halide including copper (II) iodide and the like can also be used.
In case of halogen molecule or perhalide is used, the compound Ic or Id can be reacted in an inert organic solvent such as halogenated hydrocarbon; ether/ alcohol oncluding methanol (MeOH), ethanol (EtOH), 2-propanol (iPrOH) , ethyleneglycol and the like; aromatic hydrocarbon; acetic acid; ester including ethyl acetate (AcOEt) and the like. If necessary the reaction may be carried out in the presence of a small amount of a catalyst such as hydrogen halide. It is preferable to carry out the reaction at -30 0C to reflux temperature of the used solvent.
In case a hydrogen halide is used as a halogenation agent, the compound Ie can be reacted therewith in an acid solution or a base solution such as sodium hydroxide aqueous solution, and the reaction is preferably carried out at -300C to reflux temperature of the used solvent. And in case a metal agent is used as a halogenation agent, the compound Ie is generally dissolved in an inert organic solvent such as halogenated hydrocarbon, ether, alcohol, aromatic hydrocarbon, acetic acid, ester and the like, or water, or a mixture thereof to react with the agent, and if necessary, it is advantageous to carry out the reaction in the presence of a small amount of a catalyst such as hydrogen halide, under ambient temperature to heating. For oxidation reaction of the step 1-2, oxidation method of sulfur atom of sulfanyl group which is well-known by one skilled in the art is applicable, for example, m-chloroperbenzoic acid, hydrogen peroxide or caboxylic peracid like as acetic peracid or trifluoroacetic peracid can be used for the oxidation.
The step 1-1, which includes a substituation reaction of Ia with Ib (step 1-1), can be carried out in accordance with the step 1-4.
Process 2
Figure imgf000020_0001
[wherein any symbols are as defined in the foregoing.]
Any steps can be carried out in accordance with the steps of the Process 1.
In addition to the processes as mentioned above, the compound (I) and a salt thereof can be prepared, for example, according to the procedures as illustrated in Examples in the present specification or in a manner similar thereto. The starting compounds can be prepared, for example, according to the procedures- as illustrated in Preparations in the present specification or in a manner similar thereto. The compound (I) and a salt thereof can be prepared according to the methods as shown in Preparations or Examples, or in a manner similar thereto.
And, the thus-obtained compounds can be subjected to a process commonly used in the art such as alkylation, acylation, substitution, oxidation, reduction, hydrolysis, and the like to prepare some of the compounds of the general formula (I) .
The thus-prepared compound of the present invention is isolated and purified as its free form or as a salt thereof. A salt of the compound (I) can be prepared by subjecting it to a usual salt formation reaction. The isolation and purification are carried out by usual chemical manipulations such as extraction, concentration, eλ^aporation, crystallization, filtration, recrystallization, various types of chromatography and the like.
Various types of isomers can be separated by usual method using the difference in physicochemical properties among isomers. For example, a racemic mixture can be separated by a general racemic mixture resolution method, e.g., a method in which racemic mixture is converted into diastereomer salts with an optically active acid such as tartaric acid and the like and then subjected to optical resolution. And, diastereomers can be separated by fraction crystallization or various types of chromatography or the like. Also, optically active compounds can be prepared using appropriate optically active starting materials .
INDUSTRIAL APPLICABILITY
In order to show the usefulness of the compound of the present invention, the pharmacological test result of the representative compound of the present invention is shown in the following. Assay for Lck activity
The Src substrate peptide (Upstate) was coated onto 96-well Maxisorp plates (Nunc) . Plates were sealed and incubated at 40C' for 16 hours, washed three times with TBST
(20 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.1% Tween-20). The plates were blocked with 0.1% BSA and washed three times with
TBST. Purified Lck (Upstate) was incubated in 10OmM Tris-HCl pH 7.5, 125 mM MgCl2, 25 mM MnCl2, 2 mM EGTA, 0.25 mM Sodium Vanadate, 2 mM DTT, 0.05 mM ATP with or without inhibitors at 300C for 60 minuites and washed with TBST three times. For quantification of phosphorylated tyrosines, plates were incubated with anti-phosphotyrosine, HRP conjugate (4GlO, Upstate) for 1 hour at ambient temperature and washed three times with TBST. Detection was carried out using a color reagent, TMB (KPL) . Ten minute after TMB addition the OD at 450 nm was measured.
Following IC50 values were obtained: 81 nM for Example 127, 97 nM for Example 153, 460 nM for Example 16, 380 nM for Example 44, 350 nM for Example 47, 310 nM for Example 102, 410 nM for Example 106, and 320 nM for Example 249.
The result clearly suggest that the compound of the present invention have Lck inhibitory activity. The fused heterocycle and the salt thereof of the present invention have excellent Lck inhibitory activity as shown above. Thus a pharmaceutical composition comprising the compound of the present invention represented by the formula (I) is useful as a therapeutic or prophylactic agent for diseases or conditions caused by undesirable cytokine signal transduction, such as rejection reaction in organ transplantation, autoimmune diseases, asthma, atopic dermatitis, cancer and leukemia as exemplified below: Rejection reactions by transplantation of organs or tissues such as the heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, islet, small intestine, limb, muscle, nerve, intervertebral disc, trachea, myoblast, cartilage, etc.; and graft-versus-host reactions following bone marrow transplantation; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes and complications from diabetes, etc.
Furthermore, a pharmaceutical composition comprising Lck inhibitor such as the compound of the present invention represented by the formula (I) is useful for the therapy or prophylaxis of the following diseases:
Inflammatory or hyperproliferative skin diseases or cutaneous manifestations of immunologically-mediated diseases (e.g., psoriasis, atopic dermatitis, contact dermatitis, eczematoid dermatitis, seborrheic dermatitis, lichen planus, pemphigus, bullous penphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, erythema, dermal eosinophilia, lupus erythematosus, acne, alopecia areata, etc.); autoimmune diseases of the eye (e.g., keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical keratitis, corneal epithelial dystrophy, keratoleukoma, ocular premphigus, Mooren's ulcer, ' scleritis, Grave's ophthalmopathy, Vogt-Koyanagi-Harada syndrome, keratoconjunctivitis sicca (dry eye) , phlyctenule, iridocyclitis, sarcoidosis, endocrine ophthalmopathy, etc.); reversible obstructive airways diseases [asthma (e.g., bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, etc.), particularly chronic or inveterate asthma (e.g., late asthma, airway hyper-responsiveness, etc.), bronchitis, etc.]; mucosal or vascular inflammations (e.g., gastric ulcer, ischemic or thrombotic vascular injury, ischemic bowel diseases, enteritis, necrotizing enterocolitis, intestinal damages associated with thermal burns, leukotriene B4-mediated diseases, etc.); intestinal inflammations/allergies (e.g., coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, etc.); food-related allergic diseases with symptomatic manifestation remote from the gastrointestinal tract (e . g . , migrain, rhinitis, eczema, etc.); autoimmune diseases and inflammatory conditions (e.g., primary mucosal edema, autoimmune atrophic gastritis, premature menopause, male sterility, juvenile diabetes mellitus, pemphigus vulgaris, pemphigoid, sympathetic ophthalmitis, lens-induced uveitis, idiopathic leukopenia, active chronic hepatitis, idiopathic cirrhosis, discoid lupus erythematosus, autoimmune orchitis, arthritis (e.g., arthritis deformans, etc.), polychondritis, etc.); allergic conjunctivitis .
Therefore, the pharmaceutical composition of the present invention is useful for the therapy and prophylaxis of liver diseases [e.g., immunogenic diseases (e.g., chronic autoimmune liver diseases such as autoimmune hepatic diseases, primary biliary cirrhosis, sclerosing cholangitis, etc.), partial liver resection, acute liver necrosis (e.g., necrosis caused by toxins, viral hepatitis, shock, anoxia, etc.), hepatitis B, non-A non-B hepatitis, hepatocirrhosis, hepatic failure (e.g., fulminant hepatitis, late-onset hepatitis, "acute-on-chronic" liver failure (acute liver failure on chronic liver diseases, etc.), etc.), etc.]. The pharmaceutical composition of the present invention can be used in- the form of pharmaceutical preparation, for example, in a solid, semisolid or liquid form, which contains the compound of the present invention represented by the formula
(I) as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral administrations. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, injections, ointments, linimnts, eyedrops, lotion,' gel, cream, and any other form suitable for use.
The carriers those can be used for the present invention include water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, cornstarch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations in a solid, semisolid, or liquid -form. Furthermore,- auxiliary, stabilizing, thickening, solubilizing and coloring agents and perfumes may be used. For applying the composition to human, it is preferable to apply it by intravenous, intramuscular, topical or oral administration, or by a vascular stent impregnated with the compound (I) . In the case of oral administration, a daily dose is approximately 0.0001-50 mg/kg of body weight, preferably approximately 0.001-10 mg/kg, and more preferably approximately 0.01-1 mg/kg, and the daily dose is administered once a day or by dividing it into 2 to 4 doses per day. In the case of intravenous or intramuscular administration, a daily dose is approximately 0.0001-1 mg/kg of body weight, preferably approximately 0.0001-0.1 mg/kg, and the daily dose is administered once a day or by dividing it into plural doses per day. The dose is appropriately decided by taking symptoms, age, and sex of the patient to be treated and the like into consideration. During the preparation of the above-mentioned pharmaceutical administration forms, the compound (I) or a salt thereof can also be combined together with other immunosuppressive substances, for example rapamycin, mycophenolic acid, cyclosporin A, tacrolimus or brequinar sodium.
The pharmaceutical compositions of the present invention, either from alone or in combination with one of more additional agents which may include but are not limited to cyclosporin A, tacrolimus, sirolimus, everolimus, micophenolate (e.g. Cellcept (R) , etc.), aza'thioprine, brequinar, lefulunomide, fingolimod, anti-IL-2 receptor antibody (e.g. daclizumab, etc.), anti-CD3 antibody (e.g. OKT3, etc.), Anti-T cell immunogloblin (e.g. AtGam, etc.) aspirin, acetaminophen, ibuprofen, naproxen, piroxicam, and anti inflammatory steroid (e.g. prednisolone or dexamethasone) may be administrated as part of the same or separate dosage forms, via the same or different routes of administration, and on the same or different administration schedules according to standard pharmaceutical pracitce .
BEST MODE FOR CARRYING OUT OF THE INVENTION
The following describes the invention more illustratively with reference to Examples, but the present invention is not limited to these examples . In this connection, novel materials are included in the starting materials to be used in the Examples, and production methods of the starting materials from known materials are described as Preparations. Preparation 1 The solution of 5-chloropyrazolo [ 1, 5-a] pyrimidine (200 mg) and trans-4-methoxycyclohexanamine (168 mg) in isopropylalcohol
(2 ml) was refluxed for 3 hours. After cooling to ambient temperature, the reaction mixture was poured into water, then extracted with ethyl acetate . The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel elυting with chloroform/methanol ( 100 : 0 to 100:10) to give N- (trans-4-methoxycyclohexyl)pyrazolo [1, 5-a] pyrimidin-5- amine (70 mg) .
1H-NMR (DMSO-d6) 5:1.13-1.34 (4H,m) ,1-91-2.08 (4H,m) , 3.09-3.20 ( IH, m) ,3.33 (3H,s) , 3.70-3.86 (lH,m) ,5.95 (IH, d, J=2. OHz) ,6.19 (IH , d, J=7.6Hz) , 7.26(lH,d, J=7.4Hz) ,7.74 ( IH, d, J=2. OHz) , 8.41 (IH, d , J=7.6 Hz) . MS:247 (MH-H)+. Preparation 2 To a stirred mixture of 6-chloro-3-iodoimidazo [ 1, 2-b] pyridazine (100 mg) and 4- (4, 4, 5, 5-tetramethyl-l, 3, 2- dioxaborolan-2-yl) pyridine (220 mg) in 1, 2-dimethoxyethane (3.3 ml) was added aqueous 2M NaOH aqueous solution (1.08mL) at ambient temperature. Tetrakis (triphenylphosphine) palladium (0) (24.8 mg) was then added to the mixture at ambient temperature. After addition, the resulting mixture was stirred at 85 0C for 1 hour. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (20mL/20mL) . The resulting mixture was acidified with IM HCl aqueous solution to pH 2 and extracted with ethyl acetate. The aqueous phase was then neutralized by the addition of 2M NaOH aqueous solution to pH 8. The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chlσroform/methanol (20 : 1) to give the following compounds .
6-Chloro-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine .
1H-NMR(CDCl3) δ:7.19(lH,d, J=4.8Hz) ,7.52-7.57 ( IH, m), 8.00-8.06 (3H,m) ,8.25 (IH, s) ,8.73-8.78 (2H,d,J=9.5Hz) .
3, 6-Di-4-pyridinylimidazo [1, 2-b] pyridazine.
1H-NMR(CDCI3-CD3OD (9:1) ) δ : 7.76 (IH, d, J=9.5Hz) ,7.99 (2H,d, J=6.2
Hz) ,8.17 (2H,d, J=6.2Hz) , 8.26 (IH, d, J=9.2Hz) , 8.34 (IH, s) , 8.73 (2
H,d, J=5.9Hz) , 8.83(2H,d, J=6.2Hz) . MS:274 (M+H)+.
Preparation 3
To a solution of 2- ( 4-methyl-3-nitrophenoxy) tetrahydro-
2H-pyran (4750 mg) in methanol (10OmL) was added 10% palladium on carbon (600 mg) . The resulting mixture was stirred under atmospheric hydrogen at ambient temperature for 3 hours. The mixture was filtered through Celite and washed with methanol.
The filtrate was concentrated in vacuo to give 2-methyl-5-
(tetrahydro-2H-pyran-2-yloxy) aniline (4140 mg) .
1H-NMR (DMSO-ds) 5:1.45-1.92 ( 6H,m) , 1.96 (3H, s) , 3.45-3.58 (lH,m) ,3.68-3.80 ( IH, m) , 4.79 (2H, bs) , 5.25 (IH, t , J=3. OHz) , 6.12 (IH, dd,
J=2.5,8.5Hz) , 6.29 (IH, d, J=2.5Hz) , 6.76 (IH, d, J=8.5Hz) .
MS:230 (M+Na)\
The following compound was obtained in a similar manner to that of Preparation 3. Preparation 4 [2-Chloro-5- (tetrahydro-2H-pyran-2-yloxy) phenyl] amine .
MS:269.
Preparation 5 trans-4- ( Imidazo [1, 2-b] pyridazin-β-ylamino) cyclohexanol (110 mg) and N-iodosuccinimide (117 rag) in N, N- dimethylformamide (1.1 ml) was stirred at ambient temperature for 4 hours. The reaction mixture was poured into a mixture of 10% sodium thiosulfate aqueous solution and chloroform.
Then the organic layer was washed with aqueous saturated sodium hydrogen carbonate, water, brine, dried over magnesium sulfate, and evaporated in vacuo. Resulting precipitates were collected by filtration and washed with diisopropyl ether to give trans-4-[ (3-iodoimidazo [1, 2-b] pyridazin-6-yl) amino] cyclohexanol as an brown solid (140 mg) . 1H-NMR (DMSO-d6) 5:1.12-1.34 (4H,m) , 1.77-1.90 (2H, m) , 1.94-2.10 (
2H,m) ,3.38-3.60 (2H,m) ,4.57 (IH, d, J=4. OHz) , 6.59 (IH, d, J=9.9Hz)
,6.73(lH,d,J=7.3Hz) ,7.34 (lH,brs) , 7.64 (IH, d, J=9.9Hz) , 7.79 ( IH
,brs) .
MS:233 (M+H)+. The following compounds were obtained in a similar manner to that of Preparation 5.
Preparation 6
3-Iodo-N- (trans-4-methoxycyclohexyl)pyrazolo [1, 5-a] pyrimidin-5-amine . 1H-NMR (DMSO-d6) 5:1.10-1.37 (4H,m) , 1.93-2.10 (4H,m) ,3.08-3.25 ( IH, m) ,3.25 (3H, s) ,3.72-3.91 (lH,m) , 6.23 ( IH, d, J=7.5Hz) ,7.5 (IH, d, J=7.3Hz) ,7.81(1H7S) , 8.42 (IH, d, J=7.5Hz) .
MS:373 (M+H)+.
Preparation 7 • 6-chloro-3-iodo-8-methoxyimidazo [1, 2-b] pyridazine . *
MS:332 (M+Na)+.
Preparation 8
5-Chloropyrazolo [1, 5-a] pyrimidine (100 mg) and
N-iodosuccinimide (161 mg) in N, N-dimethylformamide (ImI) was stirred at ambient temperature for 4 hours. The reaction mixture was poured into a mixture of 10% sodium thiosulfate aqueous solution and chloroform. Then the organic layer was washed with saturated NaHCU3 aqueous solution, water, brine, dried over magnesium sulfate, and evaporated in vacuo. Resulting precipitates were collected by filtration and washed with diisopropyl ether to give 5-chloro-3-iodopyrazolo [ 1, 5-a] pyrimidine as an brown solid (180 mg) .
1H-NMR(DMSO-d6)δ:7.42 ( IH, d, J=9.5Hz) , 7.97 ( IH, s) , 8.23 ( IH, d, J=
9.2Hz) . MS:279 (M+H)+.
The following compounds were obtained in a similar manner to that of Preparation 8.
Preparation 9 β-Chloro-3-iodo-7-methylimidazo [1, 2-b] pyridazine . MS:294 (M+H)+. Preparation 10 β-Chloro-S-iodo-S-methylimidazo [1, 2-b] pyridazine . MS:294 (M+H)+. Preparation 11 To a solution of β-chloro-3-pyridazinamine (470.8 mg) in N, N-dimethylformamide (5mL) was added 2-bromo-l, 2- diphenylethanone (500 mg) and the mixture was stirred at 80 0C for 5 hours. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was poured into saturated NaHCU3 aqueous solution (10 mL) . The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (40:1 to 20:1) to give β-chloro-2, 3-diphenylimidazo [1, 2-b] pyridazine (286.7 mg) .
1H-NMR (DMSO-d6) δ : 7.32-7.39 (2H, m) ,7.43 (lH,d, J=9.6HΞ) ,7.55-7. 63 (8H,m) ,8.30(lH,d, J=9.6Hz) . MS:306(M+H)+. Preparation 12
Trans-4- [ (3-iodoimidazo [1, 2-b] pyridazin-6-yl) amino] cyclohexanol (300 mg) was dissolved in dimethylsulfoxide (6.0 mL) and methanol (3.6 ml) . To this solution were added triethylamine (0.35 mL) , palladium acetate (II) (=Pd (OAc) 2, 18.8 mg) and 1, 3-bis (diphenylphosphino) propane (=DPPP, 34.5 mg) at ambient temperature. The resulting mixture was stirred at 800C for 5 hours under CO (1 atm) . After all starting material had been consumed, as judged by TLC plate, the reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (1OmL/1OmL) . The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (40:1 to 20:1) to give methyl 6- [ (trans-4-hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazine-3-carboxylate ( 175.1 mg) .
1H-NMR (DMSO-d6) δ : 1.15-1.40 (4H,m) , 1..78-1.97 (2H,m) ,2.01-2.20 ( 2H,m) ,3.36-3.68 (2H,m) , 3.82 (3H, s) , 4.56 ( IH, d, J=4.6Hz) , 6.81 (IH , d, J=9.6Hz) ,7.01 (lH,d, J=6.8Hz) ,7.78 (IH, d, J=9.6Hz) ,7.99 (IH, s ) .
MS:291(M+H)+.
Preparation 13
To a solution of Sn (186.9 mg) in cone. HCl aqueous solution
(1.9 mL) was added trans-4- [ (3-nitroimidazo [1, 2-b] pyridazin- 6-yl) amino] cyclohexanol (291 mg) at 00C for 30 minutes, which was stirred at ambient temperature for 30 minutes. The mixture was diluted with ice-cooled water, basified with ammonium hydroxide, and extracted with n-butylalcohol . The organic layer was washed with brine, dried over sodium sulfate, filtered, and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give trans-4- [ (3- aminoimidazo [1 , 2-b] pyridazin-β-yl) amino] cyclohexanol (282 mg) as a brown amorphous. MS:248 (M+H)+. Preparation 14
To a stirred mixture of 4-methyl-3-nitrophenol (3828 mg) and 3, 4-dihydro-2H-pyran (5257 mg) in dichloromethane (1 mL) was added catalytic amount of pyridine 4-methylbenzenesulfonate (628.3 mg) at ambient temperature. The resulting mixture was stirred at ambient temperature for 3 hours. Quenching the reaction with saturated sodium hydrogen carbonate and concentrated in vacuo. The residue was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with n-hexane/ethyl acetate (10:1 to 3:1) to give 2- (4-methyl- 3-nitrophenoxy) tetrahydro-2H-pyran (5920 mg) . 1H-NMR (DMSO-d6) 5:1.50-1.98 (6H,m) , 2.44 (3H, s) , 3.51-3.62 (lH,m) ,3.63-3.73 (IH, m) ,5.58 (IH, t, J=3. OHz) ,7.30 (IH, dd, J=2.5, 8.5Hz) ,7.42 (lH,d, J=8.5Hz) ,7.61 (IH, d, J=2.5Hz) . MS:260 (M+Na)+.
The following compound was obtained in a similar manner to that of Preparation 14. Preparation 15 2- (4-Chloro-3-nitrophenoxy) tetrahydro-2H-pyran. MS:258 (M+H)+. Preparation 16
The suspention of benzyl (cis-4-fluorocyclohexyl) carbamate (130 mg) and 10% Pd-C 50% wet (50 mg) in methanol (5 ml) was stirred at ambient temperature for 2 hours under H2 atmosphere. After filtration, the reaction mixture was evaporated in vacuo to give cis-4-fluorocyclohexanamine (17 mg) . 1H-NMR (DMSO-d6)δ: 1.23-1.69 (6H,m) , 1.79-1.97 (2H,m) , 2.64-2.89 ( IH, m) ,4.57-4.65 (0.5H,m) , 4.79-4.89 (0.5H,m) . Preparation 17
A solution of (diethylamino) sulfur trifluoride (1.48 ml) in dichloromethane (8 ml) was added dropwise to a solution of benzyl (trans-4-hydroxycyclohexyl) carbamate (2.8 g) in dichloromethane (20 ml) . After stirring at 00C for 1 hour, the reaction mixture was poured into saturated NaHCO3 aqueous solution, and extracted with dichloromethane. The organic layer was dried over magnesium sulfate, and evaporated in vacuo . The residue was purified by column chromatography on silica gel eluting with n-hexane/ethyl acetate (10:1 to 5:1) to give benzyl (cis-4-fluorocyclohexyl) carbamate (130 mg) .
1H-NMR(CDCl3) 5:1.42-2.11 (8H,m) , 3.44-3.71 ( IH, m) ,4.60-4.73 (IH ,m) ,4.83-4.92 (IH, m) ,5.10 (2H, s ) , 7.30-7.39 (5H,m) . Preparation 18 6-Chloroimidazo[l,2-b]pyridazine (15 g) , trans-4- aminocyclohexanol (11.25 g) , sodium tert-butoxide (14.1 g) , (R) - 2, 2' -Bis (diphenylphosphino)-l, 1' -binaphthyl (= (R) -BINAP, 1.83 g) , and tris (dibenzylideneacetone) dipalladium (0 ) chloroform adduct (1.01 g) in toluene (430 ml) was refluxed for 1.5 hours. After the reaction mixture was cooled to ambient temperature, dichloromethane (300 ml) and methanol (30 ml) was added and filtrated with Celite pad. The filtrate was evaporated in vacuo. The residue was purified by chromatography on silica gel eluting with chloroform/methanol
(100:2 to 10:1) to give trans-4- (imidazo [1, 2-b] pyridazin-6- ylamino) cyclohexanol (7.5 g) .
1H-NMR (DMSO-de) 5:1.12-1.34 (4H,m) , 1.77-1.90 (2H,m) , 1.94-2.10 ( 2H,m) ,3.38-3.60 (2H,m) ,4.57 ( IH, d, J=4. OHz) ,6.59 (lH,d, J=9.9Hz) ,6.73 (lH,d, J=7.3Hz) ,7.34 (lH,brs) ,7.64 (IH, d, J=9.9Hz) ,7.79 (IH ,brs) . MS:233 (M+H)+. Preparation 19
A mixture of 6-chloro-3- ( 4-pyridinyl) imidazo [ 1, 2-b] pyridazine (300 mg) and 28% ammmonia aqueous solution (5.0 mL) were heated at 1800C in a stainless sealed tube for 15 hours. After cooling, the mixture was concentrated under reduced pressure. The resulting crystals were collected by filtration, washed with water and dried under a vacuum to give 3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (201.3 mg) . 1H-NMR(DMSO-d6)δ:6.62 (2H, bs) , 6.76 (IH, d, J=9.5Hz) , 7.84 ( IH, d, J =9.5Hz) ,8.17 (IH, s) ,8.23 (2H, d, J=6. OHz) ,8.60 (2H, d, J=6. OHz) . MS:212 (M+H)+. Preparation 20
A mixture of 6-chloro-3-nitroimidazo [1, 2-b] pyridazine (193 mg) , trans-4-aminocyclohexanol (280 mg) in dimethylsulfoxide (579 μL) was stirred at 700C for 7 hours. The resultant was poured into water. The precipitate was filtered, and washed cold water to give trans-4- [ ( 3-nitroimidazo [1, 2-b] pyridazin-6-yl) amino] cyclohexanol (244.4mg) as a yellow powder. MS:300 (M+Na)+. Preparation 21
To a stirred mixture of β-chloro-3-iodoimidazo [1, 2-b] pyridazine (1.00 g) and 4- (4 , 4 , 5, 5-tetramethyl-l, 3, 2- dioxaborolan-2-yl) pyridine (1.47 g) in dioxane (30 ml) was added 2M NaOH aqueous solution (5.725 mL) at ambient temperature . The suspension turned to a clear yellow solution, palladium acetate (II) (=Pd (OAc) 2, 40.2 mg) and triphenylphosphine (188 mg) were then added to the mixture at ambient temperature. After addition, the resulting mixture was stirred at 1000C for 3 hours . The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (20mL/20mL) . The resulting mixture was acidified with 1 M HCl aqueous solution to pH 2 and extracted with ethyl acetate. The aqueous phase was then neutralized by the addition of 2 M NaOH aqueous solution to pH 8. The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (50 : 1 to 20:1) to give 6-chloro~3- (4- pyridinyl) imidazo [ 1, 2-b] pyridazine. 1HHUMR ( DMSO-Cl6) δ: 7.19 ( IH, d,J=4.8Hz) ,7.52-7.57 (lH,m) ,8.00-8.
06(3H,m) ,8.25 (IH, s) ,8.73-8.78 (2H, d, J=9.5Hz) .
MS:231 (M+H)+.
The following compounds were obtained in a similar manner to that of Preparation 21. Preparation 22
6-Chloro-8-methyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine .
MS:245 (M+H)+.
Preparation 23
6-Chloro-7-methyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine . MS:245(M+H)+.
The following compounds were obtained in a similar manner to that of Examplelβ .
Preparation 24
3- (4-Pyridinyl) imidazo [l,2-b]pyridazin-6-ol. 'MS: 213(M+H)+.
Preparation 25 tert-Butyl (trans-4-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexyl) carbamate .
1H-NMR (DMSO-d6)δ: 1.21-1.4 β(4H,m) , 1.40 (9H, s) , 1.84-1.96 (2H, m) , 2.11-2.21 (2H,m) ,3.47-3.64 (2H,m) , 6.75 (IH, d, J=9.9Hz) , 6.79 (IH ,d, J=7.3Hz) ,7.17 (lH,d, J=6.6Hz) , 7.80 (IH, d, J=9.5Hz) , 8. lβ (IH, s
) , 8.21(lH,d, J=6.2Hz) , 8.60 (IH, d, J=6.2Hz) .
MS:409(M+H)+.
Preparation 26 tert-Butyl (cis-4-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-
6-yl ] amino } cyclohexyl ) carbamate .
1H-NMR(DMSO-d5)δ:1.39(9H,s) , 1.59-1.99 ( 9H,m) , 3.72-3.88 (lH,m)
, 6.78-6.91 ( IH, m) , 6.86 (IH, d, J=IO . OHz) ,7.05 ( IH, d, J=5.5Hz) ,7.8
(lH,d, J=9.5Hz) , 8.16 (IH, s ) , 8.19 (2H, d, J=6. OHz) , 8.6 (2H, d, J=6.0 Hz) .
MS:409 (M+H)+.
The following compounds were obtained in a similar manner to that of Example 86.
Preparation 27 6-Chloro-3- (2-chlorophenyl) imidazo [1, 2-b] pyridazine.
1H-NMR(CDCl3) δ:7.12 ( IH, d,J=9.5Hz) , 7.38-7.45 (2H,m) ,7.55-760 (
IH, m) ,7.65-7.70 ( IH, m) ,7.98 (IH, d, J=9.5Hz) ,8.02 (IH, s) .
MS:264 (M+H)+.
Preparation 28 6-Chloro-3- (4-phenoxyphenyl) imidazo [1, 2-b] pyridazine .
1H-NMR(CDCl3) 5:7.03-7.19 (6H,m) ,7.38 (2H, t , J=7.3Hz) ,7.92-8.04 (4H,m) .
MS:322 (M+H)+.
Preparation 29 6-Chloro-3- [4- ( trifluoromethoxy) phenyl] imidazo [1, 2-b] pyridazine .
1H-NMR(CDCl3) δ:7.14 (IH, d, J=9.5Hz) ,7.38 (2H, d, J=8.8Hz) ,8.00 (1
H,d, J=9.5Hz) ,8.08 (IH, s) , 8.10 (2H, d, J=8.8Hz) .
MS:314 (M+H)+. Preparation 30
6-Chloro-3- (4-methoxyphenyl) imidazo [1 , 2-b] pyridazine .
1H-NMR(DMSO-d6)δ:3.83 (3H,s) ,7.13 (2H, d, J=9.2Hz) , 7.39 (IH, d, J=
9.5Hz) ,8.03 (2H,d, J=8.8Hz) ,8.24(lH,s),8.28 ( IH, d, J=9.5Hz) .
MS:260 (M+H)+. Preparation 31
3- (3-Bromophenyl) -6-chloroimidazo [ 1, 2-b] pyridazine .
1H-NMR(DMSO-d6)δ:7.48 ( IH, d, J=9.5Hz) ,7.53 ( IH, d, J=8. IHz) ,7.60
-7.65 ( IH, m) ,8.12-8.17 (lH,m) ,8.33 ( IH, d, J=9.5Hz) ,8.34-8.37 (IH
,m) ,8.43 (IH, s) . MS:308 (M+H)+.
The following compounds were obtained in a similar manner to that of Example 122.
Preparation 32
5-Methoxy-2-adamantanamine . MS.-182 (M+H)+.
Preparation 33
4-Methoxy-l-adamantanamine .
MS: 182 (M+H)+.
Preparation 34 4-Fluoro-l-adamantanamine . MS:170 (M+H)+. Preparation 35
To a mixture of benzyl 4-amino-l-adamantanol (1.0 g) and benzyl chloridocarbonate (1.02 g) in tetrahydrofuran (10 ml) were added IM NaOH aqueous solution (5.98 mL) at O0C. The reaction mixture was stirred for 3 hours at 0°C. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was quenched with saturated KHSO4 aqueous solution. The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (98:2 to 90:10) to give benzyl ( 5-hydroxyadamantan-2- yl) carbamate (1.502 g) . MS:324 (M+Na)+.
The following compound was obtained in a similar manner to that of Preparation 35
Preparation 36
Benzyl (4-hydroxyadamantan-l-yl) carbamate. MS: 324 (M-I-Na)+. Preparation 37
To a solution of 4-bromo-6-chloro-3-pyridazinamine (500.0 mg) in methanol (10.0 ml), sodium methoxide (518.4 mg) was added at O0C. The reaction mixture was stirred at 25°C for 5 hours. After all starting material had been consumed, as judged by TLC plate, the resulting solution was concentrated in vacuo. The residue was poured into water (2OmL) . The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (98 : 2 to 90:10) to give 6-chloro~4-methoxy-3-pyridazinamine (286.7 mg) . MS:182 (M+Na)+. Preparation 38
To a solution of 6-chloro-4-methoxy-3-pyridazinamine (800.0 mg) in water (8.0 ml), chloroacetaldehyde (1.64 ml) was added at ambient temperature . The reaction mixture was stirred at 900C for 15 hours. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was cooled to ambient temperature and neutralized with NaHCO3 aqueous solution. The resulting precipitates were collected by filtration and washed with diisopropyl ether to give 6-chloro-8-methoxyimidazo [1, 2-b] pyridazine (702.3 mg) . MS:184 (MH-H) + .
Preparation 39
To a stirred mixture of tert-butyl (trans-4-hydroxycyclohexyl) carbamate (1 g) and triphenylphosphine (7.31 g) in tetrahydrofuran (25 ml) were added dropwise 2,2,2- trifluoroethanol (4.98 mL) and diethylazodicarboxylate (4.39 mL) at 00C. After stirring at ambient temperature for 96 hours, the reaction mixture was evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with ethyl acetate/n-hexane (5:1) to give tert-butyl [cis-4- (2, 2, 2- trifluoroethoxy) cyclohexyl] carbamate (54 mg) .
MS-.320 (M+Na)+.
The following compounds were obtained in a similar manner to that of Preparation 39.
Preparation 40 tert-Butyl (cis-4-p'henoxycyclohexyl) carbamate.
MS: 314 (M+Na)+.
Preparation 41 tert-Butyl [cis-4- (phenoxymethyl) cyclohexyl] carbamate.
MS:328 (M+Na)+. The following compound was obtained in a similar manner to that of Example 276.
Preparation 42
4-Bromo-6-chloro-3-pyridazinamine.
MS :232 (M+Na) + : Preparation 43
To a stirred mixture of benzyl (5-hydroxyadamantan-2-yl)
Figure imgf000044_0001
carbamate (2'.Og) and trimthyloxonium tetrafluoroborate (1.963 g) in dichloromethane (20 ml) were added 2, 6-di-tert-butyl-4- methylpyridine (3.407 g) at ambient temperature. The reaction mixture was refluxed for 3 hours. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was cooled to ambient temperature. After cooling, the solvent and reagent were evaporated. Resultings were triturated by ethyl acetate to remove white powder. The filtration was diluted with ethyl acetate/water (50mL/50mL) . The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with n-hexane/ethyl acetate
I (95:5 to 70:30) to give benzyl (5-methoxyadamantan-2-yl) carbamate (1.04 g) .
MS:338 (M+Na)+.
The following compound was obtained in a similar manner to that of Preparation 43. Preparation 44
Benzyl (4-methoxyadamantan-l-yl) carbamate.
MS:338 (M+Na)+.
Preparation 45
To a suspension of 60% NaH (122 mg) in N, N-dimethylformamide (3 mL) was added 2- (trans-4-hydroxycyclohexyl) -lH-isoindole-
1, 3 (2H) -dione (500 mg) at 0 0C. After stirring at ambient temperature for 0.5 hour, bromoethyl methylether was added to this reaction mixture at 00C. The reaction mixture was stirred at ambient temperature for 3 hours. The reaction mixture was poured into saturated NH4Cl aq. and extracted with ethyl acetate three times. The combined extracts were washed with water and brine, dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate/n-hexane (1:1) to give 2- [trans-4- (2-methoxyethoxy) cyclohexyl] -lH-isoindole- l,3(2H)-dione (130 mg) .
MS:32β (M+Na)+.
The following compounds were obtained in a similar manner to that of Preparation 45. Preparation 46 tert-Butyl{ [trans-4- (1, 3-dioxo-l, 3-dihydro-2H-isoindol-2- yl) cyclohexyl] oxy } acetate .
MS:382 (M+Na)+.
The following compounds were obtained in a similar manner to that of Example 140.
Preparation 47
Benzyl (4-fluoroadamantan-1-yl) carbamate.
MS:32β (M+Na)+.
Preparation 48 tert-Butyl (trans-4-fluorocyclohexyl) carbamate .
MS:240 (M+Na)+.
Preparation 49
To the slution of { [trans-4- (1, 3-dioxo-l, 3-dihydro-2H- isoindol-2-yl) cyclohexyl] oxy }acetic acid (303 mg) in dichloromethane (3 mL) was added oxallylchloride (0.174 mL) at ambient temperature. To the solution was added a few portion of N, N-dimethylformamide . After stirring at ambient temperature for 45 minutes. Then, the solution was concentrated. Resulting residue was dissolved to tetrahydrofuran (5 ml) , and the solution was added dropwise to the solution of
N-methylmethanamine (2M in methanol, 1 mL) in tetrahydrofuran (2 ml) at 00C. The mixture was stirred for 2hours at this temperature. To the mixture was added water and was extracted with ethyl acetate. The combined organics were dried over magnesium sulfate, and concentrated to give 2-{ [trans-4- (1, 3-dioxo-1, 3-dihydro-2H-isoindol-2-yl) cyclohexyl] oxy } - N, N-dimethylacetamide . MS-.353 (M+Na)+. Preparation 50 A mixture of 6-chloro-3-nitroimidazo [1, 2-b] pyridazine (6 g) , [ (IS) -1-phenylethyl] amine (11.6 g) in dimethylsulfoxide (18 mL) was stirred at 800C for 14 hours. The reaction mixture was cooled to ambient temperature and diluted with water. The resulting solution was extracted with ethyl acetate three times. The combined extracts were washed with water and brine, dried over magnesium sulfate and concentrated under reduced pressure . The residue1 was purified by silica gel column chromatography eluting with ethyl acetate/n-hexane (2:1) to give 3-nitro-N- [ (IS) -1-phenylethyl] imidazo [1, 2-b] pyridazin-β-amine (7.6 g) . MS:306(M+Na)\ Preparation 51
To a stirred solustion of 2- [trans-4- (2-methoxyethoxy) cyclohexyl] -lH-isoindole-1, 3 (2H) -dione (110 mg) in tetrahydrofuran/ethanol (2 mL/2 mL) was added hydrazine hydrate (0.07 mL) at ambient temperature. After stirring for 4.5 hours under reflux, the reaction mixture was poured into IM NaOH aqueous solution and extracted with chloroform/methanol (9:1) . The organic layer was dried over magnesium sulfate, and concentrated under reduced pressure . 4M HCl in 1, 4-dioxane (453 μl) was added to the solution of this residue in methanol (5 ml) under stirring at 00C. After stirring at ambient temperature for 1 hour, the reaction mixture was evaporated in vacuo to give trans-4- (2-methoxyethoxy) cyclohexanamine hydrochloride. MS:174 (Mfree+H)+. Preparation 52
To a stirred solustion of 2-{ [trans-4- (1, 3-dioxo-l, 3-dihydro- 2H-isoindol-2-yl) cyclohexyl] oxy} -N, N-dimethylacetamide (180 mg) in tetrahydrofuran/ethanol (3mL/3mL) was added hydrazine hydrate (0.106 mL) at ambient temperature. After stirring for 4.5 hours under reflux, the reaction mixture was poured into IM NaOH aqueous solution and extracted with chloroform/methanol (8:1) . The organic layer was dried over magnesium sulfate, and concentrated under reduced pressure to give 2-[(trans-4- aminocyclohexyl) oxy] -N, N-dimethylacetamide. MS:201 (M+H)+. Preparation 53
To a stirred solution of 3-nitro-N- [ (IS) -1-phenylethyl] imidazo [ 1, 2-b] pyridazin-β-amine (567 mg) in ethanol (30 ml) were added FeC-I3 (32.4 mg) , activated carbon (280 mg) and hydrazine hydrate (0.388 ml) at 800C. The reaction mixture was stirred at this temperature for 2 hours. After filtration, the reaction mixture was evaporated in vacuo. The residue was purified by silica' gel column chromatography eluting with chloroform/methanol (9:1) to give N-β- [( IS) -1-phenylethyl] imidazo [1, 2-b] pyridazine-3, 6-diamine (450 mg) .
MS:254 (M+H)+.
The following compounds were obtained in a similar manner to that of Example 223.
Preparation 54 cis-4-Phenoxycyclohexanamine hydrochloride.
MS:192 (Mfree+H)+.
Preparation 55 cis-4- (Phenoxymethyl) cyclohexanamine hydrochloride.
MS:206(Mfree+H)+. Preparation 56 cis-4-(2,2,2-Trifluoroethoxy) cyclohexanamine hydrochloride .
MS:198 (Mfree+H)+.
Preparation 57 trans-4-Fluorocyclohexanamine hydrochloride . MS.118 (Mfree+H)+. Preparation 58
{ [trans-4- (1, 3-Dioxo-l, 3-dihydro-2H-isoindol-2-yl) cyclohexyl] oxy} acetic acid.
MS:32β(M+Na)+. The following compound was obtained in a similar manner to that of Preparation 21.
Example 1
N- (trans-4-Methoxycyclohexyl) -3- (4-pyridinyl) pyrazolo [1,5- a] pyrimidin-5-amine . 1H-NMR (DMSO-d6) δ: 1.25-1.40 (4H,m) , 1.75-2.00 (4H,m) ,3.00-3.17 (
IH, m) ,3.22 (3H, s) , 3.79-3.96 (IH, m) ,6.31 (lH,d, J=7.6Hz) ,7.40-7.
50 (lH,m) ,7.70-7.85 (3H,m) ,8.40-8.57 (3H,m) .
MS:324 (M+H)+.
Example 2 To a solution of trans-4- [ (3-aminoimidazo [ 1, 2-b] pyridazin- β-yl) amino] cyclohexanol (30 mg) in pyridine (1.OmL) was added
N, O-bis ( trimethylsilyl) acetamide (30 μL), which was stirred at ambient temperature for 10 minutes. To the mixture was added isonicotinoyl chloride hydrochloride (23.8 mg) at 00C, which was stirred at ambient temperature for 24 hours. To the resultant was added water. The mixture was extracted with dichloromethane. The organic layer was washed with brine, dried over sodium sulfate, filtered, and evaporated in vacuo. The residure was purified by preparative TLC to give N-{6-[ (trans- 4-hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl } isonicotinamide (14 mg) as a yellow powder. MS:353(M+H)+. Example 3
To a solution of N- [2-methyl-5- (tetrahydro-2H-pyran-2- yloxy) phenyl] -3- ( 4-pyridinyl) imidazo [l,2~b]pyridazin-6- amine (70 mg) in methanol (1 mL) was added catalytic amount of pyridinium p-toluenesulfonate (=PPTS,8.76 mg) at ambient temperature. The resulting mixture was stirred at 500C for 1 hour. Quenching the reaction with saturated sodium hydrogen carbonate and concentrated in vacuo . The residue was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, and concentrated in vacuo . The residue was purified by silica gel column chromatography eluting with chloroform/methanol (50:1 to 20:1) to give 4-methyl-3-{ [ 3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino}phenol (27.6 mg) .
1H-NMR (DMSOd6) δ: 2.16 (3H, s) , 6.57 (IH, dd, J=2.5, 8.0Hz) ,7.08 (IH ,dd, J=2.5, 8.0Hz) , 7.09 (IH, d, J=IO . OHz) ,7.17 (IH, d, J=2. OHz) ,7.9 7 (IH, d, J=IO. OHz) ,8.11 (2H, d, J=6. OHz) , 8.25 ( IH, s) , 8.50 (2H, d, J= 6.0Hz) ,8.63 (lH,bs) , 9.28 (lH,bs) . MS:318 (M+H)+.
The following compounds were obtained in a similar manner to that of Example 3. Example 4 4-Chloro-3-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino }phenol .
MS:338 (M+H)+.
Example 5
4-Methyl-3-{ [8-methyl-3- ( 4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino}phenol .
1H-NMR(DMSO-d6)δ:2.08 (3H, s) , 2.42 (3H, s) , 6.67 ( IH, dd) , 6.87 ( IH, d) ,7.14 (IH, d) ,7.85 (IH, s) ,7.92 (2H,d) ,8.02 (IH, s) ,8.18 (IH, s) ,8
.36(2H,d) ,9.27 (IH, s) .
MS:332 (M+Na)+. Example 6
CF3CO2H (35 μL) was added to a solution of tert-butyl trans-4-{ [3- (4-pyridinyl-) imidazo [1, 2-b] pyridazin-6-yl] amino
} cyclohexanecarboxylate (9 mg) in dichloromethane (1 ml).
After stirring at ambient temperature for overnight, the reaction mixture was evaporated in vacuo to give trans-4-{ [3-(4- pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanecarboxylic acid bis (trifluoroacetate) (9 mg) .
1H-NMR (DMSO-d6) : 1.17-2.35 ( 8H, m) , 3.52-3.75 (2H, m) , 6.96 ( IH, d, J =9.8Hz) ,7.47 ( IH, d, J=6. IHz) ,7.93 ( IH, d, J=9.8Hz) , 8.60 ( IH, s) , 8.
70 (2H,d, J=6.3Hz) ,8.87 (2H, d, J=6.3Hz) .
MS:338 (Mfree+H) +.
Example 7
A mixture of 6-chloro-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine (80 mg) and (3-pyridinylmethyl) amine (375.1 mg) were subjected to microwave irradiation at 1800C for 1 hour. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (1OmL: 1OmL). The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (40:1 to 20:1) to give 3- (4-pyridinyl) -N- (3-pyridinylmethyl) imidazo [ 1, 2-b] pyridazin-6-amine (56.3 mg) .
1H-NMR(DMSO-d6)δ:4.57 (2H, d, J=5.4Hz) ,6.88 ( IH, d, J=9.7Hz) ,7.39 (IH, dd, J=4.8,7.7Hz) , 7.80-7.94 (2H,m) , 7.86 (IH, d, J=9.7Hz) ,7.95 (2H,d, J=6.3Hz) ,8.14(lH,s),8.47 (IH, d, J=3.5Hz) ,8.53 (2H,d, J=6. 3Hz) ,8.67 (IH, s) . MS:303 (M+H)+.
The following compounds were obtained in a similar manner to that of Example 7. Example 8 (±) -N- [3- (4-Pyridinyl) imidazo [1 , 2-b] pyridazin-6-yl] -1 , 2- cyclohexanediamine . MS:309(M+H)+. Example 9 N- (2-Fluorobenzyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin- 6-amine. 1H-NMR(DMSO-Cl6) δ:4.58 (2H,d, J=5.6Hz) ,6.89 (lH,d, J=9.6Hz) ,7.14 -7.18 (IH, m) ,7.27-7.34 (2H,m) ,7.44-7.49 (IH, m) ,7.84-7.87 (2H,m) ,7.96-7.98 (2H,m) ,8.13 (IH, s) ,8.50-8.52 (2H,m) . MS:320 (M+H)+. Example 10
3- ( { [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } methyl ) phenol .
1H-NMR (DMSO-d6) δ:4.44 (2H,d, J=5.6Hz) ,6.63-6.66 (IH, m) ,6.83-6. 89(3H,m) ,7.16(lH,t, J=7.8Hz) ,7.78-7.82 (lH,m) ,7.83 (lH,d, J=9.6 Hz),7.98-8.00(2H,m),8.13(lH,s) ,8.52-8.54 (2H,m) , 9.33(lH,brs)
MS:318 (M+H)+. Example 11
2- ( { [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} methyl) phenol.
1H-NMR (DMSO-d6) δ:4.47 (2H, d, J=5.4Hz) , 6.72-6.77 ( IH, m), 6.89 (IH
, d, J=9.6Hz) , 6.90-6.92 (lH,m) ,7.05-7.09 ( IH, m) , 7.24-7.26 ( IH, m)
,7.60-6.63 (IH, m) ,7.82 ( IH, d, J=9.6Hz) ,8.04-8.06(2H,m),8.13(lH
,s) ,8.52-8.54 (2H,m) ,9.62 (lH,brs) . MS:318 (M+H)+.
Example 12
(lS,2R,4R)-4-{ [3- (4-Pyridinyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino }-l, 2-cyclohexanediol .
1H-NMR (DMSO-de) 5:1.40-2.08 (6H,m) ,3.55-3.81 (3H,m) , 4.29 (IH, d, J=2.6Hz) , 4.59(lH,d, J=5.5Hz) , 6.75 ( IH, d, J=9.8Hz) ,7.14 (lH,d, J= 7.0Hz) ,7.79 (IH, d, J=9.8Hz) ,8.16(lH,s) ,8.21 (2H,'d, J=6.3Hz) ,8.6 0 (2H,d, J=6.3Hz) . MS:32β(M+H)+. Example 13 (lR,2S,4R)-4-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} -1, 2-cyclohexanediol .
1H-NMR(DMSO-Ci6) δ : 1.25-1.46 (2H,m) ,1.56-1.85 (2H,m) , 1.91-2.12 ( IH, m) , 2.16-2.36 ( IH, m) ,3.48-3.62 (IH, m) ,3.80-3.92 (lH,m) ,3.95- 4.18 (lH,m) ,4.48 (lH,d, J=2.6Hz) , 4.49 ( IH, d, J=5.5Hz) , 6.75 (IH, d, J=9.7Hz) ,7.03 (lH,d, J=6.8Hz) ,7.78 (IH, d, J=9.7Hz) ,8.18(lH,s),8
.29 (2H,d, J=6.2Hz) , 8.59 (2H, d, J=6.2Hz) .
MS:326 (M+H)+.
Example 14
(2S) -2-Phenyl-2-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6- yl] amino}ethanol .
MS:332 (M+H)+.
Example 15
(2R) -2-Phenyl-2-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6- yl] amino }ethanol. 1H-NMR (DMSO-de) 5:3.60-3.80 (2H,m) ,4.82 (IH, dd, J=7.3, 13.4Hz) ,5
.07 (lH,dd, J=5.7,5._7Hz) ,7.01 ( IH, d, J=9.6Hz) , 7.18-7.51 ( 5H,m) , 7
.77 (lH,d, J=6.0Hz) ,7.82 (IH, d, J=9.6Hz) , 7.85 (2H, d, J=6. IHz) ,8.0
9 (IH, s) ,8.52 (2H,d, J=6.1Hz) .
MS:332 (M+H)+. Example 16 To a solution of 6-chloro-3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazine (653 mg) and tetrahydro-2H-pyran-4-amine (859.1 mg) in toluene (56.8 mL) was added tris (dibenzylidenacetone) dipalladium chloroform complex (=Pd2dba3'CHCl3, 87.9 mg) , 2,2' -Bis (diphenylphosphino) -I11' -binaphthyl (=BINAP, 158.7 mg) and sodium tert-butoxide (1.22 g) . The mixture was stirred at 1100C for 1.5 hours under nitrogen atmosphere. The resultant was poured into a mixt re of water and dichloromethane, and acidified with 1 MHCl aqueous solution (pH 3) . The aqueous phase was separated, adjusted to pH 8.5 by IM NaOH aqueous solution, and extracted with dichloromethane. The organic phase was separated, washed with brine, and dried over sodium sulfate. Evaporation of the solvent gave a residue, which was purified by column chromatography on silica gel to give 3- (4-pyridinyl) - N- (tetrahydro-2H-pyran-4-yl) imidazo [1, 2-b] pyridazin-6- amine (710 mg) as a yellow powder.
1H-NMR (DMSO-d6)δ: 1.52 (2H, ddd, J=23.6, 11.0,4.0Hz) ,2.01 (2H,d, J =10.5Hz) ,3.52 (2H,dt,J=2.0,11.3Hz) ,3.81-4.02 (3H,m) ,6.78 (IH, d , J=9.7Hz) ,7.24 (IH, d, J=6.6Hz) ,7.83 ( IH, d, J=9.7Hz) , 8.17 (IH, s) , 8.19 (2H,d, J=6.2Hz) .
The following compounds were obtained in a similar manner to that of Example 16.
Example 17
3- (4-Pyridinyl) -N- (tetrahydro-2-furanylmethyl) imidazo [1,2- b]pyridazin-6-amine. 1H-NMR(CDCI3-CD3ODO:!) ) 5:1.63-1.81 (lH,m) , 1.91-2.18 (3H,m) , 3.
32-3.44 (lH,m) ,3.61-3.71 ( IH, m) , 3.79-3.99 (2H,m) , 4.18-4.32 (IH, m) , 5.71-5.80 (lH,m) , 6.69 ( IH, d, J=9.5Hz) ,7.68 ( IH, d, J=9.5Hz) ,7.
94 (IH, s) , 8.11 (2H,d,J=6.6Hz) , 8.59 (2H, d, J=6.2Hz) . MS:296(M+H)+.
Example 18
N- (cis-4-Methoxycyclohexyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
1H-NMR (DMSO-d6) δ : 1.53-1.92 ( 8H, m) , 3.25 ( 3H, s ) , 3.34-3.42 ( IH, m) , 3.70-3.83 ( IH, m) , 6.79 ( IH, d, J=9.7Hz) ,7.12 ( IH, d, J=6.7Hz) ,7.8 (
IH, d, J=9.7Hz) ,8.16(lH,s),8.2 (2H,dd, J=I.6Hz, 4.6Hz) ,8.6(2H,dd
,J=I.6Hz, 4.6Hz) .
MS:324 (M+H)+.
Example 19 3-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino}-l- adamantanol .
1H-NMR (DMSO-d6) δ:1.42-1.74 (6H,m) ,1.91-2.34 ( 6H,m) , 2.17-2.34 (
2H,m) ,4.62 (IH, s) , 6.79 (IH, d, J=9.8Hz) , 6.87 (IH, s) , 7.77 ( IH, d, J=
9.8Hz) ,8.13(lH,s),8.18 (2H, d, J=6. IHz) ,8.60 (2H, d, J=6. IHz) . MS:362 (M+H)+.
Example 20
N- (4, 4-Difluorocyclohexyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
MS:330 (M+H) + . Example 21 trans-4-{ [3- (2-Chlorophenyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanol .
1H-NMR(CDCl3)OrLIe-I^S (4H,m) ,1-96-2.07 (2H,m) , 2.14-2.24 (2H
,m) ,3.51-3.78 (2H,m) ,4.12 ( IH, d, J=6.6Hz) , 6.42 ( IH, d, J=9.5Hz) , 7 .31-7.39(2H,m) , 7.51-7.55 ( IH, m) , 7.69 (IH, d, J=9.5Hz) ,7.76-7.83
(IH, m) ,7.80 (IH, s) .
MS:343 (M+H)+.
Example 22
(lS,2R)-2-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanol .
1H-NMR (DMSO-d6)δ: 1.29-1.48 (2H,m) ,1.52-1.84 (6H,m) ,3.72-3.86 (
IH, m) , 4.03-4.11 ( IH, m) , 4.70 (IH, d, J=4. OHz) , 6.94 ( IH, d, J=9.9Hz)
,6.95 (lH,d, J=7.0Hz) ,7.78 (IH, d, J=9.5Hz) ,8.19 (2H,d, J=6.6Hz) ,8
.60 (2H,d, J=6.2Hz) . MS:310(M+H)+ .
Example 23
3- (3-Bromophenyl) -N- (2-thienylmethyl) imidazo [1, 2-b] pyridazin-6-amine .
1H-NMR(CDCl3)O^-SO (2H,s) , 6.5 (IH, d, J=9.5Hz) ,6.99 (lH,dd, J=I. 8,3.3Hz) ,7.09-7.12 ( IH, m) ,7.24 (IH, dd, J=I .1, 5. IHz) ,7.31 (IH, t,
J=7.7Hz) ,7.42-7.47 ( IH, m) ,7.72 ( IH, d, J=9.5Hz) ,7.84 (lH,brs) ,7.
94-8.00 (IH, m) , 8.35-8.38 (lH,m) .
MS:385 (M+H)+.
Example 24 N, N-Dimethyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine 1H-NMR (CDCl3-CD3OD (95: 5) )δ:3.20 (6H,s) ,6.87 (IH, d, J=9.9Hz) ,7.7
8 (lH,d, J=9.9Hz) , 8.02 (IH, s) , 8.10 (2H, d, J=5.9Hz) , 8.66 (2H, brs) .
MS:240 (M+H)+. Example 25
N- (2-Methoxyethyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-
6-amine .
1H-NMR (CDCl3-CD3OD (9:1) ) δ : 3.44 ( 3H, s) , 3.60-3.66 (2H,m) ,3.68-3.
74 (2H,m) , 6.68 (IH, d, J=9.9Hz) ,7.68 (IH, d, J=9.9Hz) , 7.95 ( IH, s) , 8 .11 (2H,d, J=6.2Hz) ,8.59 (2H, d, J=6.2Hz) .
MS:270 (M+H)+.
Example 26
3- (4-Pyridinyl) -N- (2-thienylmethyl) imidazo [1, 2-b] pyridazin-
6-amine. ' 1H-NMR (CDCl3-CD3OD (9:1) ) δ : 4.79 (2H, d, J=O .73Hz) , 6.69 (IH, d, J=9.
5Hz) , 6.98-7.03 ( IH, m) , 7.08-7.11 (lH,m) ,7.23-7.27 ( IH, m) , 7.70 (1
H,d, J=9.9Hz) ,7.94 (IH, s) ,8.04 (2H, d, J=6.2Hz) ,8.56 (2H,d, J=6.2H
z) •
MS:308 (M+H)+. Example 27
(cis-4-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexyl ) methanol .
1H-NMR (DMSO-d6) 5:1.00-1.48 (5H,m) , 1.78-1.90 (2H,m) ,2.14-2.26 (
2H,m) ,3.28 (2H, d, J=6. OHz) , 3.51-3.69 ( IH, m) ,4.45 (IH, t, J=6. OHz) , 6.75 (IH, d, J=9.5Hz) , 7-.13 (IH, d, J=6.5Hz) , 7.79 (IH, d, J= 9.5Hz) , 8 .16 (IH, s) , 8.21 (2H,d, J=β.0Hz) ,8.6 (2H, d, J=6. OHz) .
MS:324 (M+H)+.
Example 28
N- [ (IR, 2R) -2- (Benzyloxy) cyclohexyl] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
1H-NMR (DMSO-d6) 5:1.21-1.58 (4H,m) , 1.62-1.86 (2H,m) ,1.97-2.26 (
2H,m) ,3.38-3.64 (IH, m) , 3.75-3.98 ( IH, m) ,4.52 (IH, d, J=Il .5Hz) , 4
.62 (IH, d, J=Il.5Hz) ,6.86(lH,d, J=9.8Hz) , 7.10-7.29 ( 6H,m) ,7.80 (
IH, d, J=9.5Hz) ,8.14 (IH, s) ,8.19(2H,dd, J=I.5, 5. OHz) ,8.56(2H,dd ,J=I.5, 4.5Hz-) .
MS: 400 (M+H)+, 422 (M+Na)+.
Example 29
N- (3-Methoxy-l-adamantyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amirie . 1H-NMR (DMSO-d6)δ: 1.56-1.75 (6H,m) , 1.97-2.18 ( 6H,m) , 2.26-2.35 (
2H,m) ,3.13 (3H,s) , 6.8 (IH, d, J=9.8Hz) ,6.93(lH,s),7.78 (lH,d, J=9
.8Hz) ,8.13 (IH, s) ,8.17 (2H, d, J=6.2Hz) , 8.6 (2H, d, J=6.2Hz) .
MS:376 (M+H)+.
Example 30 N- (cis-4-Fluorocyclohexyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine.
1H-NMR (DMSO-de) δ : 1.49-2.09 (8H,m) , 3.64-3.86 ( IH, m) , 4.73 (0.5H, br) ,4.97 (0.5H,br) , 6.55 (0.5H,s) , 6.79 (IH, d, J=IO . OHz) ,7.19 (IH, d, J=.7.0Hz) ,7.81 (IH, d, J=9.5Hz) ,8.17 (0.5H,s) ,8.2 (2H, d, J=6. OHz ) ,8.6(2H,d, J=6.0Hz) . ' MS:312 (M+H) + . '
Example 31.
N- [trans-4- (Methoxymethyl) cyclohexyl] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine . 1H-NMR(DMSO^6)0: 1.02-1.35 (4H,m) , 1.53-1.66 (lH,m) ,1.77-1.91 (
2H,m) ,2.14-2.27 (2H,m) ,3.21 (2H,d, J=6.3Hz) , 3.26(3H,s) ,3.51-3.
67 (IH, m) , 6.75 ( IH, d, J=9.5Hz) ,7.13 ( IH, d, J=7. OHz) , 7.79 (IH, d, J=
9.5Hz) ,8.16(lH,s),8.2 (2H, dd, J=I .5Hz, 4.5Hz) , 8.6 (2H, dd, J=I .5H z, 4.5Hz) . MS:338 (M+H)+.
Example 32 trans-4- { [3- (4-Phenoxyphenyl) imidazo [l,2-b]pyridazin-6-yl] amino } cyclohexanol .
1H-NMR (CDCl3) δ: 1.21-1.67 (4H,m) ,2.00-2.12 (2H,m) ,2.22-2.34 (2H ,m) ,3.63-3.81 (2H,m) , 4.19 ( IH, d, J=7.3Hz) , 6.40 ( IH, d, J=9.5Hz) , 7
.05-7.17 (3H,m) ,7.11 (2H, d, J=8.8Hz) ,7.33-7.41 (2H,m) , 7.68 (IH, d
, J=9.9Hz) ,7.77(lH,s),8.07 (2H, d, J=9.2Hz) .
MS.401.2 (M+H)+.
Example 33 trans-4- ( {3- [4- (Trifluoromethoxy) phenyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol .
1H-NMR (CDCl3-CD3OD (9:1) ) 5:1.22-1.55 (4H,m) , 1.99-2.13 (2H,m) ,2.
20-2.32 (2H,m) ,3.59-3.77 (2H,m) , 6.54 ( IH, d, J=9.2Hz) ,7.30 (2H,d,
J=9..5Hz) ,7.62 (IH, d, J=9.5Hz) ,7.73(lH,.s) , 8.15 (2H, d, J=8.8Hz) . MS:393 (M+H) + .. Example 34 trans-4-{ [3- (4-Methoxyphenyl) imidazo [1, 2-b] pyridazin-β-yl] amino } cyclohexanol .
1H-NMR (CDCl3-CD3OD (9:1) ) δ : 1.23-1.39 (2H, m) , 1.39-1.56 (2H,m) , 1. 99-2.12 (2H,m) ,2.20-2.32 (2H,m) , 3.60-3.77 (2H,m) , 3.87 (3H, s) , 6.
49(lH,d, J=9.5Hz) , 7.00 (2H, d, J=8.8Hz) ,7.58 ( IH, d, J=9.5Hz) ,7.64
(IH, s) ,8.03 (2H,d, J=9.2Hz) .
MS:339 (M+H)+.
Example 35 3- (4-Pyridinyl) -N- (3,4, 5-trimethoxyphenyl) imidazo [1, 2-b] pyridazin-6-amine .
1H-NMR(CDCI3)OIS-SI (6H,S),3.88(3H,S) ,6.48 (lH,brs) , 6.74 (2H,s
) ,6.77 (lH,d, J=9.9Hz) ,6.85 ( IH, d, J=9.5Hz) ,8.02 (2H, d, J=5.5Hz) ,
8.03 (IH, s) , 8.66(2H,d, J=6.6Hz) . MS:378 (M+H)+.
Example 36
N- (2-Chlorophenyl) -3- ( 4-pyridinyl) imidazo [ 1, 2-b] pyridazin- 6-amine .
1H-NMR(CDCl3)O: 6.84 (lH,d, J=9.5Hz) , 6.92 (lH,brs) ,7.05-7.13 (IH ,m) ,7.31-7.38 (lH,m) , 7.45-7.50 (lH,m) , 7.91 (IH, d,-J=9.5Hz) ,8.00
(2H,d, J=6.2Hz) , 8.05 (IH, s ) ,8.26-8.32 ( IH, m) ,8.69 (2H, d, J=6.2Hz
) •
MS:322 (M+H)+. Example 37 N- (4-Phenoxyphenyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin- 6-amine .
1H-NMR(CDCI3-CD3ODO:!) )δ:6.91 (IH, d, J=9.5Hz) , 7.01-7.16 (5H, m)
,7.62 (2H,d, J=9.1Hz) ,7.78 ( IH, d, J=9.5Hz) ,7.96(lH,s),8.08(2H,d
, J=6.2Hz) ,8.57 (2H,d, J=6.2Hz) ,7.33-7.41 (2H,m) . MS:380 (M+H)+.
Example 38 trans-4-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanol .
1H-NMR(CDCI3-CD3ODO:!) ) δ : 1.24-1.58 (4H,m) ,2.03-2.14 (2H,m) ,2. 22-2.34 (2H,m) ,3.61-3.79 (2H,m) , 6.62 ( IH, d, J=9.9Hz) ,7.64 (IH, d,
J=9.5Hz) ,7.94 (IH, s) ,8.14 (2H, d, J=6.2Hz) ,8.58 (2H, d, J=5. IHz) .
MS:310 (M+H)+.
Example 39
(trans-4-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexyl) formamide .
1H-NMR(DMSO-d6)δ:1.26-1.48 (4H, m), 1.81-1.98 (2H,m) ,2.09-2.24 (
2H,m) ,3.53-3.80(2H,m) , 6.76 ( IH, d, J=9.5Hz) ,7.18 (IH, d, J=6.5Hz)
,7.8 (lH,d, J=8.1Hz) , 7.98-8.09 (2H,m) ,8.16(lH,s) , 8.21 (2H, d, J=6
.0Hz) ,8.60 (2H,d, J=6.0Hz) . MS:337 (M+H)+.
Example 40
(trans-4~{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexyl) methanol .
1H-NMR (DMSO-de)δ: 1.31-1.91 (9H,m) ,3.23-3.42 (2H,m) ,3.90-4.02 ( IH, m) ,4.44 (IH, t, J=5.5Hz) ,6.88 (IH, d, J=9.5Hz) ,7.04 (lH,d, J=6.0 Hz) ,7.79(lH,d, J=9.5Hz) , 8.16(lH,s) , 8.20 (2H, d, J= 6. OHz) ,8.60 (2
H,d, J=β.0Hz) .
MS:324 (M+H)+.
Example 41 N- (trans-4-Ethoxycyclohexyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-β-amine .
1H-NMR (DMSO-d5) :1.12 (3H, t , J=7. OHz) , 1.24-1.48 (4H,m) , 1.95-2.2
3 (4H,m) ,3.21-3.38 (lH,m) , 3.49 (2H, q, J=7. OHz) ,3.57-3.74 (lH,m) ,
6.76 (IH, d, J=9.5Hz) ,7.12 (IH, d, J=6.5Hz) , 7.80 ( IH, d, J=9.5Hz) , 8. 16 ( IH, s), 8.20 (2H, d, J=I .5Hz, 4.5Hz) ,8.61 (2H, d, J=I .5Hz, 4.5Hz) .
MS:338 (M+H)+.
Example 42
N-[(lS,2S)-2- (Benzyloxy) cyclohexyl] -3- (4-pyridinyl) imidazo
[1, 2-b] pyridazin-β-amine . MS:400 (M+H)+.
Example 43
N- (trans-4-Methoxycyclohexyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
1H-NMR (DMSO-d6) 5:1.20-1.45 (4H,m) , 1.94-2.27 (4H,m) ,3.12-3.42 ( IH, m) ,3.27 (3H,s) ,3.51-3.74 (lH,m) , 6.76 ( IH, d, J=9.9Hz) ,7.14 (IH
, d, J=6.7Hz) ,7.80 (lH,d, J=9.9Hz) ,8.16(lH,s),8.20 (2H, dd, J=I .5H z, 4.9Hz) ,8.60 (2H,dd, J=I .5Hz, 4.9Hz) .
MS:324 (M+H)+.
Example 44 N-Cyclohexy1-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine 1H-NMR(DMSO-O6) δ : 1.16-1.51 ( 4H, m) , 1.59-1.71 ( IH, m) , 1.72-1.86 (
2H,m) ,2.03-2.16 (2H,m) , 3.57-3.73 (lH,m) , 6.78 (IH, d, J=9.9Hz) ,7.
12 (lH,d, J=7.0Hz) ,7.79(lH,d, J=9.9Hz) ,8.16(lH,s) ,8.21 (2H,d, J= 6.2Hz) ,8.60 (2H,d, J=6.2Hz) .
MS:294 (M+H)+.
Example 45 cis-4- { [3- (4-Pyridinyl) imidazo [l,2-b]pyridazin-6-yl] amino} cyclohexanol . 1H-NMR (DMSO-d6) δ : 1.54-1.84 (8H,m) , 3.67-3.80 (2H,m) , 4.49 (IH, d,
J=2.9Hz) ,6.82 (IH, d,J=9.5Hz) ,7.12 ( IH, d, J=7.3Hz) , 7.79 ( IH, d, J=
9.9Hz) ,8.16 (IH, s) ,8.20 (2H,d, J=6.2Hz) ,8.60(2H,d, J=5.9Hz) .
MS:310 (M+H)+.
Example 46 3- ( 4-Pyridinyl) -N- (2-pyridinylmethyl) imidazo [1, 2-b] pyridazin-6-amine .
1H-NMR(DMSOd6)O: 4.62 (IH, d, J=5.5Hz) ,6.95 (IH, d, J=9.5Hz) ,7.24
-7.31 ( IH, m) ,7.45 (IH, d,J=8. IHz) , 7.72-7.79 (lH,m) , 7.86 (IH, d, J=
9.5Hz) ,7.90 (2H,d, J=6.2Hz) ,7.97 (IH, t, J=6.2Hz) , 8.14 (IH, s) , 8.4 9(2H,d, J=6.2Hz) , 8.60-8.65 (lH,m) .
MS:303 (M+H)+.
Example 47
N-Phenyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
1H-NMR (DMSOd6) δ:7.04 (IH, d, J=9.9Hz) , 7.06 ( IH, t, J=8.4Hz) ,7.42 (2H,t, J=7.3Hz) ,7.72 (2H, d, J=7.3Hz) ,8.01 (IH, d, J=9.9Hz) ,8.15(2 H,d, J=6.2Hz) ,8.22 (IH, s) , 8.67 (2H, d, J=9.9Hz) , 9.56 (IH, s) .
MS:288 (M+H)+.
Example 48
N-Propyl-3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6-amine . 1H-NMR (DMSO-d6)δ: 1.00 (3H, t , J=7.3Hz) ,1.61-1.77 (2H,m) , 3.24-3.
39(2H,m) , 6.79 (IH, d, J=9.5Hz) ,7.24 ( IH, t , J=5.5Hz) , 7.80 (IH, d, J=
9.9Hz) ,8.17(lH,s),8.21 (2H, d, J=6.2Hz) ,8.61 (2H, d, J=6.2Hz) .
MS:254 (M+H)+.
Example 49 tert-Butyl trans-4- { [3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino} cyclohexanecarboxylate .
1H-NMR (DMSO-ds)δ: 1.25-1.56 (4H,m) , 1.42 (9H,s) ,1.92-2.05 (2H,m)
,2.12-2.29 (3H,m) , 3.53-3.71 (lH,m) , 6.76 (IH, d, J=9.5Hz) ,7.14 (IH
, d, J=7.0Hz) ,7.8 (IH, d, J=9.5Hz) ,8.16(lH,s),8.19 (2H, d, J=6.5Hz) ,8.59(2H,d, J=6.5Hz) .
MS:394 (M+H)+.
Example 50
N-Bicyclo [2.2.1] hept-2-yl-3- (4-pyridinyl) imidazo [1,2-b] pyridazin-6-amine . 1H-NMR (DMSO-d6) δ : 0.94-1.06 (IH, m) , 1.22-1.42 (3H,m) ,1.46-1.70 (
3H,m) ,2.04-2.18 (IH, m) ,2.20-2.30 ( IH, m) , 2.64-2.73 (lH,m) ,3.93-
4.07 (IH, m) , 6.85 (IH, d, J=9.5Hz) ,7.27 (IH, d, J=5.5Hz) ,7.80 (IH, d,
J=9.5Hz) ,8.15 (IH, s) ,8.21 (2H,d, J=6.2Hz) ,8.61 (2H, d, J=6.2Hz) .
MS:306(M+H)+. Example 51 N- [ (2R) -Bicyclo[2.2.1] hept-2-yl] -3- (4-pyridinyl) imidazo t 1, 2-b] pyridazin-6-amine .
1H-NMR ( DMSOd6) δ: 1.13-1.26 (2H,m) , 1.28-1.68 (5H,m) , 1.73-1.86 (
IH, m) ,2.25-2.33 (IH, m) ,2.41-2.47 (lH,m) , 3.53-3.63 (IH, m) , 6.76( IH, d, J=9.5Hz) ,7.13 (lH,d, J=5.9Hz) ,7.80 (IH, d, J=9.5Hz) ,8.18 (IH
,s) , 8.26 (2H,d, J=^6.2Hz) , 8.60 (2H, d, J=6.2Hz) .
MS:306(M+H)+.
Example 52
N- ( 5-Fluoro-2-methylphenyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine.
MS:320.(M+H) + .
Example 53
N-Methoxy-4-methyl-3-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} benzamide . ■ MS:375 (M+H)+.
Example 54 tert-Butyl 3-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } -1-piperidinecarboxylate .
1H-NMR (DMSO-d6) δ : 1.06-2.01 ( 14 H, m) ,1.39(3H,s),3.74 (2H,brs) , 6- .84 (lH,d, J=9.6Hz) ,7.13 (lH,d, J=6.6Hz) ,7.84 (IH, d, J=9.6Hz) ,8.1
7-8.21 (3H,m) ,8.58-8.61 (2H,m) .
MS: 395 (M+H)+,417 (M+Na)+.
Example 55
4-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino }-l- adamantanol. 1H-NMR(DMSO-Ci6)O': 1.35-1.45 (2H,m) , 1.65-2.07 (9H,m) ,2.26-2.33 (
2H,m) ,3.90 (IH, bs) ,4.51 (IH, s) ,6.96(lH,d) ,7.11 (IH, d) ,7.81 (IH, d) ,8.16(lH,s) ,8.19(2H,d) ,8.58 (2H,d) .
MS:362 (M+H)+. Example 56
4-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} -1- adamantanol.
, 1H-NMR (DMSO-d6) 6:1.38-2.18 (llH,m) , 2.35-2.42 (2H,m) ,3.81 (IH, b s),4.44(lH,s),6.96(lH,d),7.11(lH,d),7.80(lH,d),8.16(lH,s),8 .19(2H,d) ,8.58 (2H,d) .
MS:362 (M+H)+.
Example 57
3- (4-Pyridinyl) -N- (2, 3, 6-trifluorobenzyl) imidazo [1,2-b] pyridazin-6-amine . 1H-NMR(DMSO-d6)δ:4.66(2H,d) , 6.82 (IH, d) ,7.15-7.28 ( IH, m) ,7.38
-7.58 (IH, m) ,7.70-7.81 (lH,m) ,7.85 (lH,d) ,8.15 (2H,d) ,8.17 (IH, s
) ,8.61 (2H,d) .
MS:356(M+H)+.
Example 58 2-(3-{ [3- (4-Pyridinyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino} benzyl) -lH-isoindole-1, 3 (2H) -dione.
MS:447 (M+H)+.
Example 59
N- (5-Methoxyadamantan-2-yl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine. 1H-NMR(DMSO-Cl6) δ : 1.38-1.59 (2H, m) , 1.62-2.22 ( 9H,m) , 2.34-2.56 (
2H,m) ,3.16(3H,d) , 3.80-4.00 (lH,m) , 6.96 (IH, d) , 7.08-7.20 (lH,m)
,7.81 (lH,d) ,8.16(lH,s) ,8.19(2H,d) ,8.59(2H,d) .
MS:376 (M+H)+. Example 60
N- (4-Methoxyadamantan-l-yl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
1H-NMR (DMSOd6) 5:1.40-1.48 (2H,m) , 1.91-2.26 (llH,m) ,3.30 (3H,s
) ,3.41 (IH, s) ,6.79 (IH, d) ,6.84 (IH, s) ,7.77 (IH, d) ,8.12 (IH, s) ,8. 17 (2H,d) ,8.60 (2H,d) .
MS: 376 (M-I-H)+.
Example 61
N- (4-Fluoroadamantan-l-yl) -3- ( 4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine . 1H-NMR (CDCl3) δ: 0.82-2.63 (13H,m) ,4.61-4.85 ( IH, m) , 6.40-6.60 ( 1
H,m) ,7.74 (IH, dd) ,8.02-8.60 (4H,m) , 8.67 (2H, dd) .
MS:364 (M+H)+.
Example 62
8-Methyl-N-[ ( IS, 2R) -2-methylcyclohexyl] -3- (4-pyridinyl) imidazo [ 1 , 2-b] pyridazin-6-amine .
1H-NMR (DMSO-de) δ:0.92 (3H,d) ,1.19-1.98 (8H,m) , 2.28 (3H, s) , 2.39
-2.55(lH,m) , 3.95-4.13 (IH, m) , 5.77 ( IH, d) , 7.71 (IH, s) , 8.14 (IH, s
) ,8.19(2H,d) ,8.59(2H,d) .
MS:344 (M+Na)+. Example 63 8-Methyl-N- [2-methyl-5- (tetrahydro-2H-pyran-2-yloxy) phenyl] -3- (4-pyridinyl ) imidazo [1, 2-b] pyridazin-6-amine .
1H-NMR (DMSO-d6) δ:1.40-1.89(6H,m),2.14(3H,s),2.43(3H,s),
3.42-3.55 ( IH, m) , 3.67-3.83 (IH7-Ti) , 5.42 (IH, t) , 6.93 (IH, dd) , 7.16 (IH, d) ,7.26(lH,d) ,7.87 (IH, d) , 7.89(2H,d) ,8.07 (IH, s) ,8.19 (IH, s) ,8.36(2H,d) .
MS:416(M+Na)+.
Example 64
5-{ [8-Methyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } -2-adamantanol .
1H-NMR(CDCl3) 5:1.52-2.85 (13H,m) ,2.25(3H,s) , 3.91 (0.37H, t ) ,4.
05(0.63H,t) ,4.12 (0.63H,s) , 4.15 (0.37H, s) , 7.58 (IH, s) , 7.95 (0.6
3H, s) ,8.00 (0.37H,s) , 8.09 ( 1.26H, d) , 8.24 (0.74H, d) , 8.66 (2H, d) .
MS:376(M+H)+. Example 65 trans-4-{ [3- (2-Chloro-4-pyridinyl) -8-methylimidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanol .
1H-NMR (DMSO-d6) 5:1.35-1.51 (4H,m) , 1.86-1.97 (2H,m) ,2.03-2.21 (
2H,m) ,2.23 (3H, s) , 3.40-3.55 (IH, m) , 3.62-3.79 (IH, in) ,4.62 (IH, s) , 6.20 (IH, d) ,7.73 (IH, d) ,8.06 (IH, dd) ,8.25 (IH, s) ,8.39 (IH, d) ,8.
54 (IH, s) .
MS:358 (M+H)+.
Example 66 trans-4-{ [8-Methoxy-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin- 6-yl] amino} cyclohexanol . 1H-NMR(DMSO-Cl6) 5:1.20-1.82 (8H,m) , 2.10 ( IH, d) , 2.30 (lH,d) ,
3.59-3.66 ( IH, m) ,3.70-3.83 ( IH, m) , 4.03 (3H, s) , 5.79 ( IH, s) , 7.90 (
IH, s) ,8.06 (2H,d) ,8.64 (2H,d) .
MS:340(M+H)+. Example 67
N- (cis-4-Phenoxycyclohexyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
MS:386(M+H)+.
Example 68 N- [cis-4- (Phenoxymethyl) cyclohexyl] -3- (4-pyridinyl) imidazo
[1, 2-b] pyridazin-6-amine .
MS:400 (M+H)+.
Example 69
3- (4-Pyridinyl) -N- [cis-4- (2,2, 2-trifluoroethoxy) cyclohexyl] imidazo [1, 2-b] pyridazin-6-amine.
MS:392 (M+H)+.
Example 70
N- (4-Isopropoxycyclohexyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine . 1H-NMR (DMSO-d5) δ:1.09 ( 6H, d, J=6. OHz) , 1.57-1.85 (8H,m) ,3.55-3.
60 (lH,m) ,3.63-3.72 (lH,m) ,3.72-3.81 (lH,m) , 6.80 (IH, d, J=9.6Hz)
,7.12(lH,d, J=6.8Hz) , 7.79 ( IH, d, J=9.6Hz) , 8.16 (IH, s) , 8.19-8.21
(2H,m) ,8.59-8.61 (2H,m) .
MS:352 (M+H)+. Example 71 N- [trans-4- (Benzyloxy) cyclohexyl] -3- (4-pyridinyl) imidazo
[1, 2-b] pyridazin-β-amine .
MS:400 (M+H) + .
Example 72 N- (4-Methoxy-2-methylphenyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-β-amine .
MS:332 (M+H)+.
Example 73
N- [trans-4- (2-Methoxyethoxy) cyclohexyl] -3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6-amine .
1H-NMR (DMSO-d6) 5:1.23-1.45 (4H,m) ,2.01-2.22 (4H,m) , 3.27 (3H, s)
,3.31-3.48 (3H,m) ,3.53-3.72 (3H,m) , 6.76 (IH, d, J=9.6Hz) ,7.12 (IH
,d, J=6.4Hz) ,7.79 (IH, d, J=9.6Hz) , 8.16 ( IH, s) , 8.18-8.23 (2H,m) , 8
.59-8.63(2H,m) . MS:390 (M+Na)+.
Example 74
N-(I, l-Dioxidotetrahydro-2H-thiopyran-4-yl) -3- (4- pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
MS:3β6(M+Na)+. Example 75
N- [3-Methoxy-5- (trifluoromethyl) phenyl] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine.
MS:386(M+H)+.
Example 76 3- (4-Pyridinyl) -N- (1, 2, 3, 4-tetrahydro-l-naphthalenyl) imidazo [1, 2-b] pyridazin-β-amine .
MS:342 (M+H)+..
Example 77
3- (4-Pyridinyl) -N- [(1R,2S,4R)-1, 7 , 7-trimethylbicyclo [2.2.1] hept-2-yl] imidazo [1, 2-b] pyridazin-6-amine .
MS:348 (M+H)+.
Example 78
3-(4-Pyridinyl)-N-[ (1R,2R,4R) -1, 7 , 7-trimethylbicyclo [2.2.1] hept-2-yl] imidazo [1, 2-b] pyridazin-6-amine . MS:348 (M+H)+.
Example 79
N- (trans-4-Ethoxycyclohexyl) -8-methyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-β-amine .
1H-NMR(CDCl3) δ:1.25 ( 3H, t , J=7.2Hz) , 1.26-1.61 (4H,m) ,2.09-2.42 (4H,m) ,2.24 (3H,s) , 3.27-3.43 (lH,m) ,3.57 (2H, q, J=7.2Hz) ,3.79-3
.96 (IH, m) ,4.19 (IH, d, J=6.4Hz) , 7.56-7.58 (lH,m) , 7.98 (IH, s) , 8.0
8-8.12 (2H,m) , 8.62-8.66 (2H,m) .
MS:352 (M+H)+.
Example 80 tert-Butyl [ (trans-4-{ [3- (4-pyridinyl) imidazo [L, 2-b] pyridazin-6-yl] amino } cyclohexyl) oxy] acetate.
MS:446(M+Na)+.
Example 81
2-Methyl-N- [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] - 1,2,3, 4-tetrahydro-7-isoquinolinamine. 1H-NMR(DMSO-Ci6) δ : 2.37 ( 3H, s) , 2.62 (2H, t , J=β . OHz) , 2.80 (2H, t, J=
6. OHz) ,3.51(2H,s),7.00 (lH,d, J=9.6Hz) ,7.12 (IH, d, J=8. OHz) ,7.2
9 (IH, dd, J=8.4,2.2Hz) ,7.62 (IH, d, J=2.2Hz) ,7.98 (IH, d, J=9.6Hz) ,
8.13-8.15 (2H,m) ,8.20 (IH, s) ,8.64-8.66 (2H,m) ,9.45 (IH, s) . MS:357 (M+H)+.
Example 82
N- (trans-4-Fluorocyclohexyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
1H-NMR (DMSO-d5) 5:1.40-1.51 (2H,m) , 1.69-1.82 (2H,m) , 2.12-2.23 ( 2H,m) ,2.28-2.36(2H,m) , 3.81-3.90 (IH, m) ,4.52-4.74 (2H,m) , 6.59 (
IH, d, J=9.6Hz) ,7.77 (IH, d, J=9.6Hz) , 8.0δ' (IH, s) , 8.21-8.23 (2H,m)
,8.64-8.68 (2H,m) .
MS-312 (M+H)+.
Example 83 N,N-Dimethyl-2- [ (trans-4-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexyl) oxy] acetamide .
MS:417 (M+Na)+.
Example 84
6-tert-Butoxy-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine MS:269 (M+H)+.
Example 85
To a solution of trans-N- [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] -1, 4-cyclohexanediamine trihydrochloride (7 mg) in pyridine (0.5 ml) was added acetic anhydride (2 μl). After stirring for 1 hour, the mixture was evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with chloroform/methanol ( 100 : 2 to 10:1) to give N-(trans-4-{ [3-(4-pyridinyl) imida^o [1, 2-b] pyridazin-β-yl] amino } cyclohexyl) acetamide as an yellow solid (2 mg) . 1H-NMR (DMSO-d6) δ : 1.07-1.49 ( 4H, m) , 1.81 ( 3H, s ) , 1.85-2.00 (2H,m) ,2.12-2.22 (2H,m) , 3.51-3.70 (2H, m) , 6.77 ( IH, d, J=9.5Hz) , 7.20 (IH , d, J=6.5Hz) ,7.78-7.83(2H,m),8.16(lH,s),8.21 (2H, d, J=β . OHz) ,8 .60 (2H,d, J=β.0Hz) . MS:351 (M+H)+. Example 86
To a stirred mixture of trans-4- [ (3-iodoimidazo [ 1, 2-b] pyridazin-6-yl ) amino] cyclohexanol (40 mg) and phenylboronic acid (54.5 mg) in 1, 2-dimethoxyethane (0.45 ml) was added 2 M sodium carbonate aqueous solution (0.448 mL) at ambient temperature. Bis (triphenylphosphine) palladium (II) chloride
(4.7 mg) was then added to the mixture at ambient temperature.
After addition, the resulting mixture was stirred at 850C for
• 1 hour. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (2OmL: 2OmL) . The resulting mixture was acidified with IM HCl aqueous solution to pH 2 and extracted with ethyl acetate. The aqueous phase was then neutralized by the addition of 2M NaOH aqueous solution to pH 8. The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (20:1) to give trans-4- [ ( 3-phenylimidazo [ 1 , 2-b] pyridazin-6-yl) amino] cyclohexanol .
1H-NMR (DMSO-de) δ: 1.17-1.41 (4H,m) , 1.83-1.96 (2H,m) , 2.04-2.18 ( 2H,m) ,3.39-3.65 (2H,m) ,4.61 ( IH, d, J=4.4Hz) ,6.67 ( IH, d, J=9.5Hz) ,6.96 (lH,d, J=6.6Hz) ,7.32 ( IH, t , J=7.2Hz) ,7.45 (2H, t , J=7.9Hz) ,7 .74 (lH,d, J=9.9Hz) ,7.88(lH,s),8.20 (2H, d, J=7.7Hz) . MS:309(M+H)+. The following compounds were obtained in a similar manner to that of Example 86. Example 87 trans-4- ( { 3- [3- (Trifluoromethoxy) phenyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol . '
1H-NMR (DMSO-ds) 5:1.22-1.37 ( 4H,m) , 1.83-1.95 (2H, m) , 2.04-2.16 ( 2H,m) ,3.42-3.66(2H,m) , 4.62 ( IH, d, J=4. OHz) , 6.71 (IH, d, J=9.5Hz) ,7.04 (IH, d, J=7.0Hz) ,7.30 ( IH, d, J=9.5Hz) ,7.58 (IH, d, J=8. IHz) ,7 .77 (lH,d, J=9.5Hz) ,8.04(lH,s),8.09 ( IH, d, J=7.7Hz) , 8.48 (IH, s) . MS:393(M+H)+. Example 88 trans-4- ( {3- [3- (Benzyloxy) phenyl] imidazo [1, 2-b] pyridazin-6- yl } amino) cyclohexanol .
1H-NMR (DMSO-d6) 5: 1.18-1.41 (4H,m) ,1.83-1.94 (2H,m) ,2.05-2.17 ( 2H,m) ,3.41-3.68 (2H,m) ,4.58 ( IH, d, J=4. OHz) , 5.19 (2H, s) , 6.67 (IH , d, J=9.9Hz) , 6.92-7.01 (2H,m) ,7.34 (IH, d, J=8. IHz) , 7.42 (3H, t , J= 7.7Hz) ,7.50 (2H,d,J=7. OHz) , 7.71-7.80 (2H,m) , 7.89-7.94 (2H,m) . MS:415 (M+H)+.
Example 89 trans-4-{ [3- (3-Biphenylyl) imidazo [1, 2-b] pyridazin-β-yl] amino } cyclohexanol . 1H-NMR (DMSO-d6) 5:1.10-1.34 (4H,m) , 1.74-1.85 (2H, m) ,2.02-2.13 (
2H,m) , 3.37-3.71(2H,m) ,4.54 ( IH, d, J=3.7Hz) , 6.69 (IH, d, J=9.9Hz)
,6.93 (lH,d, J=7.3Hz) , 7.37-7.45 (5H,m) , 7.48-7.64 (4H,m) , 7.75 (IH
,d, J=9.2Hz) ,7.97 (IH, s) ,8.11 ( IH, d, J=7.7Hz) ,8.51(lH,s) .
MS(ESI) :385 (M+H)+. I Example 90
4-{ 6- [ (trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl }phenol .
MS:325 (M+H)+.
Example 91 trans-4-{ [3- ( 3-Methoxyphenyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanol .
1H-NMR (DMSO-d6)δ: 1.19-1.36 (4H,m) ,1.82-1.94 (2H,m) ,2.05-2.16 (
2H,m) ,3.40-3.67 (2H,m) , 3.84 (3H, s) , 4.60 ( IH, d, J=4.4Hz) , 6.67 (IH
, d, J=9.5Hz) , 6.86-6.97 (2H,m) ,7.35 (IH, t , J=8. IHz) , 7.68-7.73 (IH ,m) ,7.73 ( IH, d, J=9.5Hz) ,7.85-7.93 ( IH, m) , 7.89 (IH, s) .
MS:339 (M+H)+.
Example 92 trans-4- ( {3- [3- (Trifluoromethyl) phenyl] imidazo [1, 2-b] pyridazin-6-yl} amino) cyclohexanol. 1H-NMR (DMSO-d6) 5:1.18-1.37 (4H,m) , 1.79-1.95 (2H,m) ,2.01-2.14 ( 2H7ItI) ,3.04-3.67 (2H,m) ,4.62 ( IH, d, J=4. OHz) ,6.72 (IH, d, J=9.5Hz)
,7.02 (IH, d, J=7.3Hz) , 7.64-7.72 (2H, m) , 7.77 ( IH, d, J=9.5Hz) ,8.05
(IH, s) , ,8.28-8.35 (IH, in) , 8.83 ( IH, brs) .
MS:377 (M+H)+. Example 93
3- { 6- [ (trans-4-Hydroxyeyelohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl }phenol .
1H-NMR (DMSO-d6) δ:1.15-1.43(4H,m),1.81-1.94(2H,m) ,2.06-2.18 (
2H,m) ,3.41-3.65 (2H,m) ,4.60 (IH, d, J=4. OHz) ,6.65 (IH, d, J=9.5Hz) ,6.73(lH,d,J=8. IHz) ,6.91 (IH, d, J=7. OHz) , 7.22 ( IH, t, J=7.3Hz) , 7
.59 (lH,d, J=7.7Hz) , 7.64 (IH, s) , 7.71 (IH, d, J=9.5Hz) ,7.79 (IH, s) ,
9.45 (IH, s) .
MS: 325 (M+H)+.
Example 94 tra"ns-4-{ [3- ( 3-Pyridinyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino} cyclohexanol .
1H-NMR (DMSO-de) δ : 1.18-1.40 (4H,m), 1.84-1.95 (2H,m), 2.04-2.15 (
2H,m) ,3.41-3.66(2H,m) , 4.61 (IH, d, J=4.4Hz) ,6.71 (IH, d, J=9.5Hz)
,7.04 (IH, d, J=7.0Hz) , 7.44-7.52 (lH,m) , 7.77 ( IH, d, J=9.5Hz) ,8.01 (IH, s ) ,8.48-8.59(2H,m) ,9.38 (IH, d, J=I .8Hz) .
MS:310 (M+H)+.
Example 95
4-{ 6- [ (trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl } -2-methoxyphenol . 1H-NMR(CDCI3-CD3ODO:!) ) δ : 1.17-1.56 (4H,m) , 1.96-2.10 (2H,m) , 2. 13-2.29 (2H,m) , 3.57-3.82 (2H,m) , 3.97 (3H, s) , 6.48 (IH, d) , 6.97 ( IH
,d) ,7.53-7.67 (4H,m) .
MS:355 (M+H)+.
Example 96 trans-4-{ [3- (3-Bromophenyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino } cyclohexanol .
1H-NMR(CDCI3-CD3ODO:!) ) δ : 1.23-1.40 (2H,m) , 1.47-1.64 (2H,m) , 1.
99-2.11 (2H,m) ,2.23-2.34 (2H,m) , 3.60-3.81 (2H,m) , 6.54 (lH,d, J=9
.5Hz) ,7.31 (IH, d, J=7.7Hz) , 7.42-7.49 ( IH, m) , 7.61 (IH, d, J=9.9Hz) ,7.75 (IH, s) ,7.86-7.92 (lH,m) ,8.52-8.56 (lH,m) .
MS:387 (MH-H) + .
Example 97 trans-4-{ [3- (2-Pyridinyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino } cyclohexanol . 1H-NMR(CDCI3-CD3ODOSIS) ) δ : 1.07-1.65 (4H,m) , 2.03-2.16 (2H,m) ,2
.25-2.40 (2H,m) ,3.64-3.88 (2H,m) , 6.47 (IH, d) ,7.17-7.36 (IH, m) ,7
.68-7.84 (2H,m) , 8.29 (IH, s) , 8.60-8.73 (2H,m) .
MS:310 (M+H)+.
Example 98 A mixture of 6-chloro-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine (20 mg) and morpholine (1.0 mL) was stirred at 110
0C for 2 hours. Evaporation of the volatile components gave a residue, which was purified by silica gel column chromatography eluting with chloroform/methanol (20:1) to give 6-(4- morpholinyl) -3- (4- pyridinyl) imidazo [1, 2-b] pyridazine (6.63 mg) .
1H-NMR (CDCl3) δ: 3.50-3.61 (4H,m) , 3.85-3.96 (4H, m) , 6.92 (IH, d, J= 9.9Hz) , 7.85(lH,d, J=9.9Hz) , 8.02 (2H, d, J=6.2Hz) , 8.05 (IH, s) , 8.6 9(2H,d, J=6.2Hz) ,2.99-3.09 (IH, m) ,3.13-3.25 ( IH, m) , 3.51-3.61 (5 H,m) ,3.62-3.80 (2H,m) , 3.82-3.99 (5H,m) , 4.18-4.29 (lH,m) ,4.60-4 .71 (IH, m) ,7.09 (IH, s) ,7.97-8.04 (3H,m) ,8.67 (2H, d, J=6.2Hz) . MS : 282.1 (M+H) +. ) as a yeHow powder and further elution to give 6, 7-di-4-morpholinyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine (16.7 mg . MS : 367 (M+H) +. ) as a yellow powder. Example 99
To a stirred mixture of 6-chloro-3- (4-pyridinyl) imidazo [1,2-b] pyridazine (100 mg) and [ (IR) -1-phenylethyl] amine (157 mg) in toluene (5 ml) were added sodium tert-butoxyde (187 mg) , (R) -2, 2' -Bis (diphenylphosphino) -1 , 1' -binaphthyl (= (R) -BINAP, 24.3 mg) , and tris (dibenzylideneacetone) dipalladium chloroform complex (=Pd2 (dba) 3'CHCl3, 13.5 mg) at ambient temperature. The reaction was stirred at 1100C for 3 hours. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (1OmL: 1OmL). The resulting mixture was acidified with 1 M HCl aqueous solution to pH 2 and extracted with ethyl acetate. The aqueous phase was then adjusted to pH 8 with 2M NaOH aqueous solution. The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol
(40:1 to 20:1) to give N- [ (IR) -1- phenylethyl] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (101.3 mg) . 1H-NMR(DMSO-d6)δ:1.51 (3H, d, J=7. OHz) , 4.81-4.93 (lH,m) , 6.90 ( IH
,d, J=9.9Hz) ,7.20 (IH, t, J=7.3Hz) ,7.37 (2H, t, J=7.3Hz) ,7.46(2H,d
, J=6.6Hz) ,7.78 (lH,d, J=5.9Hz) ,7.82 (IH, d, J=9.5Hz) ,7.84 (2H,d, J
=6.2Hz) ,8.09(lH,s),8.51 (2H, d, J=6.2Hz) .
MS:316(M+H)+. [α]D=+412° (c=0.50, methanol, 240C) .
The following compounds were obtained in a similar manner to that of Example 99.
Example 100
N- [2- (Benzyloxy) phenyl] -3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-β-amine.
MS:394 (M+H) +.
Example 101
N-3-Pyridinyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-β- amine . 1H-NMR(DMSO-d6)δ:7.06(lH,d, J=9.5Hz) ,7.45 (IH, dd, J=5.0, 8. OHz)
,8.06(lH,d, J=9.5Hz) , 8.09 (2H, d, J=β . OHz) , 8.22 (IH, s) , 8.16-8.30
(2H,m) , 8.66(2H,d, J=6.0Hz) ,8.84 ( IH, d, J=2.5Hz) , 9.77 (IH, bs) .
MS:289 (M+H)+.
Example 102 N-Benzyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-β-amine . 1H-NMR(DMSO-Ci6)OM-SS (2H, d, J=5.5HΞ) ,6.88 (lH,d, J=9.5Hz) ,7.20
-7.48 (5H,m) ,7.84 ( IH, d, J=9.5Hz) , 7.85 ( IH, s) , 7.98 (2H, d, J=6.5Hz
) , 8.13 (IH, s) , 8.52 (2H, d, J=β .5Hz) .
MS:302 (M+H)+. Example 103 trans-4- [ (2, 3-Diphenylimidazo [1, 2~b]pyridazin-6-yl) amino] cyclohexanol .
MS:385 (M+H)+.
Example 104 Ethyl
4-{ [3-(4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} bensoate .
MS:360 (M+H)+.
Example 105 N- [2-Methyl-5- (tetrahydro~2H-pyran-2-yloxy) phenyl] -3-
(4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
1H-NMR (DMSO-d6) δ : 1.40-1.96 ( 6H, m) , 2.24 ( 3H, s ) , 3.40-3.52 ( IH, m)
, 3.68-3.81 (IH, m) ,5.38 (IH, t , J=4. OHz) ,6.81 (IH, dd, J=2.5, 8.5Hz)
,7.15(lH,d, J=9.5Hz) , 7.19 ( IH, d, J=7. OHz) , 7.50 (IH, d, J=2.5Hz) ,8 .00 (lH,d, J=9.5Hz) , 8.09 (2H, d, J=6. OHz) , 8.25 ( IH, s) , 8.51 (2H, d, J
=6. OHz) ,8.65 (IH, bs) . '
MS:402 (M+H)+.
Example 106
N, 3-Di-4-pyridinylimidazo [1, 2-b] pyridazin-6-amine. 1H-NMR (DMSO-de) δ:7.08 ( IH, d, J=9.5Hz) ,7.66 (2H, d, J=6. OHz) ,8.11 (lH,d, J=9.5Hz) ,8.12 (2H, d, J=6. OHz) ,8.27 (lH,s) ,8.47 (2H,d, J=6.
OHz) ,8.73 (2H,d, J=6.0Hz) , 10.04 ( IH, bs) .
MS:289 (M+H)+.
Example 107 N, N-Dimethyl-N ' - [3- (4-pyridinyl) imidazo [l,2-b]pyridazin-6- yl] -1, 4-benzenediamine .
1H-NMR(DMSO-O6) δ:2.90(6H,s),6.82 (2H, d, J=9. OHz) , 6.95 (IH, d, J=
9.5Hz) ,7.52 (2H,d, J=9.0Hz) ,7.92 (IH, d, J=9.5Hz) , 8.16 (2H, d, J=β .
5Hz) ,8.18 (IH, s) ,8.64 (2H, d, J=6.5Hz) , 9.20 (IH, bs) . MS:331 (M+H)+.
Example 108
N- [ (IS) -1-Phenylethyl] -3- (4-pyridinyl) imidazo [1 , 2-b] pyridazin-6-amine .
1H-NMR (DMSO-d6) δ:1.51 (3H, d, J=7. OHz) , 4.81-4.93 ( IH, m) , 6.90 ( IH , d, J=9.9Hz) ,7.20 (IH, t , J=7.3Hz) ,7.37 (2H, t , J=7.3Hz) ,7.46 (2H,d
, J=6.6Hz) ,7.78 (IH, d, J=5.9Hz) ,7.82 (IH, d, J=9.5Hz) ,7.84 (2H,d, J
=6.2Hz) ,8.09 (IH, s) , 8.51 (2H, d, J=6.2Hz) .
MS:316(M+H)+.
[a] (D)=-389° (c=0.50, methanol, 240C) . Example 109
N- [4- (Benzyloxy) phenyl] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine.
1H-NMR (DMSO-de) δ : 5.15 (2H, s) , 6.97 ( IH, d) , 7.09 (2H, d, J=9. OHz) ,7
.32-7.53 (5H,m) ,7.61 (2H, d, J=9. OHz) , 7.96 (IH, d, J=9.5Hz) ,8.14 (2 H,d, J=6.0Hz) , 8.19 (IH, s) , 8.64 (2H, d, J=6. OHz) , 9.38 ( IH, bs) . MS:394 (M+H)+.
Example 110
N- [3- (Benzyloxy) phenyl] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-β-amine . 1H-NMR(DMSO-d6)δ:5.09(2H,s) ,6.72 (IH, dd, J=8.0, 8. OHz) ,7.03 (IH
, d, J=9.5Hz) ,7.17 ( IH*, d, J=8. OHz) ,7.29 (IH, d, J=8. OHz) ,7.32-7.50
(5H,m) , 7.56(lH,t, J=2.6Hz) ,8.02 ( IH, d, J=9.5Hz) ,8.15 (2H,d, J=6.
0H2) ,8.21(lH,s),8.59 (2H, d, J=6. OHz) , 9.57 (lH,bs) .
MS:394 (M+H)+. Example 111
To a suspension of trans-4- { [3- (4-pyridinyl) imidazo [1 , 2-b] pyridazin-6-yl] amino } cyclohexanol (60 mg) in dichloromethane
(1.2 ml) was added diethylaminosulfur trifluoride (=DAST, 51 μl),
After stirring for 1 hour, the mixture was poured into saturated NaHCO3 aqueous solution and extracted with 10% methanol in chloroform, dried over sodium sulfate and evaporated in vacuo.
The residue was purified by column chromatography on silica gel " eluting with chloroform/methanol (100 : 2 to 10:1) to give N-3- cyclohexen-l-yl-3- ( 4-pyridinyl) imidazo [1, 2-b] pyridazin-6- amine as an pale yellow solid (35 mg) .
1H-NMR (DMSO-d6)δ: 1.48-1.69 ( IH, m) , 1.94-2.20 (4H,m) , 2.46-2.53 (
IH, m) ,3.87-3.95 (IH, m) ,5.67-5.79 (2H,m) ,6.81 (IH, d, J=9.5Hz) ,7.
18 (IH, d, J=7.0Hz) ,7.81 ( IH, d, J=9.5Hz) ,8.16(lH,s) ,8.18-8.21 (2H
,m) ,8.58-8.61(2H,m) . MS:292 (M+H)+. Example 112
To a mixture of 6-chloro-3- ( 4-pyridinyl) imidazo [ 1, 2-b] pyridazine (80 mg) and cyclopropylamine (72 μL) in toluene (6.9 mL) was added tris (dibenzylidenacetone) dipalladium chloroform complex (=Pd2dba3-CHCl3, 10.8 mg) , 2,2'-
Bis (diphenylphosphino) -I11' -binaphthyl (=BINAP, 19.4 mg), and sodium tert-butoxide (150.0 mg) , which was subjected to microwave irradiation at 1100C for 2 hours. The resultant was partitioned between dichloromethane and water. Organic phase was separated, washed with brine and dried over sodium sulfate. Evaporation of the solvent gave a residue, which was purified by column chromatography on silica gel to give N-cyclopropyl- 3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-β-amine (26.1 mg) as a yellow powder.' 1H-NMR (DMSO-dδ)δ: 0.48-0.59 (2H,m) , 0.78-0.91 (2H,m) ,2.60-2.79 ( IH, m) ,6.75 ( IH, d, J=9.7Hz) ,7.52 (lH,brs) ,7.83 ( IH, d, J=IO . OHz) ,8 .22 (IH, s) ,8.34 (2H, dd, J=I .5, 4.5Hz) ,8.62 (2H, dd, J=I .5, 4.5Hz) . MS:252 (M+H)+. Example 113 To a suspension of trans-N- [3- ( 4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] -1, 4-cyclohexanediamine trihydrochloride (20 mg) in dichloromethane (0.4 ml) was added methanesulfonyl chloride (10 μl) and triethylamine (26 μl) . After stirring at ambient temperature for 2 hours, the mixture was poured into saturated NaHCO3 aqueous solution and extracted with 10% methanol in chloroform. The organic layer was washed with brine, dried over sodium sulfate, and evaporated in vacuo. The resulting precipitates were collected by filtration to give
N-(trans-4-{ [3- ( 4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6- yl] amino} cyclohexyl) methanesulfonamide as an oil (5 mg) .
1H-NMR (DMSOd6) δ:1.23-1.43 (5H,m) , 1.89-2.19 (4H,m) , 2.95 (3H,s)
,3.31-3.37 (lH,m) ,6.77 (lH,d, J=10.0Hz) ,7.0β(lH,d, J=7.5Hz) ,7.2
2 (lH,d, J=6.5Hz) ,7.8 ( IH, d, J=9.5Hz) , 8.17 (IH, s) , 8.22 (2H,d, J=6.
OHz) ,8.61 (2H,d, J=6.0Hz) . MS:387 (M+H)+.
Example 114
N- [1- (methylsulfonyl) -3-piperidinyl] -3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6-amine .
1H-NMR (DMSO-d6) 5:1.55-2.18 (5H,m) ,2.62-2.72 (lH,m) ,2.80-3.00 ( IH, m) ,2.89 (3H,s) ,3.32-3.50 (2H,m) ,3.88 (lH,brs) , 3.98-4.04 (IH, m) , 6.83 (lH,d, J=9.6Hz) ,7.28 (IH, d, J=6.6Hz) ,7.85 (IH, d, J=9.6Hz)
,8.13-8.16(3H,m) , 8.57-8.60 (2H,m) .
MS:373(M+H)+,395 (MH-Na)+.
Example 115 To a solution of 6-chloro-3- ( 4-pyridinyl) imidazo [1, 2-b] pyridazine (80 mg) and ethyl 4-amino-l-piperidinecarboxylate (179.2 mg) in toluene (6.9 mL) was added tris (dibenzylidenacetone) dipalladium chloroform complex (=Pd2dba3-CHCl3 ,10.8 mg) , 2, 2' -Bis (diphenylphosphino) - 1, l'-binaphthyl (=BINAP, 19.5 mg) , and sodium tert-butoxide (150.0 mg) , which was stirred at 110 0C for 2.5 hours under nitrogen atmosphere. The solvent was evaporated, the residue was dissolved in dimethylsulfoxide and the resulting solution was desalted using solid-phase extraction cartridge. Evaporation of the solvent gave a residue, which was purified by column chromatography on silica gel to give 4-{[3--(4- pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino }-l- piperidinecarboxylate (39.1mg) as a brown powder. 1H-NMR (DMSO-d6) δ:1.20 (3H, t, J=4.5Hz) ,1.42 (2H, ddd, J=3.5, 10.5, 20.6Hz) ,1.99-2.20 (2H,m) ,3.11 (2H, dd, J=IO .5, 10.5Hz) ,3.78-4.02 (3H,m) ,4.06 (2H,q,J=7. OHz) , 6.78 (IH, d1, J=9.7Hz) ,7.24 (IH, d, J=6. 7Hz) ,7.83(lH,d, J=9.6Hz) ,8.17 (IH, s) ,8.19(2H,d, J=5.0Hz) ,8.62 ( 2H,d, J=6.5Hz) . MS:367 (M+H)+. The following compounds were obtained in a similar manner to that of Example 115. Example 116
N- [ (3R) -l-Benzyl-3-pyrrolidinyl] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine . 1H-NMR (DMSO-d5)δ: 1.64-1.86 (IH, m) ,2.21-2.80 (4H,m),2.81-3.05( IH, m) , 3.59(lH,d, J=13.0Hz) ,3.68 ( IH, d, J=13. OHz ) ,4.17-4.37 (IH, m) , 6.79 (IH, d, J=9.5Hz) , 7.14-7.49 ( 6H,m) , 7.81 ( IH, d, J=IO . OHz) ,8 .15 (IH, s) ,8.17 (2H,d, J=6.0Hz) , 8.59 (2H, d, J=6. OHz) . MS:371 (M+H)+. Example 117 N-Cyclopentyl-3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6- amine.
1H-NMR(DMSO-d6)δ:1.47-1.83 ( 6H,m) , 1.91-2.15 (2H, m) , 4.00-4.20 (
IH, m) ,6.7β(lH,d, J=9.7Hz) ,7.21 ( IH, d, J=5.8Hz) ,7.79 (lH,d, J=9.8 Hz) ,8.16 (IH, s) ,8.23 (2H, d, J=6. OHz) ,8.61 (2H, d, J=6. OHz) .
MS:280 (M+H)+.
Example 118
N- [ (3S) -l-Benzyl-3-pyrrolidinyl] -3- (4-pyridinyl) imidazo
[1, 2-b] pyridazin-6-amine . 1H-NMR (DMSO-d6) δ : 1.64-1.86 ( IH, m) ,2.21-2.80 (4H,m) , 2.81-3.05 (
IH, m) ,3.59(lH,d, J=13.0Hz) ,3.68 (IH, d, J=I3. OHz) , 4.17-4.37 ( IH, m) , 6.79 ( IH, d, J=9.5Hz) , 7.14-7.49 ( 6H,m) , 7.81 (IH, d, J=IO . OHz) ,8
.15(lH,s),8.17 (2H,d, J=6.0Hz) ,8.59 (2H, d, J=6. OHz) .
MS:371 (M+H)+. Example 119
N- ( l-Benzyl-4-piperidinyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
1H-NMR(DMSO-d5)δ:1.52 (2H, dd, J=IO1.0, 20.6Hz) ,2.00-2.28 (4H,m) ,
2.68-2.97 (2H,m) ,3.52 (2H,s) , 3.56-3:78 (lH,m) , 6.78 (lH,d, J=9.8H z) ,7.15-7.40 (6H,m) ,7.81 (IH, d, J=9.8Hz) , 8.16 ( IH, s) , 8.18 (2H, dd
,J=I.5, 5. OHz) ,8.60 (2H, dd, J=I .0, 5. OHz) .
MS:385 (M+H) + .
Example 120 tert-butyl (3R) -3-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin- 6-yl] amino} -1-pyrrolidinecarboxylate . 1H-NMR ( DMSO-d6) δ: 1.23-1.50 ( 1OH, m) , 1.89-2.11 (IH7-Ti) ,2.12-2.35 ( IH, m) ,3.27-3.51 (2H,m) ,3.59-3.81 (lH,m) ,4.22-4.41 ( IH, m) ,6.79 (IH, d, J=9.7Hz) ,7.48 (IH, d, J=5. IHz) ,7.85 (IH, d, J=9.7Hz) ,8.19(1 H, s) ,8.19 (2H,d, J=6.0Hz) ,8.61 (2H, d, J=6. OHz) . MS:381(M+H)\403(M+Na)+. Example 121 tert-Butyl 4-{ [3- (4-pyridinyl) imidazo [1 , 2-b] pyridazin-6-yl] amino } -1-piperidinecarboxylate . 1H-NMR (DMSO~d6)δ: 1.20-1.56 (2H,m) ,1.42 (9H,s) , 2.00-2.15 (2H, m) ,2.90-3.20 (2H,m) , 3.73-4.14 ( 3H,m) , 6.77 ( IH, d, J=9.7Hz) ,7.22 (IH , d, J=6.6Hz) ,7.82 ( IH, d, J=9.7Hz) ,8.17(lH,s),8.18 (2H, d, J=5.5Hz ) ,8.62 (2H,d, J=6.0Hz) . MS: 395 (M+H)+, 417 (M+Na)+. Example 122 To a stirred mixture of N- [ 4- (benzyloxy) phenyl] -
3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (80 mg) and cyclohexene (648 mg) in ethanol/tetrahydrofuran (1 mL/lmL) was added palladium hydroxide (=Pd(OH)2 ,16 mg) at ambient temperature. The resulting mixture was stirred at 800C for 5 hours under nitrogen. The mixture was filtered through Celite and washed with ethanol and tetrahydrofuran, successively. The filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (50:1 to 20:1) to give 4-{[3-(4- pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino}phenol (26.3 mg) .
1H-NMR (DMSOd6) δ: 6.81 (2H, d, J=9. OHz) ,6.95 (IH, d, J=9.5Hz) ,7.48
(2H,d, J=9.0Hz) ,7.93(lH,d, J=9.5Hz) , 8.13 (2H, d, J=6. OHz) ,8.18 (1
H, s) , 8.61 (2H,d, J=6.0Hz) , 9.23 (IH, bs) , 9.24 (IH, bs) . MS:304 (M+H)+.
The following compounds were obtained in a similar manner to that of Example 122.
Example 123
3-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} phenol.
1H-NMR (DMSO-d6) δ : 6.45-6.54 ( IH, m) , 7.02 ( IH, d, J=9.5Hz) ,7.11-7.
26(3H,m) ,7.99 (IH, d, J=9.5Hz) ,8.18 (2H, d, J=6.5Hz) , 8.22 ( IH, s ) , 8
.64 (2H,d, J=6.5Hz) , 9.44 (IH, bs) , 9.48 (IH, bs) .
MS:304 (M+H)+. Example 124
2-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino }pheno
1.
MS:304 (M+H)+.
Example 125 2-Chloro~4-{ 6- [ (trans-4-hydroxycyclohexyl) amino] imidazo
[1, 2-b] pyridazin-3-yl } phenol .
1H-NMR ( DMSO-d6) δ: 1.21-1.42 (4H,m) , 1.86-1.94 (2H,m) ,2.10-2.17 (
2H,m) ,3.35-3.61(2H,m) ,4.60 (lH,brs) ,6.64 (IH, d, J=9.6Hz) , 6.95(
IH, d, J=7.2Hz) ,7.05 (IH, d, J=8.4Hz) , 7.70 (IH, d, J=9.6Hz) , 7.81-7. 83 (2H7ITi) ,8.44 ( IH, d, J=2. OHz) , 10.36 (IH, brs) . MS : 359 (M+H) + .
Example 126
2-Hydroxy-5-{ 6- [ (trans-4-hydroxycyclohexyl) amino] imidazo
[1, 2-b]pyridazin-3-yl }benzonitrile . 1H-NMR (DMSO-d6) δ: 1.22-1.40 (4H,m) , 1.86-1.93 (2H,m) ,2.09-2.16 (
2H,m) ,3.35-3.58 (2H,m) , 4.61 (lH,brs) , 6.66 (IH, d, J=9.6Hz) , 6.96 (
IH, d, J=7.2Hz) ,7.06(lH,d, J=8.8Hz) ,7.71 (IH, d, J=9.6Hz) ,7.82 (IH
,brs) ,8.16 (IH, m) ,8.49 ( IH, d, J=2.4Hz) .
MS:350 (M+H)+. Example 127
2, 6-dichloro-4-{6- [ (trans-4-hydroxycyclohexyl) amino] imidazo [ 1, 2-b] pyridazin-3-yl } phenol .
1H-NMR (DMSO-d6) δ:1.15-1.47(4H,m) ,1.85-2.17 (4H,m) ,3.32-3.61 (
2H,m) , 4.61 (lH,brs) ,6.67 ( IH, d, J=9.6Hz) ,7.00 ( IH, d, J=6.4Hz) ,7. 72 (lH,d, J=9.6Hz) ,7.95(lH,s),8.29(2H,s),10.28 (lH,brs) .
MS:393 (M+H)+.
Example 128
To a suspension of N-4-piperidinyl-3- (4-pyridinyl) imidazo
[1, 2-b] pyridazin-6-amine trihydrochloride (lOOmg) in N,N-dimethylformamide (2.0 ml) was added K2CO3 (171.1 mg) ,
1, 1 ' - (bromomethylene) dibenzene ( 67.3 mg) , the mixture was stirred at 600C for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic extract was washed with water twice and brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography eluted with 5%-10% methanol in chloroform to give N- [1- (diphenylmethyl) -4- piperidinyl] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6- amine (32 mg) . 1H-NMR (DMSO-dδ)δ:l.60-1.70 (2H,m) , 2.03-2.14 (4H,m) , 2.78-2.84 (
2H,m) ,3.63 (lH,m) ,4.38 (IH, s) , 6.78 (IH, d, J=9.7Hz) ,7.15-7.48 (12
H7ITi) , 7.79(lH,d, J=9.7Hz) , 8.14-8..17 (2H,m) , 8.55-8.65 (2H,m) .
MS:461 (M+H)+.
The following compound was obtained in a similar manner to that of Example 128.
Example 129
N- (l-Benzyl-3-piperidinyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
1H-NMR (DMSO-d6)δ: 1.22-1.36 ( IH, m) ,1.40-1.91 (2H,m) ,1.95-2.14 ( 3H,m) ,2.68-2.73 (IH, m) ,3.06-3.11 (IH, m) , 3.53 (2H, dd, J=13.4Hz) ,
3.87 (lH,brs) ,6.78 (lH,d, J=9.6Hz) , 7.08-7.35 ( 6H,m) , 7.79 (IH, d, J
=9.6Hz) ,8.15-8.18 (3H,m) , 8.59-8.62 (2H, m) .
MS:385.
Example 130 To a solution iof N-4-piperidinyl-3- (4-pyridinyl ) imidazo
[1, 2-b] pyridazin-6-amine trihydrochloride (56 mg) and triethylamine (81.2 μl) in N, N-dimethylformamide (1.12 ml) was added benzoyl chloride (16.9 μl) , the mixture was stirred at 230C for 1 hour. The reaction mixture was poured into water and extracted with ethyl acetate. The organic extract was washed with water twice and brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography eluted with chloroform/methanol (95:5 to 90:10) to give N- ( l-benzoyl-4-piperidinyl) -3- ( 4- pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (41mg).
1H-NMR (DMSO-d6) 5:1.42-1.60 (2H,brs) ,2.13 (2H,brs) ,3.34 (4H,brs ) , 3.53-4.36 (IH, m) , 3.96 (IH, brs) , 6.79 (IH, d, J=9.7Hz) , 7.28 ( IH, d , J=6.6Hz) ,7.39-7.49 (5H,m) ,7.83 ( IH, d, J=9.7Hz) ,8.17(lH,s),8.1 9-8.20 (2H,m) ,8.62 (2H, dd, J=I .4 , 4.9Hz) . MS:399(M+H)+. Example 131
To a solution of N- ( trans-4-methoxycyclohexyl) -3- (4- pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (50 mg) was added m-chloroperoxybenzoic acid (33.4 mg) and the mixture was stirred at ambient temperature for 2 hours. The reaction mixture was washed with a mixture of saturated NaHCO3 aqueous solution and brine, 5% sodium sulfite aqueous solution, water and brine, successively. The organic phase was dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (40:1 to 20:1) to give N-(trans-4- methoxycyclohexyl) -3- (l-oxido-4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (34.5 mg) . 1H-NMR (DMSO-de) 5:1.20-1.43 (4H,m) , 1.98-2.19 (4H,m) , 3.14-3.30 ( IH, m) ,3.33(3H,s) ,3.55-3.78 (lH,m) , 6.74 (IH, d, J=9.8Hz) ,7.13 (IH , d, J=6.7Hz) ,7.78 (lH,d, J=9.8Hz) , 8.10 (IH, s) ,8.20-8.32 (4H,m) . MS:340 (M+H) + . Example 132 trans-4- [ (3-Iodoimidazo [1, 2-b] pyridazin-6-yl) amino] cyclohexanol (100 mg) and vinylbenzene (291 mg) were dissolved in N, N-dimethyformamide (2.5 ml) . To this solution were added triethylamine (0.4OmL), water (0.4OmL) and dichlorobis (triphenylphosphine)palladium(II) (=PdCl2 (PPh3)O ,39.2 mg) at ambient temperature. The resulting mixture was subjected to microwave irradiation at 1000C for 1 hour. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (lOmL/lOmL). The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (40:1 to 20:1) to give a mixture of trans-4- ( { 3- [ (E) -2-phenylvinyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol (35.8 mg) . 1H-NMR (DMSO-d6) δ: 1.18-1.48 (4H,m), 1.88-2.01 (2H,m), 2.08-2.22 ( 2H,m) ,3.41-3.77 (2H,m) ,4.64 ( IH, d, J=4. IHz) ,6.67 (IH, d, J=9.6Hz) ,6.97 (lH,d, J=6.6Hz) , 7.20-7.35 (2H,m) , 7.42 (2H, d, J=7.2Hz) ,7.54 (2H,d, J=7.2Hz) ,7.63 (IH, s) ,7.65-7.88 (2H,m) .) and trans-4- { [3- (1-phenylvinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanol (5.6 mg) . 1H-NMR(DMSO-Ci6) 5:1.03-1.42 (4H,m) , 1.88-2.10 (4H,m) ,3.35-3.43 (
IH, m) ,3.55-3.70 ( IH, m) , 5.32 (IH, s) , 5.56 (IH, d, J=I .6Hz) , 6.25 (IH
, d, J=I.6Hz) ,6.48 (IH, d, J=9.6Hz) ,7.32-7.41 (7H, m) , 7.58 ( IH, d, J=
9.6Hz). The following compounds were obtained in a similar manner to that of Example 132.
Example 133 trans-4- ( { 3- [ (E) -2- ( 4-Pyridinyl) vinyl] imidazo [1, 2-b] pyridazin-6-yl} amino) cyclohexanol . MS:336(M+H)+.
Example 134 trans-4- ({3- [ (E) -2- (3-Pyridinyl) vinyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol .
MS:336(M+H)+. Example 135 trans-4- ( {3- [ (E) -2- (2-Pyridinyl) vinyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol .
MS:336(M+H)+.
Example 136 trans-4- [ (3-Iodoimidazo [1, 2-b] pyridazin-6-yl) amino] cyclohexanol (100 mg) , dichlorobis (triphenylphosphine) palladium(II) (PdCl2 (PPh3) 2 ,9.80 mg) and CuI (5.32 mg) were dissolved in N, N-dimethylformamide (2.5 mL) and triethylamine
(2.5 ml) . The mixture was stirred at ambient temperature for 10 minutes. Then ethynylbenze'ne (34.22 mg) was added. The resulting mixture was subjected to microwave irradiation at 80 0C for 1 hour. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (1OmL: 1OmL) . The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (40:1 to 20:1) to give trans-4-{[3- (phenylethynyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino } cyclohexanol ( 68.6 mg) .
1H-NMR (DMSO-de) 5:1.15-1.41 (4H,m) , 1.80-1.99 (2H, m) , 2.02-2.24 ( 2H,m) ,3.40-3.70 (2H,m) ,4.59 (IH, d, J=4.5Hz) ,6.72 (IH, d, J=9.6Hz) ,7.00 (lH,d, J=6.6Hz) , 7.40-7.59 (5H,m) , 7.72 ( IH, d, J=3.9Hz) ,7.75 (IH, d, J=5.7Hz) . Example 137
To a stirred mixture of trans-4- ( { 3- [4- (benzyloxy) -3- fluorophenyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol (150 mg) and cyclohexene (1.5mL) in ethanol/ tetrahydrofuran (3mL/3mL) was added palladium hydroxide (=Pd(OH)2 A 60 mg) at ambient temperature. The resulting mixture was stirred at 800C for 5 hours under nitrogen. The mixture was filtered through Celite and washed with methanol and tetrahydrofuran, successively. The filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (50:1 to 10:1) to give 2-fluoro-4- { 6- [ ( trans-4-hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl }phenol (35.6 mg) . 1H-NMR (DMSO-d6) δ: 1.13-1.42 (4H,m) , 1.82-2.00 (2H,m) ,2.03-2.19 ( 2H,m) ,3.34-3.62 (2H,m) , 4.62 ( IH, d, J=4.3Hz) ,6.64 (IH, d, J=9.6Hz) , 6.96(lH,d, J=5.4Hz) ,7.04 (IH, d, J=9.2Hz) ,7.71 ( IH, d, J=9.6Hz) ,7 .75 (IH, d, J=9.2Hz) ,7.81(lH,s),8.17 (IH, dd, J=2.0, 13.7Hz) , 10.0 ( IH, bs) . The following compound was obtained in a similar manner to that of Example 137. Example 138
5- { 6- [ (trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl } -2-methoxyphenol . 1H-NMR (DMSO-de) δ : 1.20-1.32 ( 4H, m) , 1.84-1.93 (2H, m) ,2.05-2.13 ( 2H,m) ,3.42-3.51 (lH,m) , 3.56-3.69 ( IH, m) , 3.87 (3H, s) , 4.60 (IH, d, J=4.4Hz) ,6.61 (IH, d, J=9.7Hz) ,6.84 (2H, d, J=8.2Hz) , 7.54 ( IH, dd, J =8.2, 1.8Hz) ,7.68 ( IH, d, J=9.7Hz) ,7.73(lH,s),7.77 (IH, d, J=I .8Hz ),9.18(lH,s) . MS:355 (M+H)+. Example 139
To a stirred mixture of 3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (30.0 mg) and acetic anhydride (43.5 mg) in pyridine (1.15 mL) was added 4-dimethylaminopyridine (3.47 mg) at ice-bath temperature. The reaction was stirred at 1000C for 3 hours. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was poured into IM HCl aqueous solution (1OmL). The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (40:1 to 20:1) to give N- [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] acetamide (12.6 mg) . 1H-NMR(DMSO-d6)δ:3.16(3H,s) ,7.95 (2H, d, J=2. IHz) , 8.04 (IH, d, J= 4.9Hz) ,8.14 (IH, s) ,8.34 (IH, d,J=4.9Hz) ,8.73 (2H,d,J=2. IHz) , 9.6 9(lH,bs) . MS:254 (M+H)+. Example 140 Diethylaminosulfur trifluoride (=DAST, 31 μl) was added dropwise to a solution of (trans-4- { [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexyl) methanol (23 mg) in dichloromethane (ImI). After stirring at 00C for 4 hours, the reaction mixture was poured into saturated aqueous NaHCO3, and extracted with dichloromethane 10% methanol. The organic layer was dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by preparative TLC eluting with dichloromethane/methanol (10 : 1 ) to give N-[trans-4- (fluoromethyl) cyclohexyl] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine ( 1 mg) . 1H-NMR ( DMSOd6) δ: 1.17-1.31 (5H,m) , 1.77-1.88 (2H,m) ,2.15-2.29 ( 2H,m) ,3.50-3.70 ( IH, m) ,4.21 (IH, d, J=5.9Hz) ,4.45 (lH,d, J=5.9Hz)
,6.76 (lH,d, J=9.7Hz) , 7.16 ( IH, d, J=6. IHz) ,7.80 (IH, d, J=9.7Hz) , 8
.15(lH,s),8.20 (2H,d, J=6.3Hz) ,8.60 (2H, d, J=6.3Hz) .
MS:326(M+H)+. • The following compounds were obtained in a similar manner to that of Example 140.
Example 141
N- [cis-4- (Fluoromethyl) cyclohexyl] -3- ( 4-pyridinyl) imidazo
[1, 2-b] pyridazin-6-amine . 1H-NMR (DMSO-d5) : 1.40-2.00 (9H,m) ,3'.93-4.05 ( IH, m) , 4.22 (0.5H, d
, J=5.2Hz) ,4.46(0.5H,d, J=6.0Hz) ,5.76(0.5H,s),6.55(0.5H,s),6.
89(lH,d, J=9.5Hz) ,7.07 (IH, d, J=5.8Hz) ,7.8 ( IH, d, J=9.6Hz) ,8.16( IH, s) ,8.19 (2H,d, J=5.3Hz) , 8..6(2H,d, J=5.3Hz) .
MS:326(M+H)+. Example 142
N- (3-Fluoro-l-adamantyl) -3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6-amine.
1H-NMR (DMSO-ds) : 1.57-1.63 (2H, m) , 1.85-1.93 (4H,m) , 2.04-2.18 ( 4
H,m),2.27-2.42(4H,m),6.80 ( IH, d, J=IO . OHz) , 7.01 ( IH, s), 7.80 (IH , d, J=IO. OHz) , 8.11-8.17 (3H,m) ,8.61 (2H, d, J=6. OHz)-.
MS:364 (M+H)+.
Example 143
N- (5-fluoroadamantan-2-yl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine . 1H-NMR (DMSO-d6)δ:l.60-1.95 (8H,m) , 2.12-2.36 (3H, m) ,2.46-2.59 ( 2H, m) , 3 . 80-3 . 94 ( IH, m) , 6 . 94 ( IH , d) , 7 . 19 ( IH , d) , 7 . 83 ( IH, d) , 8 . 17
( IH, s) ,8.20 (2H,d) , 8.59 (2H,d) . MS:364 (M+H)+. Example 144 N- (5-fluoroadamantan-2-yl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-β-amine .
1H-NMR (DMSO-d6) δ:l.62-1.96 (8H,m) ,2.13-2.37 (3H,m) , 2.48-2.58 ( 2H,m) ,3.78-3.93 (IH, m) ,6.94 (IH, d) ,7.19 (IH, d) ,7.83 (IH, d) ,8.17
(IH, s) ,8.20 (2H,d) ,8.59 (2H,d) . MS:364 (M+H)+. Example 145
To a mixture of trans-4- [ (3-iodoimidazo [1, 2-b] pyridazin- 6-yl) amino] cyclohexanol (80 mg) and 2- (N, N-dimethylamino) pyridine-5-boronic acid hydrate (74.1 mg) in 1,2- dimethoxyethane (40OuL) was added tetrakis
(triphenylphosphine)palladium(O) (25.8 mg), sodium hydroxide
(35.7 mg) , and water (200 μL) , which was subjected to microwave irradiation at 1350C for 30 minutes. To the resultant was added water. The mixture was extracted with dichloromethane . The organic layer was washed with brine, dried over sodium sulfate, filtered, and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give trans-4- ({ 3- [ 6-
(dimethylamino) -3-pyridinyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol (49.7 mg) as a yellow powder. MS(ES+) :353(M+H)+. The following compounds were obtained in a similar manner to that of Example 145.
Example 146 trans-4-{ [3- ( 1, 3-Benzodioxol-5~yl) imidazo [ 1, 2-b] pyridazin- 6-yl] amino} cyclohexanol .
MS-.353 (M+H)+.
Example 147 trans-4-{ [3- (2-Methoxy-5-pyrimidinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanol . MS:341 (M+H)+.
Example 148 trans-4-{ [3- ( 6-Methoxy-3-pyridinyl) imidazo [1, 2-b] pyridazin- 6-yl] amino} cyclohexanol.
MS:340 (M+H)+. Example 149 trans-4-{ [3- (3-Chloro-4-fluorophenyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanol .
1H-NMR(DMSO-Cl6) 5:1.22-1.38 (4H,m) ,1-86-1.93 (2Hm) ,2.11-2.15 (2
H,m) ,3.35-3.55(2H,m) ,4.61 (lH,brs) , 6.70 ( IH, d, J=9.8Hz) , 7.04 (1 H,d, J=6.7Hz) , 7.76 (IH, d, J=9.8Hz) ,7.71 ( IH, d, J=9.6Hz) ,7.98 (IH, brs) ,8.06 (IH, m) ,8.68 (IH, m) .
MS:361(M+H)+.
Example 150 trans-4-{ [3- (4-Chloro-3-fluorophenyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanol . MS:3βl (M+H)+.
Example 151 trans-4-{ [3- (l-Methyl-lH-pyrazol-4-yl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanol . 1H-NMR(DMSO-Ci6)0: 1.24-1.47 (4H,m) , 1.89-1.94 (2H,m) , 2.14-2.17 (
2H,m) ,3.48-3.61 (2H,brs) , 3.92 (3H, s) , 4.61 (IH, d, J=4.4Hz) ,6.55-
6.62(lH,m) , 6.89 ( IH, d, J=6.6Hz) , 6.61-6.96 (2H,m) , 8.08 (IH, s) , 8.
29 (IH, s) .
MS: 313 (M+H)+,335 (M+Na)+. Example 152 trans-4-{ [3- (2, 6-Dichloro-4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino} cyclohexanol .
1H-NMR (DMSO-d6)δ: 1.25-1.91 (4H,m) , 1.91-1.99 (2H,m) ,2.11-2.23 (
2H,m) ,3.54 (2H,brs) ,4.63 (lH,brs) ,3.79 ( IH, d, J=9.6Hz) ,7.23 (IH, d, J=6.6Hz) ,7.81 (lH,d, J=9.6Hz) ,8.37 (1H,S) ,8.42 (1H,S) .
MS:401 (M+Na)+.
Example 153 trans-4-{ [3- (2-Fluoro-4-pyridinyl) imidazo [1, 2-b] pyridazin- 6-yl] amino} cyclohexanol . 1H-NMR (DMSO-d6) 5:1.25-1.39 (4H,m) ,1.90 (2H,brs) , 2.17 (2H,m) , 3.
51 (2H,brs) ,4.64 (lH,d, J=4.5Hz) ,6.79 ( IH, d, J=9.6Hz) ,7.20 (IH, d,
J=6.6Hz) ,7.82 (lH,d, J=9.6Hz) ,8.04 (IH, d, J=5.5Hz) ,8.17(lH,s),8
.25 (lH,d, J=5.5Hz) , 8.27 (IH, s) .
MS: 328 (M+H)+,350 (M+Na)+. Example 154 trans-4- { [ 3- ( 2-Bromo-4 -pyridinyl ) imidazo [ l , 2-b] pyridazin-6- yl ] amino } cyclohexanol .
1H-NMR (DMSO-d6) δ: 1.25-1.46 (4H,m) , 1 • 90-1.92 (2H,m) , 2.12-2.15 (
2H,m) , 3.46-3.50(2H,m) ,3.57-3.61(1H7In) , 6.82 (IH, d, J=9.6Hz) , 7. 24 (lH,d, J=6.6Hz) ,7.83 ( IH, d, J=9.6Hz) ,8.09 (IH, dd, J=I .4 , 5.3Hz)
,8.31(lH,s),8.39 ( IH, d, J=5.3Hz) ,8.71 (IH, d, J=I .4Hz) .
MS:389(M+H)+.
Example 155
6-Chloro-3- (2-chloro-4-pyridinyl) -8-methylimidazo [1, 2-b] pyridazine.
1H-NMR(DMSO-d6)δ:2.46(3H,s) , 8.17 ( IH, dd) , 8.26 (IH, d) , 8.33 ( IH, d) ,8.52 (IH, d) ,8.63(lH,s) .
MS:301 (M)+, 303 (M+2)+.
Example 156 6- [ (E) -2-Phenylvinyl] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazine .
1H-NMR (DMSO-d6)δ: 7.30-7.53 (4H,m) ,7.72-7.92 (4H,m) , 8.20-8.35 (
3H,m) ,8.54 (IH, s) , 8.71 (2H,d) .
MS:299(M+H)+. Example 157
6-Chloro-8-methoxy-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine .
MS:261 (M-I-H)+.
Example 158 trans-4- ( {3- [2- (4-Methyl-1-piperazinyl) -4-pyridinyl] imidazo [1, 2-b] pyridazin-6-yl} amino) cyclohexanol. MS:408 (M+H)+.
Example 159
2- (Benzyloxy) -5-{ 6- [ (trans-4-hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl }benzonitrile . MS:462 (M+Na)+.
Example 160 trans-4- ( { 3- [4- (Benzyloxy) -3-chlorophenyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol .
MS:449(M+H)+. Example 161
1— ( 3— { 6— [ (trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl } phenyl) ethanone .
1H-NMR(DMSOd6) 6:1.14-1.43 (4H, m) , 1.80-1.94 (2H,m) ,2.03-2.15 (
2H,m) ,2.67 (3H,s) , 3.36-3.76 (2H,m) ,4.58 (IH, d, 4. OHz) ,6.70 (lH,d , J=9.6Hz) , 6.95 ( IH, d, J=7.6Hz) ,7.60(lH,t, J=7.6Hz) ,7.75 (IH, d, J
=9.6Hz) ,7.87-7.90 (IH, m) ,7.97 (IH, s) , 8.32-8.39 ( IH, ra) ,8.80-8.8
3(lH,m) .
MS:351 (M+H)+.
Example 162 4-{ 6- [ (trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl} -2, β-dimethylphenol .
MS:353 (M+H)+.
Example 163 trans-4- ( {3- [4- (Benzyloxy) -3, 5-dichlorophenyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol . 1H-NMR(DMSO-CJ6) δ : 1.24-1.44 ( 4H, m) , 1.88-1.94 (2H, m) , 2.12-2.17 ( 2H,m) , 3.43-3.61(2H,m) ,4.61 (lH,d, J=4.2Hz) ,5.08 (2H,s) ,6.71 (IH , d, J=9.6Hz) ,7.08 (lH,d, J=6.8Hz) , 7.39-7.47 (3H,m) , 7.56-7.59 (2H ,m) ,7.76(lH,d, J=9.6Hz) ,8.09(lH,s) ,8.46(2H,s) . MS:483 (M+H)+. Example 164
N- (3-{ 6- [ (trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl }phenyl) acetamide . MS:388 (M+Na)+. Example 165
N- (4-{ 6- [ (trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl } -2-methoxyphenyl) -l-methyl-lH-indole-2- carboxamide . 1H-NMR (DMSO-de) 5:1.23-1.34 (4H, m) , 1.86-1.93 (2H,m) , 2.07-2.15 ( 2H,m) ,3.42-3.51 (IH, m) ,3.63-3.71 ( IH, m) , 3.99 (3H, s) , 4.04 (3H, s) ,4.61 (IH, d, J=4.4Hz) ,6.68 (IH, d, J=9.6Hz) ,6.94 ( IH, d, J=7.2Hz) ,7 .13-7.17 (lH,m) , 7.31-7.35 (2H,m) , 7.57-7.59 (lH,m) , 7.69-7.71 ( IH ,m) ,7.74 (IH, d, J=9.6Hz) ,7.81-7.84 (lH,m) ,7.93-7.97 (3H,m) ,9.43 (IH, s) . MS: 511 (M+H)+. Example 166
AcOH (300 μl) was added to a suspention of trans-4-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexano 1 (50 mg) in dichloromethane (3.3 ml). Then, methylisocyanate (30 μl) was added to the mixture .After stirring at ambient temperature for overnight, the reaction mixture was evaporated in vacuo. The residue was purified by preparative TLC eluting with dichloromethane/methanol (10 : 1) to give trans-4- { [3- (4-pyridinyl) imidazo [1, 2j-b] pyridazin-6-yl] amino} cyclohexyl methylcarbamate (27 mg) .
1H-NMR (DMSO-d6) 5:1.25-1.63 (4H,m) , 1.95-2.26 (4H,m) ,2.57 (3H,d, J=4.5Hz) , 3.57-3.76 ( IH, m) ,4.49-4.67 (IH, m) , 6.77 (IH, d, J=IO . OHz ) , 6.95 (lH,q, J=4.5Hz) , 7.16 ( IH, d, J=6.5Hz) ,7.8 ( IH, d, J=9.5Hz) , 8 .16(lH,s),8.2 (2H,d, J=6.5Hz) ,8.6 (2H, d, J=6.5Hz) . MS:367 (M+H)+.
The following compounds were obtained in a similar manner to that of Example 166.
Example 167 trans-4- { [3-(4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexyl ethylcarbamate . MS:381 (M+H)+. Example 168
N-Methyl-N' - (trans-4-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexyl) urea . 1H-NMR (DMSO-d6) 5:1.24-1.38 (4H,m) , 1.86-1.96 (2H,m) ,2.10-2.23 ( 2H,m) ,2.54 (3H, d, J=5. OHz) ,3.52-3.71 (lH,m) , 5.57-5.76 (2H, m) , 5. 82 (lH,d, J=8.0Hz) , 6.76 ( IH, d, J=9.6Hz) ,7.15 (IH, d, J=6.8Hz) ,7.80 (lH,d, J=9.8Hz) ,8.16(lH,s),8.21 (2H, d, J=6.2Hz) ,8.60 (2H,d, J=6. 2Hz) . MS:366(M+H)+. Example 169
To a stirred mixture of trans-4- [ (3-iodoimidazo [1, 2-b] pyridazin-β-yl) amino] cyclohexanol (100 mg) and (4-methylphenyl) boronic acid (76.0 mg) in dioxane (3 ml) was added 2M sodium carbonate aqueous solution ( 0.447 mL) at ambient temperature. The suspension turned to a clear yellow solution, palladium acetate (II) (=Pd(OAc)2, 3.13 mg) and triphenylphosphine (14.6 mg) were then added to the mixture at ambient temperature. After addition, the resulting mixture was subjected to microwave irradiation at 100 0C for 1 hour. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (20mL/20mL) . The resulting solution was extracted with ethyl acetate three times . The organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (50:1 to 20:1) to give trans-4-{ [3- ( 4-methylphenyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino} cyclohexanol (63.7 mg) . 1H-NMR (DMSO-de) δ : 1.15-1.42 ( 4H, m) ,1.82-2.00 (2H,m) , 2.01-2.21 ( 2H,m) ,2.35(3H,s) ,3.35-3.64 (2H,m) ,4.61 ( IH, d, J=4.3Hz) ,6.64 (IH , d, J=9.6Hz) , 6.93 ( IH, d, J=6.6Hz) , 7.26 (2H, d, J=8.2Hz) ,7.72 (IH, d , J=9.6Hz) ,7.83(lH,s),8.10 (2H, d, J=8.2Hz) . MS:323 (M+H)+ The following compounds were obtained in a similar manner to that of Example 169. Example 170
3- { 6- [ (trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl }benzonitrile.
1H-NMR (DMSO-d6) 5:1.16-1.48 (4H,m), 1.78-1.99 (2H,m) ,2.02-2.28 ( 2H,m) , 3.40-3.65(2H,m) ,4.60 (IH, d, J=4. OHz) , 6.73 ( IH, d, J=9.8Hz)
,7.05 (IH, d, J=6.7Hz) ,7.65 (IH, dd, J=6.2, 8. OHz) ,7.77 (lH,d, J=6.2
Hz) ,7.78 (lH,d, J=9.8Hz) ,8.05(lH,s),8.45 (IH, d, J=8. OHz) ,8.75(1
H, s).
MS:334 (M+H)+. Example 171 trans-4- { [3- (4-Fluorophenyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanol .
1H-NMR (DMSO-dg) 5:1.18-1.43 (4H,m) , 1.79-2.00 (2H,m) , 2.01-2.21 (
2H,m) ,3.39-3.63 (2H,m) , 4.59 ( IH, d, J=4.4Hz) ,6.67 ( IH, d, J=9.6Hz) , 6.96 (IH, d, J=6.8Hz) ,7.29 (2H, dd, J=9.0, 9.0Hz) ,7.73 (lH,d, J=9.6
Hz),7.86(lH,s),8.23 (2H, dd, J=5.5, 9.0Hz) .
MS:338 (M+H)+.
Example 172 trans-4- ( { 3- [4- (Dimethylamino) phenyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol .
MS:352 (M+H)+.
Example 173 trans-4- { [3- (4-Biphenylyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino } cyclohexanol . MS:385(M+H)+. Example 174 trans-4- { [3- (3-Fluorophenyl) imidazo [1, 2-b] pyridazin-6-yl ] amino } cyclohexanol .
1H-NMR(DMSO-Ci6) 5:1.15-1.46 (4H,m) ,1-80-2.01 (2H,m) ,2.02-2.28 ( 2H,m) ,3.39-3.62 (2H,m) ,4.61 ( IH, d, J=4.5Hz) ,6.70 ( IH, d, J=9.6Hz)
,7.04 (lH,d, J=6.5Hz) , 7.13 (IH, dt , J=2.6, 8.3Hz) ,7.48 (IH, dd, J=8.
1,14.5Hz) ,7.76(lH,d, J=9.6Hz) ,7.95 ( IH, d, J=8. OHz) ,8.00 (IH, s) ,
8.26(lH,d, J=ILOHz) .
MS:327 (M+H)+. Example 175
3-{ 6- [ (trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl }benzamide .
MS:352 (M+H)+.
Example 176 Methyl 3- { 6- [ (trans-4-Hydroxycyclohexyl) amino] imidazo
[ 1, 2-b] pyridazin-3-yl }benzoate .
1H-NMR (DMSO-d5)δ: 1.15-1.40 (4H,m) , 1.84-1.90 (2H,m) ,2.05-2.18 (
2H,m) , 3.39-3.55 (lH,m) ,3.35-3.75 (lH,m) , 3.91 (3H, s ) , 4.59 ( IH, d,
J=3.9Hz) ,6.71 (lH,d, J=9.6Hz) ,6.98 ( IH, d, J=6.9Hz) , 7.60 (IH, dd, J =7.8, 7.8Hz) ,7.76(lH,d, J=9.6Hz) ,7.90 (IH, d, J=7.8Hz) ,7.95 (IH, s
) ,8.31 (lH,d, J=7.8Hz) ,8.93(lH,s) .
MS:367 (M+H)+.
Example 177 trans-4-{ [3- (5-Methoxy-3-pyridinyl) imidazo [1, 2-b] pyridazin- 6-yl] amino} cyclohexanol. MS:362 (M+Na)+.
Example 178 trans-4- { [3- (3, 4-Dimethoxyphenyl) imida∑o [1, 2-b] pyridazin-6- yl ] amino } cyclohexanol . MS:369(M+H)+.
Example 179 trans-4-{ [3- (2-Chloro-4-pyridinyl) imidazo [1, 2-b] pyridazin-
6-yl] amino} cyclohexanol .
1H-NMR (DMSO-d6) 5:1.02-1.50 (4H,m) ,1-83-2.18 (4H,m) , 3.39-3.60 ( 2H,m) ,4.63 (IH, d, J=4. OHz) ,6.77 ( IH, d, J=9.7Hz) ,7.18 (lH,d, J=6.6
Hz) ,7.80 (lH,d, J=9.7Hz) ,8.05 ( IH, dd, J=I .4 , 5.5Hz) ,8.27(lH,s),8
.40 (lH,d, J=5.5Hz) ,8.57 ( IH, d, J=I .4Hz) .
MS:342 (M-H)".
Example 180 5-{ 6- [ ( trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl } -2-pyridinecarbonitrile .
MS:333 (M-H)".
Example 181 trans-4-{ [3- (3-Quinolinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanol .
MS:360 (M+H)+. '
Example 182 trans-4-{ [3- (lH-Indol-5-yl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanol . 1H-NMR (DMSO-de) 5:1.20-1.49 (4H,m) , 1.88-2.01 (2H,m) , 2.08-2.32 ( 2H,m) ,3.41-3.68 (2H,m) ,4.63 (IH, d, J=4.6Hz) ,6.44 (IH, s) , 6.62 (IH
,d,J=9.6Hz) ,6.88 (IH, d, J=6.5Hz) , 7.39 ( IH, dd, J=2.7 , 2.7Hz) ,7.45
(lH,d, J=8.6Hz) ,7.71 (IH, d, J=9.6Hz) ,7.77 (IH, dd, J=I.6, 8.7Hz) ,7
.80 (IH, s) ,8.61 (IH, s) , 11.17 (IH, bs) . MS:348 (M+H)+.
Example 183 trans-4-{ [3- (3, 4, 5-Trimethoxyphenyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanol .
1H-NMR (DMSO-de)δ: 1.14-1.31 (4H,m) , 1.80-1.90 (2H,m) ,2.03-2.10 ( 2H,m) ,3.35-3.50 ( IH, m) , 3.71 ( 3H, d) , 4.59 ( IH, d, J=4.5Hz) , 6.65 (IH
, d, J=9.6Hz) ,6.88 (IH, d, J=7.5Hz) ,7.47(2H,s),7.71 (IH, d, J=9.6Hz
),7.88(lH,s) .
MS:399(M+H)+.
Example 184 trans-4-{ [3- (5-Pyrimidinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanol .
1H-NMR (DMSO-d6) δ : 1.23-1.30 ( 4H, m) , 1.88 (2H, m) , 2.12 (2H,m) , 3.51
(2H,m) ,4.60 (IH, d, J=4. IHz) ,6.75 ( IH, d, J=9.7Hz) ,7.13 (lH,d, J=6.
6Hz) ,7.80 (IH, d,J=9.7Hz) ,8.13 (IH, s) ,9.09 (IH, s) ,9.58 (IH, s) . MS:310 (M+H)+.
Example 185 trans-4- { [3- ( 6-Fluoro-3-pyridinyl) imidazo [1, 2-b] pyridazin- 6-yl] amino} cyclohexanol.
1H-NMR (DMSO-d6) 5:1.23-1.43 (4H,m) , 1.88 (2H,m) , 2.12 (2H,m) , 3.51 (2H,m) ,4.61(lH,d,J=4. OHz) ,6.71 ( IH, d, J=9.7Hz) , 7.05 ( IH, d, J=6. 6Hz) ,7.31 (IH, dd, J=3.0,8.6Hz) ,7.77 ( IH, d, J=9.7Hz) ,7.99(lH,s) ,
8.54-8.74 (IH, m) ,9.09(lH,s) .
MS:328 (M+H)+.
Example 186 trans-4-{ [3- (2-Fluorophenyl) imidazo [ 1, 2-b] pyridazin-β-yl] amino } cyclohexanol .
MS:327 (M+H)+.
Example 187 trans-4r-{ [3-( 3-Fluoro-4-methoxyphenyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino} cyclohexanol .
1H-NMR (DMSO-d6) 5:1.05-1.43 ( 4H,m) , 1.76-1.83 (2H,m) ,2.12-2.23 (
2H,m) ,3.51 (2H,m) ,4.63 (lH,brs) ,6.74 ( IH, d, J=9.6Hz) ,7.02 (IH, d,
J=6.6Hz) ,7.24 (IH, t, J=9.0Hz) ,7.74 (IH, d, J=9.6Hz) , 7.88-7.91 (2H
,m) ,8.23 (IH, dd, J=2.0, 13.9Hz) . MS:357 (M+H)+.
Example 188 trans-4-{ [3- (2-Naphthyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanol .
1H-NMR (DMSO-d6) 5:1.06-1.49 (4H,m) , 1.94-1.98 (2H, m) , 2.20-2.25 ( 2H,m) ,3.45-3.83 (2H,m) , 4.69 (IH, d, J=4. IHz) , 6.73 (IH, d, J=9.7Hz)
,7.02 (lH,d, J=6.6Hz) , 7.48-7.58 (2H,m) , 7.78 (IH, d, J=9.7Hz) ,7.86
-7.96(2H,m) ,7.98 (IH, d, J=8.7Hz) ,8.06(lH,s),8.18 (IH, dd, J=I .6,
8.7Hz) ,8.99(lH,s) .
MS:359(M+H)+. Example 189 trans-4-{ [3- (2, 3-Dihydro-l-benzofuran-5-yl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanol . MS:351 (M+H)+. Example 190 trans-4-{[3-(3, 5-Dimethoxyphenyl) imida∑o [ 1, 2-b] pyridazin-β- yl ] amino } cyclohexanol .
1H-NMR (DMSO-d6) 5:1.18-1.37 (4H,m) , 1.79-1.92 (2H,m) , 2.01-2.19 ( 2H,m) ,3.39-3.54 ( IH, m) , 3.54-3.69 ( IH, m) , 3.82 ( 6H, s) , 4.58 ( IH, d, J=4.4Hz) ,6.47 (IH, t, J=2.2Hz) , 6.66 ( IH, d, J=9.7Hz) , 6.91 (IH, d, J= 7.1Hz) ,7.40 (2H,d, J=2.2Hz) ,7.72 (IH, d, J=9.7Hz) ,7.91 (IH, s) . MS: 369 (M+H)+. Example 191 trans-4- { [3- ( 6-Quinolinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanol . 1H-NMR (DMSOd5) : 1.18-1.48 (4H,m) , 1.92-1.97 (2H, m) ,2.18-2.23 (2 H, m) ,3.47-3.66 (2H,m) ,4.64 (IH, d, J=4. IHz) ,6.74 (IH, d, J=9.7Hz) , 7.04 (lH,d, J=6.6Hz) , 7.46-7.65 (IH, m) , 7.78 ( IH, d, J=9.7Hz) , 8.06 ( IH, d, J=9.0Hz) ,8.10(lH,s),8.28 (IH, d, J=7.8Hz) ,8.44 (lH,dd, J=I. 8, 9.0Hz) , 8.89 ( IH, dd, J=I.4, 4.2Hz) ,9.00 ( IH, d, J=I .4Hz) . Example 192 trans-4-({3-[3- (Benzyloxy) -4-methoxyphenyl] imidazo [1, 2-b] pyridazin-6-yl} amino) cyclohexanol .
1H-NMR (DMSO-d5) 5:1.1-1.35 (4H,m) , 1.78-1.95 (2H, m) ,1.95-2.19(2 H,m) ,3.36-3.53 (lH,m) ,3.53-3.71 ( IH, m) , 3.88 (3H, s) , 4.60 ( IH, d, J =4.3Hz) ,5.14 (2H, s) , 6.63 (IH, d, J=9.7Hz) ,6.90 (IH, d, J=7. IHz) ,7. 12 (IH, d, J=8.5Hz) , 7.34-7.51 (5H,m) ,7.62-7.83 (4H,m) .
MS:445 (M+H)+.
Example 193 trans-4-{ [3- (3, 4 -Difluorophenyl) imidazo [1, 2-b] pyridazin-6- yl] amino} cyclohexanol .
1H-NMR (DMSOd6) δ : 1.17-1.44 ( 4H, m) , 1.79-2.03 (2H,m) , 2.04-2.28 (
2H7ITi) , 3.39-3.65 (2H,m) ,4.62 (IH, d, J=4.2Hz) ,6.70 (IH, d, J=9.6Hz!
,7.05 (lH,d, J=6.6Hz) ,7.52 (IH, dt , J=IO .7, 8.8Hz) , 7.76 ( IH, d, J=9
6Hz) ,7.80-8.03 ( IH, m) , 7.98 ( IH, s) , 8.48-8.52 (lH,m) . MS:345 (M+H)+.
Example 194 trans-4- ( { 3- [4- ( Benzyloxy) phenyl] imidazo [1, 2-b] pyridazin-6- yl } amino) cyclohexanol .
MS:415 (M+H)+. Example 195
N- (4- { 6- [ ( trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl }phenyl) acetamide.
MS:366 (M+H)+.
Example 196 trans-4-{ [3- (4-Bromophenyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino } cyclohexanol .
MS:389 (M+H)+.
Example 197 trans-4- ( { 3— [ 4 — (Benzyloxy) -3-fluorophenyl] imidazo [1, 2-b] pyridazin-6-yl }amino) cyclohexanol . MS:360 (M+H)+. Example 198
To a solution of β-chloro-3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazine (50 mg) and trans-4-amino-4-methylcyclohexanol hydrochloride (27 mg) in toluene (5 mL) was added tris (dibenzylidenacetone) dipalladium chloroform complex (=Pd2dba3-CHCl3 ,7 mg) , 2, 2' -Bis (diphenylphosphino) - 1, 1' -binaphthyl (=BINAP ,12 mg) and sodium tert-butoxide (87 mg) . The mixture was stirred at 110 0C for 90 minutes under nitrogen atmosphere. The resultant was poured into water- dichloromethane (10% methanol), and extracted with dichloromethane . The organic phase was separated, washed with brine, and dried over sodium sulfate. Evaporation of the solvent gave a residue, which was purified by preparative TLC eluting with dichloromethane/methanol ( 10 : 1) to give trans-l-methyl-4- { [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin- 6-yl] oxy } cyclohexanamine (3 mg) .
1H-NMR(DMSO-d6)δ:1.41 ( 3H, s) , 1.37-1.86 ( 6H,m) ,2.03-2.23 (2H,m) ,5.00-5.11 ( IH, m) ,7.00 (IH, d, J=9.8Hz) , 8.11-8.17 (3H, m) , 8.38 ( IH ,s) ,8.67 (2H,d,J=6. IHz) . MS:324 (M+H)+. Example 199
To a stirred mixture of 3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (15.0 mg) and benzoyl chloride (15.0 mg) in dichloromethane (0.15 mL) was added N,N-diethylethanamine (14.4 mg) at ice-water bath temperature. The mixture was stirred for 1 hour at ambient temperature . The reaction mixture was poured into 1 M HCl and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (50:1 to 20:1) to give N- [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] benzamide (9.60 mg) . 1H-NMR(CDCl3)O :7.30 (IH, d, J=9.5Hz) , 7.38-7.53 ( 6H,m) , 8.22 ( IH, s ) ,8.23 (2H,d, J=8.5Hz) ,8.13 (2H, d, J=8.5Hz) ,8.59(lH,bs) . MS:31β(M+H)+. Example 200
To a solution of N-4-piperidinyl-3- ( 4-pyridinyl) imidazo- [1, 2-b] pyridazin-6-amine trihydrochloride (70 mg) in methanol (560 μL) was added acetic anhydride (25μL) , which was stirred at 600C for 2hours. To the mixture was added excess of triethylamine and acetic anhydride, which was stirred at 600C for 3 hours. The resultant was quenched by saturated NaHCO3 aqueous solution, and extracted with dichloromethane . The organic layer was washed with brine, dried over sodium sulfate, filtered, and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N- (l-acetyl-4- piperidinyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (57.7 mg) as a yellow powder. MS:337 (M+H)\ Example 201
To a stirred solution of ethyl 4- { [3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino } benzoate (60 mg) in methanol (1.8 ml) was added. IM NaOH aqueous solution (0.5 mL) at ambient temperature. The reaction mixture was stirred at 25 °C for 15 hours. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was diluted with ethyl acetate/water (1OmL: 1OmL). The resulting mixture was poured into water and then neutralized by the addition of aqueous IM HCl to pH 7. The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo . The residue was purified by silica gel column chromatography eluting with chloroform/methanol (50 : 1 to 20 : 1) to give 4-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-β-yl] amino }benzoic acid (23.5 mg) . 1H-NMR (DMSO-d5) δ:7.09 (IH, d, J=9.6Hz) ,7.62 (2H, d, J=8.5Hz) ,7.88 (2H,d, J=8.5Hz) ,7.99(lH,d, J=9.6Hz) , 8.16 (2H, d, J=6.2Hz) ,8.20(1 H,s),8.66(2H,d,J=6.2Hz) . Example 202 To a solution of 6-chloro-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine (653 mg) and tetrahydro-2H-pyran-4-amine (100 mg) in toluene (8.7 mL) was added tris (dibenzylidenacetone) dipalladium chloroform complex (=Pd2dba3'CHCl3 ,13 mg) , 2,2' -Bis (diphenylphosphino) -1, 1' -binaphthyl (=BINAP, 24 mg) and sodium tert-butoxide (125 mg) . The mixture was stirred at 110 0C for 1.5 hours under nitrogen atmosphere. The reaction mixture was poured into water and extracted with 10% methanol in dichloromethane . The organic layer was washed with brine, dried over sodium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel elution with chloroform/methanol (100: 0 to 100:10). The fraction was concentrated, and dissolved into HCO2NH2 (514 μl) and sodium methoxide ( 117 mg) was added. After stirring at 1000C for 2.5 hours, the reaction mixture was poured into water /dichloromethane. The resulting precipitates were collected by filtration to give trans-4- { [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanecarboxamide (6 mg) . 1H-NMR (DMSO-de) δ : 1.08-2.04 (8H,m) ,2.15-2.35 ( IH, m) , 3.80-3.99 ( IH, m) , 6.73 (IH, s) , 6.90 ( IH, d, J=9.7Hz) ,7.12 ( IH, d, J=6.2Hz) ,7.24 (IH, s) ,7.80 (lH,d, J=9.6Hz) ,8.16(lH,s) , 8.19 (2H, d, J=6. OHz) ,8.6 0 (2H,d, J=6.0Hz) . MS:337 (NRH)+. Example 203 Triethylamine (113 μl) and ethyl chloroformate (18 μl) was added to a suspention of trans-N- [3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6-yl] -1, 4-cyclohexanediamine trihydrochloride (65 mgj in dichloromethane (1.3 ml). After stirring at ambient temperture for 1 hour, the reaction mixture was evaporated in vacuo . The residue was purified by preparative TLC eluting with dichloromethane/methanol (10 : 1) to give ethyl (trans-4-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexyl ) carbamate (59 mg) .
1H-NMR (DMSO-d6)δ: 1.29-1.56 (4H,m) , 1.85-2.21 (4H,m) ,3.26-3.64 (
5H,m) ,3.99 (2H, q, J=7. OHz) , 6.79 ( IH, d, J=9.7Hz) ,7.08 (IH, d, J=7.8 Hz) ,7.25 ( IH, d, J=6.5Hz) ,7.81(lH,d, J=9.7Hz) ,8.17 (IH, s) ,8.22 (2
H,d, J=5.8Hz) ,8.61 (2H, d, J=5.8Hz) .
MS:381 (M+H)+.
Example 204
A mixture of 6-chloro-3- ( 4-pyridinyl) imidazo [1, 2-b] pyridazine (80 mg), 4-methylcylcohexylamine (231 μL) , and 1,8- diazabicyclo [5.4.0] undec-7-ene (233 μL) in n-butyl alcohol
(400 μL) was subjected to microwave irradiation at 150 0C for
2 hours. The resultant was dissolved in dimethylsulfoxide, which was, purified by HPLC. The fractions containing desired compound were combined, evaporated and dried under reduced pressure to give N- (4-methylcyclohexyl) -3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6-amine (18.7 mg) as a red powder.
MS:308 (M+H)+.
In addition, fractions containing by-product obtained from this and additional example were combined, evaporated and dried under reduced pressure to give 6-butoxy-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine as a red powder.
1H-NMR (DMSO-d6) δ:0.97 (3H, t, J=7.5Hz) ,1.50 (2H, sixtet , J=7.5Hz)
, 1.83 (2H, quintet, J=8.5Hz) , 4.43 (2H, t , J=6.4Hz) , 7.03 (IH, d, J=9. 6Hz) ,8.14 (IH, d, J=9.5Hz) ,8.18 (2H, dd, J=I .5, 4.5Hz) ,8.38 (IH, s) , 8 . 67 ( 2H, dd, J=1 . 5 , 5 . 0Hz ) . • Example 205
To a solution of 6-chloro-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine ( 80 mg) and l-methyl-4-piperidinamine ( 118.8 mg) in toluene (6.9 mL) was added tris (dibenzylidenacetone) dipalladium chloroform complex ( Pd2dba3-CHCl3, 10.8 mg) , 2,2' -Bis (diphenylphosphino) -1, 1' -binaphthyl (=BINAP , 19.5 mg) , and sodium tert-butoxide (150.0 mg) , which was stirred at 1100C for 2.5 hours under nitrogen atmosphere. The solvent was evaporated, the residue was dissolved in dimethylsulfoxide, and the resulting solution was desalted using solid-phase extraction cartridge. The solvent was evaporated and dissolved in dimethylsulfoxide (=DMSO) , which was purified by HPLC. The fractions containing desired compound were combined, evaporated and dried under reduced pressure to give
N- (l-methyl-4-piperidinyl) -3- (4- pyridinyl) imidazo [1, 2-b] pyridazin-6-amine ( 19.0 mg) as a yellow powder. 1H-NMR (DMSO-d6)δ: 1.51 (2H, dd, J=Il .3, 21.8Hz) ,1.95-2.18 (4H,m) , 2.21 (3H,s) ,2.70-2.84 (2H,m) , 3.50-3.76 (IH, m) , 6.77 (IH, d, J=9.8H z) ,7.48 (IH, d, J=6.7Hz) ,7.81 (lH,d, J=9.8Hz) ,8.16(lH,s) ,8.19(2H ,2.0, 5.0, J=2.0,5. OHz) ,8.60 (2H, dd, J=I .5, 5. OHz) . The following compound was obtained in a similar manner to that of Example 205. Example 206 3-{ [3- (4-Pyridinyl) imidazo [ 1, 2-b]φyridazin-6-yl] amino} -1- propanol .
1H-NMR(DMSO-Cl6) δ:1.82 (2H, quintet, J=6.5Hz) ,3.39 (2H, q, J=6. OHz ) , 3.56 (2H,q,J=6. OHz) , 4.57 (IH, t , J=5. OHz) , 6.78 ( IH, d, J=IO . OHz) ,7.21 (IH, t, J=5.5Hz) ,7.80 ( IH, d, J=9.5Hz) ,8.17(lH,s),8.23(2H,d d, J=2.0,5. OHz) , 8.60(2H,dd, J=I.5, 4.5Hz) . MS:270 (MH-H)+. Example 207
A mixture of 6-chloro-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine (50 mg) and (2-phenylethyl) amine ( 164 μL) in cyclopentyl methyl ether (150 μL) was subjected to microwave irradiation at 180 0C for 1 hour. Evaporation of the volatile components gave a residue, which was purified by column chromatography on silica gel to give N- (2-phenylethyl) - 3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (68.1 mg) as a brown powder.
1H-NMR (DMSO-d6) δ:2.97 (2H, t , J=6.5Hz) ,3.57 (2H, dt , J=6.5, 8. OHz) ,6.79 (IH, d, J=9.6Hz) ,7.15-7.48 (6H,m) ,7.81 (IH, d, J=9.7Hz) ,8.17 (IH, s) ,8.21 (2H,dd, J=I.5, 4.5Hz) , 8.60 (2H, dd, J=I .5, 4.5Hz) . MS:316 (M+H)+. The following compounds were obtained in a similar manner to that of Example 207. Example 208
N- [2- (4-Morpholinyl)ethyl]-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine . MS:325(M+H)+. Example 209
N- [2- (l-Benzyl-4-piperidinyl) ethyl] -3- ( 4-pyridinyl) imidazo
[1, 2-b] pyridazin-6-amine .
MS:413 (M+H)+. Example 210
N- ( 4-Piperidinylmethyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-β-amine .
MS:309 (M+H)+.
Example 211 4-(2-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} ethyl) phenol .
1H-NMR(DMSO-d6)δ:2.84 (2H,t),3.50(2H,t),6.72(2H,d),6.78(lH,d
) ,7.11(2H,d) ,7.34 (lH,t) ,7.81 (IH, d) , 8.16 (IH, s) ,8.22 (2H,d) ,8.
59(2H,d) ,9.23(lH,bs) . MS:332 (M+H)+.
Example 212
2,6-Dichloro-4-(2-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin- 6-yl] amino } ethyl) phenol .
MS:400 (M)+, 402 (M+2) + . Example 213
A mixture of trans-4- {[ 3- (2-chloro-4-pyridinyl) imidazo
[1, 2-b] pyridazin-6-yl] amino} cyclohexanol (30 mg) , Zinc cyanide (20 mg) , tetrakis ( triphenylphosphine) palladium (0) (20 mg) in N, N-dimethylformamide (0.9ml) was stirred at 1800C for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic extract was washed with water twice and brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by preparative TLC eluting with chloroform/methanol ( 10 : 1) to give 4-{6-[ (trans-4-hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl } -2-pyridinecarbonitrile (16 mg) . 1H-NMR (DMSO-d6)δ: 1.02-1.49 (4H,m) ,1.82-1.94 (2H,m) ,2.12-2.17 ( 2H,m) , 3.43-3.62 (2H,m) ,4.63 ( IH, d, J=3.9Hz) ,6.80 ( IH, d, J=9.7Hz) ,7.21 (lH,d, J=6.6Hz) ,7.82 (IH, d, J=9.7Hz) ,7.27(lH,s),7.46(lH,d d, J=I.4, 5.5Hz) ,7.74 (IH, d, J=5.5Hz) ,8.86 (IH, d, J=I .4Hz) . MS:335 (M+H) + . Example 214
To a solution of trans-4- ( { 3- [2- (methylsulfinyl) -4-pyridinyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol (66 mg) in dichloromethane (5 ml) was added 3-chloroperoxybenzoic acid (95 mg) , the mixture was stirred at 230C for 4 hours. The reaction mixture was quenched with NaHCO3 aqueous solution and purified by preparative TLC eluting with chloroform/methanol ( 10 : 1) to give trans-4- ( { 3- [2- (methylsulfonyl) -4-pyridinyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol (42 mg) .
1H-NMR (DMSO-d6) 5:1.18-1.55 (4H,m) , 1.81-1.91 (2H,m) ,2.06-2.11 ( 2H,m) , 3.31 (3H,s) ,3.31-3.78 (2H,m) ,4.55 (IH, brs) ,6.80 (lH,d, J=9 .7Hz) ,7.12 (IH, d, J=6.6Hz) ,7.82 ( IH, d, J=9.7Hz) , 7.90 ( IH, dd, J=I . 4,5.5Hz) , 8.36 (IH, s ) , 8.76 (dH, d, J=5.5Hz) , 9.14 (IH, m) . MS:388 (M+H)+. Example 215
To a solution of trans-4- ( { 3- [2- (methylthio) -4-pyridinyl] imidazo [1, 2-b] pyridazin-β-yl }amino) cyclohexanol (69 mg) in dichloromethane (5 ml) was added 3-chloroperoxybenzoic acid (49 mg) , the mixture was stirred at 230C for 3 hours. The reaction mixture was quenched with NaHCO3 aqueous solution and purified by preparative TLC eluting with chloroform/methanol (10:1) to give trans-4-({3-[2- (methylsulfinyl) -4-pyridinyl] imidazo [1, 2-b] pyridazin-β-yl }amino) cyclohexanol (83.5mg) . 1H-NMR (DMSO-ds) 5:1.05-1.57 (4H,m) , 1.80-1.85 (2H,m) , 2.06-2.10 ( 2H,m) ,2.83 (3H,s) ,3.31-3.80 (2H,m) , 4.54 (lH,brs) ,6.78 (IH, d, J=9 .7Hz) ,7.07 (lH,d, J=6.6Hz) ,7.80 (IH, d, J=9.7Hz) ,8.20 (lH,dd, J=I. 4,5.5Hz) , 8.34 (IH, s ) ,8/67 (IH, d, J=5.5Hz) ,8.95 ( IH, d, J=I .4Hz) . MS:372 (M+H)+. Example 216
To a solution of trans-4- { [3- (2-chloro-4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanol (100 mg) in toluene (4 ml), N, N-dimethylformamide (1 ml) was added sodium methanethiolate (203 mg) , the mixture was stirred at 15O 0C for 4 hours. The reaction mixture was quenched by IM HCl aqueous solution, neutralized with saturated NaHCO3 aqueous solution, poured into water and extracted with ethyl acetate. The organic extract was washed with water twice and brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by preparative TLC eluted with 15% methanol in chloroform to give trans-4- ( { 3- [2- (methylthio) -4-pyridinyl] imidazo [1, 2-b] pyridazin-β-yl } amino) cyclohexanol . 1H-NMR(DlMSO-O6) 5:1.20-1.50 (4H,m) ,1-89-1.99 (2H,m) ,2.10-2.16 ( 2H,m) ,2.57 (3H,s) ,3.44-3.63 (3H,m) ,6.83 ( IH, d, J=9.8Hz) ,7.22 (IH , d, J=6.8Hz) , 7.76 (IH, dd, J=I.4, 5.5Hz) ,7.83 ( IH, d, J=9.8Hz) ,8.27 (IH, s) ,8.33(lH,d, J=I.4Hz) ,8.46(lH,d, J=5.5Hz) . MS:356(M+H)+.
The following compound was obtained in a similar manner to that of Example 216. Example 217 trans-4- ( { 3- [2- (Phenylthio) -4-pyridinyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol .
1H-NMR (DMSO-d6) δ: 1.31-1.50 (4H,m) , 1.88-1.94 (2H,m) ,2.09-2.15 ( 2H,m) , 6.78 (IH, d, J=9.6Hz) ,7.13 (lH,d, J=6.6Hz) ,7.42-7.59 (5H,m) ,7.78-7.88 (2H,m) , 8.12 (IH, s) ,8.29 (IH, s) , 8.38-8.41 (IH, m) . MS:418. Example 218
To a solution of trans-4-{ [3- (2-chloro-4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanol (150 mg) in toluene (7.5ml) and N, N-dimethylformamide (1.5ml) was added 28% sodium methoxide in methanol (0.025 ml) . The mixture was stirred at 150 0C for 13 hours. The reaction mixture was quenched by 1 M HCl aqueous solution, neutralized with saturated NaHCC>3 aqueous solution, poured into water and extracted with ethyl acetate. The organic extract was washed with water twice and brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by preparative TLC eluted with 15% methanol in chloroform to give trans-4- { [3- (2-methoxy-4- pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanol . 1H-NMR (DMSO-d6) δ : 1.25-1.39 ( 4H,m) , 1.88-1.90 (2H,m) ,2.05-2.15 ( 2H,m) ,3.40-3.60 (2H,m) , 3.89 ( 3H, s) , 4.62 ( IH, d, J=4. IHz) ,6.74 (IH , d, J=9.7Hz) ,7.09 ( IH, d, J=6.6Hz) ,7.68 ( IH, dd, J=I .4 , 5.6Hz) ,7.77 (lH,d, J=9.7Hz) ,7.86(lH,s),8.15(lH,s),8.17 ( IH, d, J=5.6Hz) . MS:340 (M+H)+. The following compound was obtained in a similar manner to that of Example 218. Example 219 trans-4- { [3- (2-Phenoxy-4-pyridinyl) imidazo [ 1, 2-b] pyridazin- 6-yl] amino} cyclohexanol . 1H-NMR (DMSO-d6) δ: 1.17-1.38 (4H,m), 1.86-1.99 (2H,m) ,2.05-2.17 ( 2H,m) ,3.48 (lH,brs) ,4.58 ( IH, d, J=4. IHz) ,6.77 ( IH, d, J=9.6Hz) ,7. 10-7.38 (4H,m) , 7.41-7.46 (2H, m) , 7.78-7.86 (2H,m) ,8.31-8.21 (3H, m) . MS: 402 (M+H)+,424 (M+Na)+. Example 220
To a stirred solution of methyl 3- { 6- [ (trans-4- hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl } benzoate (30 mg) in methanol (0.5 ml) was added 1 M NaOH aqueous solution (123 μL) at ambient temperature . The reaction mixture was stirred at 250C for 27 hours. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was neutralized by the addition of aqueous IM HCl aqueous solution to pH 7. The resulting solution was extracted with dichloromethane. The organic layer was dried over magnesium sulfate, and concentrated in vacuo to give 3- { 6- [ (trans-4- hydroxycyclohexyl) amino] imidazo [ 1, 2-b] pyridazin-3-yl } benzoic acid (10 mg) . MS:353 (M+H)+. Example 221 To a suspention of trans-N- [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] -1, 4- cyclohexanediamine trihydrochloride (50 mg) in CH3CN (1 ml) was added triethylamine (50 μl) and 35% aqueous HCHO (21 μl) under stirring at ambient temperature. After stirring at ambient temperature for 10 minutes, sodium acetoxy borohydride (25 mg) was added to the mixture. After stirring at ambient temperature, for overnight, the reaction mixture was poured into water and extracted with 10% methanol in dichloromethane , dried over sodium sulfate and evaporated in vacuo. The residue was purified by preparative TLC eluting with dichloromethane/ methanol (10 : 1) to give trans-N, N-dimethyl-N ' - [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] -1, 4- cyclohexanediamine (15 mg) . 1H-NMR (DMSO-d6)δ: 1.05-1.49 (5H,m) , 1.83-2.00 (2H,m) ,2.10-2.29 ( 2H,m) ,2.21 (6H,s) ,3.46-3.63 (lH,m) , 6.75 (IH, d, J=9.8Hz) ,7.14 (IH , d, J=β.7Hz) ,7.79 (IH, d, J=9.7Hz) ,8.16(lH,s),8.21 (2H, d, J=6. IHz ) ,8.61 (2H,d, J=6.1Hz) . MS:337 (M+H)+. Example 222
To a suspension of trans-N- [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] -1, 4-cyclohexanediamine trihydrochloride (50 mg) in dichloromethane (1 ml) was added triethylamine (70 μl) and phenylacetylchloride (19 μl) under stirring at 00C. After stirring at ambient temperature for 2 hours, 10% methanol in dichloromethane was added to the reaction mixture and filtrated. The filtrate was evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with chloroform/methanol (100:2 to 100:25) to give 2-phenyl-N- (trans-4-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexyl) acetamide (30 mg) . 1H-NMR (DMSO-de) 5:1.19-1.50 (4H,m) , 1.79-1.99 (2H,m) , 2.07-2.29 ( 2H,m) ,3.22-3.45 (IH, m) ,3.41 (2H,s) , 3.2-3.69 (IH, m) , 6.76 (IH, d, J =9.9Hz) ,7.17 (IH, d, J=6.6Hz) ,7:21-7.35 (5H,m) ,7.80 (lH,d, J=9.9H z) ,8.05 (lH,d, J=7.7Hz) ,8.16(lH,s),8.21 (2H, d, J=6.2Hz) , 8.61 (2H ,d, J=6.2Hz) . MS:427 (M+H)+.
The following compound was obtained in a similar manner to that of Example 222.
Example 223
N- (trans-4-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexyl) benzamide . MS:413 (M+H)+. Example 224
To a solution of tert-butyl 4-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} -1-piperidinecarboxylate (40 mg) in dichloromethane (1.2 mL) was added 4 M HCl in dioxane (507 μL) at 0 0C, which was stirred at ambient temperature for 2 hours. The precipitate was filtered, and washed by diisopropyl ether to give N-4-piperidinyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine trihydrochloride (38 mg) as a yellow powder. MS:295 (M+H)+.
The following compound was obtained in a similar manner to that of Example 224.
Example 225
N-3-Piperidinyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6- amine trihydrochloride.
1H-NMR (DMSO-d6) δ: 1.45-2..10 (8H,m) ,2.63-3.61 (4H,m) , 7.14 (IH, d , J=9.8Hz) ,8.05 (IH, d, J=9.8Hz) , 8.83-8.90 (2H,m) , 9.12-9.15 (2H,m ) • MS:295. . Example 226
To a solution of trans-N- [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] -1, 4- cyclohexanediamine trihydrochloride (23 mg) in dichloroformate (0.46 ml) was added triethylamine (40 μl) and methyl chloroformate (5.1 μl) at 00C. After stirring at 00C for 40 minutes, the mixture was quenched with water and extracted with ethyl acetate . The organic layer was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by preparative TLC eluting with dichloromethane/methanol ( 10 : 1) to give methyl (trans-4- { [3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-β-yl] amino} cyclohexyl) carbamate (20 mg) as an pale yellow solid. 1H-NMR(CDCI3-CD3OD(S:!) ) δ : 1.33-1.55 (4H,m) , 1.73-1.92 (2H, m) , 2. 13-2.38 (2H,m) ,3.75-4.04 (2H,m) ,3.93 (3H,s) , 6.92 ( IH, d, J=8.4Hz) ,7.74 (lH,d, J=8.1Hz) , 8.28 ( IH, s) , 8.67-8.75 (2H,m) , 8.80-8.91 (2H ,m) .
MS:367 (NRH) + .
Example 227
The suspention of trans-N- [3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6-yl] -1, 4-cyclohexanediamine trihydrochloride (20 mg) , KOCN (8 mg) and sodium acetate (8 mg) in N, N- dimethylformamide (0.4 ml) was stirred at 500C for 4 hours. After cooling to ambient temperature, the reaction mixture was purified by praparative TLC eluting with (dichloromethane : methanol=10 : 1) to give N- (trans-4-{ [3- (4-pyridinyl) imidazo [1,2-b] pyridazin-6-yl] amino } cyclohexyl) urea (6 mg) .
1H-NMR (DMSO-de) 5:1.16-1.42 (4H,m) , 1.82-1.99 (2H,m) ,2.11-2.24 ( 2H,m) ,3.49-3.69 (lH,m) , 3.29-3.46 (3H,m) , 5.93 (IH, d, J=7.8Hz) , 6. 76(lH,d, J=9.7Hz) ,7.17 ( IH, d, J=6.7Hz) ,7.80 ( IH, d, J=9.7Hz) ,8.16 (IH, s) , 8.21 (2H,d,J=6. IHz) , 8.60 (2H, d, J=6. IHz) . MS:352 (M+H)+. The following compounds were obtained in a similar manner to that of Example 227
Example 228
N-Phenyl-3-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } -1-piperidinecarboxamide .
1H-NMR (DMSO-de) δ:l.47-1.75 (2H,m) , 1.82 (lH,brs) ,2.11 (lH,brs) ,
2.84-2.94 (IH7ItI) ,3.00-3.18 (IH, m) , 4.78 (lH,brs) ,3.95 (IH, d, J=12
.8Hz) , 4.31(lH,d, J=12.8Hz) ,6.81 ( IH, d, J=9.8Hz) , 6.92 (IH, t , J=7.
3Hz) ,7.47 (lH,d, J=7.9Hz) ,7.82 (IH, d, J=9.8Hz) , 8.14-8.19 (3H,m) , 8.48-8.51 (3H,m) .
MS: 414 (M+H)+, 436 (M+Na) + .
Example 229
N-Methyl-3-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyrida^zin-6-yl] amino } -1-piperidinecarboxamide . 1H-NMR (DMSO-d6) δ : 1.23 ( IH, m) , 1.49 (2H,m) , 1.78 ( IH, m) , 2.08 (lH,m
) ,2.66-2.72 (lH,m) ,2.88 (IH, m) ,3.71 (2H,m) ,4.25 ( IH, d, J=4.4Hz) ,
6.43 (lH,d, J=4.2Hz) ,6.80 (IH, d, J=9.8Hz) ,7.15 ( IH, d, J=6.6Hz) ,7.
80-7.83 (lH,m) , 8.16-8.22 (3H,m) , 8.57-8.59 (2H,m) .
MS: 352 (M+H)+,374 (M+Na)+. Example 230
To a suspension of trans-4-{ [3- ( 4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino}cyclohexanol (100 mg) in dichloromethane
(2 ml) was added Dess-Martin periodinane (206 mg) . After stirring for overnight, the mixture was poured into saturated aqueous NaHCO3 aqueous solution and extracted with 10% methanol in chloroform , dried over sodium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with chloroform/methanol (100 : 2 to 10:1) to give 4-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanone as an pale yellow solid (46 mg) .
1H-NMR (DMSO-de) δ : 1.71-1.90 (2H, m) ,2.23-2.62 ( 6H,m) , 4.09-4.24 ( IH, m) , 6.81 ( IH, d, J=IO. OHz) , 7.31 ( IH, d, J=6. OHz) , 7.84 (IH, d, J=9. 5Hz), 8.19 ( IH, s), 8.23 (2H, d, J=6. OHz) ,8.63 (2H, d, J=6. OHz) . MS:308 (M-I-H)+. Example 231
4 M HCl aqueous solution in 1,4-dioxane (428 μl) was added to a solution of tert-butyl, (trans-4-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexyl) carbamate (70 mg) in ethyl acetate (0.7 ml) under stirring at 00C. After stirring at ambient temperature for 4 hours, the reaction mixture was evaporated in vacuo. Resulting precipitates were collected by filtration and washed with diisopropylether to give trans-N- [3- ( 4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] -1,4- cyclohexanediamine trihydrochloride (40 mg) as an yellow solid. 1H-NMR (DMSO-de) 5:1.26-1.47 (2H,m) ,1.61-1.83 (2H,m) ,2.00-2.22 ( 4H,m) ,3.03-3.22 (lH,m) , 3.58-3.78 (lH,m) , 4.70 (3H, br) , 7.03 (IH, d , J=9.5Hz) ,7.65-7.76 ( IH, m) ,7.98 (IH, d, J=9.5Hz) , 8.18 (2H, br) , 8. 69 (IH, s ) ,8.76(2H,d, J=7.0Hz) , 8.93 (2H, d, J=7. OHz) . MS:309 (Mfree+H)+. Example 232 A mixture of
6-chloro-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine (50 mg) and
[ (l-ethyl-2-pyrrolidinyl) methyl] amine (94.8 μL) in ethylene glycol dimethyl ether (=DME, 150 μL) was subjected to microwave irradiation at 1500C for 90 minutes. Evaporation of the volatile components gave a residue, which was purified by column chromatgraphy on silica gel to give N- [ (l-ethyl-2- pyrrolidinyl) methyl] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (63.1 mg) as a yellow powder. 1H-NMR (DMSO-d6) δ:1.05 (3H, t, J=7. OHz) , 1.51-1.98 (4H,m) ,2.02-2.
37 (2H,m) ,2.61-2.79(lH,m) ,2.82-3.22 (3H,m) , 3.51-3.69 (IH, m) ,6.
85(lH,d, J=9.7Hz) ,7.18 ( IH, t , J=5.6Hz) , 7.79 ( IH, d, J=9.7Hz) ,8.15
(IH, s) ,8.20 (2H,dd, J=I.5, 4.5Hz) , 8.59 (2H, dd, J=I .5, 4.5Hz) .
MS:323 (M+H)+. The following compounds were obtained in a similar manner to that of Example 232.
Example 233
N- [2- (1-Piperidinyl) ethyl] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine . MS:323 (M+H)+.
Example 234
N,N-Dimethyl-N' - [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-y
1] -1, 2-ethanediamine.
MS:283 (M+H)+. Example 235 To a stirred mixture of β-chloro-3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazine (80 mg) and (4-pyridinylmethyl) amine (113 mg) in toluene (4 ml) were added sodium tert-butoxide (150 mg) , (R) -2, 2' -Bis (diphenylphosphino) -1, V -binaphthyl (= (R) -BINAP, 19.4 mg) , and tris (dibenzylideneacetone) dipalladium chloroform complex (=Pd2 (dba) 3'CHC13, 10.8 mg) at ambient temperature. The reaction mixture was subjected to microwave irradiation at 1000C for 1 hour. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (lOmL/lOmL) . The resulting mixture was acidified with 1 M HCl aqueous solution to pH 2 and extracted with Ethyl acetate. The aqueous phase was then adjusted to pH 8 with 2 M NaOH aqueous solution. The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (40:1 to 20:1) to give 3- (4-pyridinyl) - N- (4-pyridinylmethyl ) imidazo [ 1 , 2-b] pyridazin-β-amine .
1H-NMR (DMSO-ds) δ:4.57 (2H, d, J=5.7Hz) ,6.92 (IH, d, J=9.6Hz) ,7.44 (2H,d, J=5.8Hz) ,7.86(2H,d, J=5.8Hz) ,7.88 (IH, d, J=9.6Hz) ,7.98 (1 N H,t, J=5.7Hz) ,8.13(lH,s),8.48 (2H, d, J=4.8Hz) ,8.55 (2H,d, J=4.8H
2) • MS:303(M+H)+. The following compounds were obtained in a similar manner to that of Example 235.
Example 236
N- (2, 4-Dichloro-5-methoxyphenyl) -3- ( 4-pyridinyl) imidazo [1, 2-b]pyridazin-6-amine.
MS:388.
Example 237
N- [ (IS, 2R) -2-Methylcyclohexyl] -3- (4-pyridinyl) imidazo [1, 2- b]pyridazin-6-amine. 1H-NMR (DMSO-ds)δ: 0.92 (3H, d, J=7. OHz) , 1.31-1.73 (7H,m) , 1.78-1.
95(lH,m),,2.03-2.21(lH,m) ,3.92-4.10 (lH,m) , 6.91 (IH, d, J=7.5Hz)
,6.94 (IH, d, J=9.8Hz) , 7.78 ( IH, d, J=9.8Hz) , 8.15 ( IH, s) , 8.19 (2H, d
, J=6.4Hz) ,8.60 (2H,d, J=6.4Hz) .
MS:308 (M+H)+. Example 238
N- [2-Chloro-5- (tetrahydro-2H-pyran-2-yloxy) phenyl] -3- (4- pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
MS:422 (M+H)+.
Example 239 (3-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} phenyl ) methanol .
MS:318 (M+H)+.
Example 240
N- (5-Methoxy-2-methylphenyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine. MS:332 (M+H)+.
Example 241
N- (2-Methylphenyl) -3- (4-pyridinyl ) imidazo [1, 2-b] pyridazin-
6-amine . MS:302 (M+H)+.
Example 242
(1R,2R, 3S, 5s) -5-{ [3- (4-Pyridinyl) imidazo [ 1, 2-b] pyridazin-6- yl] amino} -2-adamantanol .
1H-NMR (DMSO-d6) 5:1.45-2.28 ( 13H,m) , 4.02 ( IH, s) , 4.24 ( IH, s) , 6.4 2(lH,d, J=9.6Hz) , 7.68 ( IH, d, J=9.6Hz) , 7.96 ( IH, s) , 8.07 (2H,d, J=6
.0Hz) ,8.67 (2H,d, J=6.0Hz) .
MS:364 (M+H)+.
(lR,2S,3S,5s)-5-{ [3- ( 4-Pyridinyl) imidazo [1, 2-b] pyridazin-6- yl] amino } -2-adamantanol . 1H-NMR (DMSO-d6) δ:1.47-2.62 (13H,m),3.88(lH,s),4.24(lH,s),6.4
1 (IH, d, J=9.6Hz) , 7.66(lH,d, J=9.6Hz) , 7.96 ( IH, s) , 8.12 (2H, d, J=6
.2Hz) ,8.64 (2H,d, J=6.2Hz) .
MS:364 (M+H)+.
Example 243 trans-4-{ [7-Methyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin- β-yl] amino }cyclohexanol .
MS:324 (M+H)+.
Example 244 trans-4-{ [8-Methyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin- 6-yl] amino} cyclohexanol . 1H-NMR ( DMSO-d6) δ: 1.28-1.56 (4H,m) , 1.82-1.99 (2H,m) ,2.07-2.21 (
2H,m) ,2.23 (3H,s) ,3.38-3.59 (lH,m) , 3.62-3.83 (IH, m) ,4.62 (IH, d,
J=4.6Hz) ,6.17 (lH,d, J=7.0Hz) ,7.69(lH,s) ,8.13(lH,s) ,8.20(2H,d
, J=6.2Hz) ,8.58 (2H,d, J=6.2Hz) . MS:324 (M+H)+.
Example 245
N- (3-Methylcyclohexyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
MS:308 (M+H)+. Example 246
N- [1- (2-Pyrazinyl) -4-piperidinyl] -3- (4-pyridinyl) imidazo
[1, 2-b] pyridazin-6-amine .
1H-NMR (DMSO-Ci6) δ:1.48-1.58(2H,m) ,2.16-2.20 (2H,m) , 3.21-3.28 (
2H,m) ,3.93-4.05 (IH, m) , 4.29-4.33 (2H,m) , 6.78 ( IH, d, J=9.8Hz) ,7. 26(lH,d, J=6.6Hz) ,7.82-7.84 (2H,m) , 8.09-8.10 ( IH, m) , 8.19 ( IH, s)
,8.21-8.22 (2H,m) ,8.40 (IH, d, J=I .4Hz) , 8.62-8.63 (2H,m) .
MS:373 (M+H)+.
Example 247
N- (l-Phenyl-4-piperidinyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine.
MS:371 (M-I-H) + .
Example 248
N-2-Adamantyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6- amine. 1H-NMR (DMSO-d6) δ:1.48-2.25(14H,m) ,3.92-4.02 (lH,m) , 6.97 (IH, d , J=9.6Hz) ,7.14 (lH,d, J=6.1Hz) ,7.80 (lH,d, J=9.6Hz) , 8.16 (IH, s) ,
8.19(2H,d, J=6.1Hz) ,8.58 (2H, d, J=6. IHz) .
MS:34β(M+H)+.
Example 249 N-l-Adamantyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6- amine .
1H-NMR (DMSO-d6) δ:1.73(6H,s),2.15(9H,s),6.80(lH,d,J=9.6Hz),6
.81 (lH,d, J=4.5Hz) ,7.86 (lH,d, J=9.6Hz) ,8.12 (IH, s) , 8.19C2H,d, J
=4.8Hz) ,8.60 (2H,d, J=4.8Hz) . MS:346 (M+H)+.
Example 250
N- [ (IS, 2R) -2-Ethylcyclohexyl] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
MS:322 (M+H)+. Example 251
3- (4-Pyridinyl) -N- [2- (2-pyridinyl) ethyl] imidazo.[1, 2-b] pyridazin-6-amine .
MS:317 (M+H)+.
Example 252 To a mixture of N-4-piperidinyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine trihydrochloride (60 mg) and K2CO3 (123.6 mg) in acetone (900 μL) was added methyl' chloroformate (69 μL) , which was stirred under reflux for 8 hours. To the resultant was added water. The mixture was extracted with dichloromethane . The organic layer was washed with brine, dried over sodium sulfate, filtered, and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give methyl 4- { [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6- yl] amino} -1-piperidinecarboxylate (35.3 mg) as a white powder . MS:353 (M+H)+. Example 253
To a mixture of N-4-piperidinyl-3- (4-pyridinyl) imidazo [1 , 2-b] pyridazin-β-amine trihydrochloride (70 mg) and formic acid (196 μL) was added acetic anhydride (19.6 μL) , which was stirred at 600C for 4 hours . To the mixture was added excess of ethyl formate and triethylamine, which was stirred at 600C for 4 hours. To the reslutant was added water. The mixture was extracted with dichloromethane . The organic layer was washed with brine, dried over sodium sulfate, filtered and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-{ [3- (4-pyridinyl) imidazo [1 , 2-b] pyridazin-6- yl] amino } -1-piperidinecarbaldehyde (5.1 mg) as a yellow powder. 1H-NMR (DMSO-d6) δ : 1.17-1.61 (2H, m) , 2.00-2.26 (2H,m) ,2.83-3.09 ( IH, m) ,3.14-3.48 (lH,m) , 3.64-4.24 (3H,m) , 6.78 (IH, d, J=9.7Hz) ,7. 28 (IH, d, J=6.6Hz) ,7.84 ( IH, d, J=9.7Hz) ,8.04(lH,s),8.14-8.24(3H ,m) , 8.63 (2H,dd, J=I.4, 4.7Hz) .
MS:323 (M+H)+. Example 254 trans-4-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanecarboxylic acid bis (trifluoroacetate) (61 mg) was dissolved into N, N-dimethylformamide (1.2 ml), and 1- hydroxybenzotriazole (=HOBT, 16 mg) , l-ethyl-3- (3- dimethylaminopropyl) carbodiimide (=EDCI, 23 mg) and triethylamine (47 μl) was added to the solution.
Then, methylamine hydrochloride (8mg) was added to the mixture . After stirring at ambient temperature for overnight, the reaction mixture was poured into water, and extracted with 10% methanol in dichloromethane . The organic layer was dried over magnesium sulfate and evaporated in vacuo. The redisue was purified by preparative TLC eluting with dichloromethane/ methanol (10:1) to give trans-N-methyl-4- { [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanecarboxamide (3 mg) . 1H-NMR (DMSO-d6) 5:1.50-2.00 (8H,m) , 2.12-2.31 ( IH, m) , 2.57 (3H, d, J=4.5Hz) ,3.88-4.01 (IH, m) , 6.91 (IH, d, J=9.7Hz) ,7.13 (lH,d, J=6.3 Hz) ,7.69 (lHrd, J=4.5Hz) ,7.80 (IH, d, J=9.7Hz) , 8.16 ( IH, s), 8.19 (2 H,d, J=6.3Hz) ,8.60 (2H, d, J=6.3Hz) . MS:351 (M+H)+. The following compound was obtained in a similar manner to that of Example 254 Example 255 trans-N,N-Dimethyl-4-{ [3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } cyclohexanecarboxamide . MS:365 (M+H)+. Example 256
A mixture of 6-chloro-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine (80 mg), 2M methylamine in tetrahydrofuran (867 μL), and methylamine hydrochloride (234 mg) 'was subjected to microwave irradiation at 1600C for 6 hours. To the resultant was added saturated NaHCO3 aqueous solution The mixture was extracted with dichloromethane . The oragic layer was washed with brine, dried over sodium sulfate, filtered, and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-methyl-3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (14mg) as a white powder. MS:226(M+H)+. Example 257 A mixture of 6-chloro-3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazine (50 mg) and (IS, 2S) -2-amino-l-phenyl-l, 3- propanediol (362.5 mg) was subjected to microwave irradiation at 1800C for 30 minutes. The resultant mixture was dissolved in dimethylsulfoxide, which was purified by HPLC to give (IS, 2S) -l-phenyl-2-{ [3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino }-l, 3-propanediol (25.1 mg.) as a yellow powder. MS:362 (M+H)+.
The following compound was obtained in a similar manner to that of Example 257. Example, 258 (lR,2S,4R)-4-{ [3- (4-Pyridinyl) imidazo [1, 2-b] pyridazin-β-yl] amino } -1, 2-cyclopentanediol .
1H-NMR (DMSO-d6) δ : 1.55-1.71 (2H, m) ,2.26-2.41 (2H,m) , 3.84-4.11 (
3H,m) ,4.48-4.53 (2H,m) , 6.82 (IH, d, J=9.7Hz) ,7.25 ( IH, d, J=6.5Hz) ,7.78 (IH, d, J=9.7Hz) ,8.14(lH,s),8.21 (2H, d, J=6.3Hz) ,8.61 (2H,d
, J=6.3Hz) .
MS:312 (M+H)+.
Example 259
N- [ (3-exo) -δ-Benzyl-δ-azabicyclo [3.2.1] oct-3-yl] -3- (4- pyridinyl) imidazo [1, 2-b] pyridazin-6-amine .
MS:411 (M+H)+.
Example 260
(lR,2R)-l-Phenyl-2-{ [3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino} -1, 3-propanediol . MS:3'62 (M+H)+.
Example 261
1 M methyl magnesium bromide in tetrahydrofuran (0.14 ml) was added dropwise to a solution of 4-{ [3- (4-pyridinyl) imidazo
[1,2-b] pyridazin-6-yl] amino} cyclohexanone (22 mg) in tetrahydrofuran (1 ml) . After stirring at ambient temperature for 2 hours, additional 1 M methyl magnesium bromide in tetrahydrofuran (0.14 ml) was added dropwise, then stirred at ambient temperature for 2 hours. 1 M HCl aqueous solution was added to the reaction mixture, and saturated NaHCU3 aqueous solution was added until pH 8. Then, extracted with 10%methanol in chloroform, dried over sodium sulfate and evaporated in vacuo. The residue was purified by preparative TLC developing with dichloromethane/methanol (10 : 1) to give l-methyl-4-{ [3- (4- pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanol (2 mg) .
1H-NMR (DMSO-de) δ : 0.97-1.31 (2H,m) , 1.17 (3H, s) , 1 , 41-1.71 (3H,m) ,1.81-2.01 (2H,m) ,2.73-2.97 (lH,m) , 3.48-3.88 ( IH, m) , 6.81 (IH, d, J=9.9Hz) ,7.09 (IH, d, J=5.5Hz) , 7.79 (IH, d, J=9.9Hz) ,8.16(lH,s),8 .20 (2H,d, J=6.2Hz) ,8.60 (2H, d, J=β .2Hz) , 8.61 (IH, s) . MS:324 (M+H)+. Example 262
To a mixture of 6-chloro-3- ( 4-pyridinyl) imidazo [1, 2-b] pyridazine (80 mg) and 1, 8-diazabicyclo [ 5.4.0] undec-7-ene (233 μL) in N-methyl-2-pyrrolidinone (240 μL) was added 4-tert-butylcyclohexylamine (310 μL) . The mixture was subjected to microwave irradiation at 1500C for 2.5 hours. To the resultant was added water. The mixture was extracted with ethyl acetate/n-hexane (4:1).' The organic layer was washed brine, dried over sodium sulfate, filtered, and evaporated in vacuo. The residue was purified by preparative TLC to give N- (4-tert-butylcyclohexyl) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (34.1 mg) as a yellow amorphous. MS:350 (M+H)+. Example 263 To a stirred .solution of trans-4-{ [3- (3, 4-dimethoxyphenyl) imidazo [1, 2-b] pyridazin-6~yl] amino }cyclohexanol (37 mg) in dichloromethane (1 ml) was added dropwise 1.0 M BBr3 in dichloromethane (1.004mL) at 0 0C. The reaction mixture was stirred at this temperature for 1 hour. The reaction mixture was neutralized with 1 M NaOH aqueous solution and extracted with chloroform/methanol (5:1). The organic layers was dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (5:1) to give 4- { 6- [ (trans-4- hydroxycyclohexyl) amino] imidazo [l,2-b]pyridazin-3-yl}~ 1,2-benzenediol (10 mg) .
1H-NMR (DMSO-d6) 5:1.20-1.38 (4H,m) , 1.85-1.91 (2H7Ri) , 2.09-2.15 ( 2H7-Ti) ,3.41-3.62 (2H,m) , 4.60 (lH,brs) , 6.59 ( IH, d, J=9.6Hz) ,6.79- 6.85 (2H,m) ,7.46-7.50 (IH, m) ,7.55 ( IH, d, J=2.4Hz) , 7.63 (IH, s) , 7. 67 (IH, d, J=9.6Hz) ,8.87 (lH,brs) ,9.14 (lH,brs) . MS:341 (M+H)+.
The following compounds were obtained in a similar manner to that of Example 263. Example 264 3-methyl-4-{ [3- (4-pyridinyl) imidazo [ 1, 2-b] pyri.dazin-6-yl] amino }phenol .
1H-NMR(DMSO-d6)δ:2.17 (3H, s) , 6.68-6.75 (2H,m) , 6.96 ( IH, d, J=9.6 Hz) ,7.31 (lH,d, J=8.4Hz) ,7.92 (IH, d, J=9.6Hz) ,8.02-8.04 (2H7 m) ,8 .20 (IH7S) 78.44-8.46 (2H7ItI) 78.58 (IH7S) 79.30 (IH7S) . MS:318(M+H)+. Example 265
3- { [3-(4-Pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino } -5- (trifluoromethyl) phenol . MS:372 (MH-H) + . Example 266
A mixture of trans~4-{ [3- (2-chloropyridin-4-yl) imidazo [1, 2- b] pyridazin-6-yl] amino} cyclohexanol ( lOOmg) , palladium acetate (=Pd(0Ac)2, 6.5mg), 1, 1' -bis (diphenylphosphino) ferrocene (=DPPF, lδ.lmg) NaHCO3 (29mg) in methanol (ImI) was stirred at reflux under CO for 4 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic extract was washed with water twice and brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography eluted with chloroform/methanol (100:0 to 95:5) to give methyl 4-{6-
[ (trans-4-hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin- 3-yl } -2-pyridinecarboxylate (40 mg) .
1H-NMR (DMSO-d6) 5:1.23-1.41 ( 6H,m) , 1.87-1.89 (2H,m) , 2.12-2.13 ( 2H,m) ,3.48-3.50 (lH,m) , 3.66-3.70 ( IH, m) ,3.94 (3H,s) ,4.60-4.63 ( IH, m) .
MS:390 (M+Na)+.
Example 267
A mixture of trans-4-{ [3- (2-chloropyridin-4-yl) imidazo
[1, 2-b]pyridazin-6-yl] amino} cyclohexanol (200mg) , phenylboronic acid (121mg), tetrakis (triphenylphosphine) palladium (0) (20mg) , sodium carbonate (98mg) in tolene (1.6ml), ethanol (0.4ml) and water (0.8ml) was stirred at 1000C for lhours . The reaction mixture was poured into water and extracted with ethyl acetate. The organic extract was washed with water twice and brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography elutedwith chloroform/ methanol (100:0 to 95:5) to give trans-4-{ [3- (2-phenyl-4-pyridinyl) imidazo [1, 2-b] pyridazin-β-yl] amino } cyclohexanol (67 mg) . 1H-NMR (DMSO-d6) δ: 1.25-1.34 (4H,m) , 1.86 (2H,brs) ,2.12 (2H,brs) , 3.47 (lH,brs) ,3.75 (lH,brs) , 4.60 ( IH, d, J=3.8Hz) ,7.77 (lH,d, J=9. 6Hz) ,7.08 (lH,d, J=6.6Hz) , 7.47-7.58 (3H,m) , 7.80 (lH,d, J=9.6Hz) , 8.09-8.18 (2H,m) ,8.28 (IH7S) , 8.69 (IH, d, J=5.3Hz) ,8.79 (IH, s) . MS : 386. Example 268
A mixture of trans-4-{ [3- (2-chloropyridin-4-yl) imidazo [ 1, 2-b] pyridazin-6-yl] amino} cyclohexanol (30mg) , aniline (24mg), palladium acetate (=Pd(OAc)2, 1.9mg), 2,2'-bis (diphenylphosphino) 1 , 1' -binaphthyl (=BINAP, 5.4mg) sodium tert-butoxide (33mg) in N, N-dimethylformamide (1.5ml) was stirred at 13O0C for 1.5 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic extract was washed with water twice and brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography eluted with chloroform/ methanol (100:0 to 95:5) to give trans-4- { [3- (2-anilino-4- pyridinyl) imidazo [1, 2-b] pyridazin-6-yl] amino }cyclohexanol
(15.2 mg) .
1H-NMR (DMSO-d6) δ : 1.24-2.30 (4H, m) , 1.82-1.90 (2H, m) ,2.05-2.12 ( 2H,m) ,3.65 (2H,brs) ,4.54 ( IH, d, J=4. OHz) ,6.73 ( IH, d, J=9.6Hz) , 6.
89-7.00(2H,m) ,7.22-7.30 (2H,m) , 7.51-7.79 (5H,m) , 7.93 (IH, s) , 8.
19 (lH,d, J=5.5Hz) , 8.99(lH,m) .
MS: 401.
Example 269 A solution of trans-4- { [3- (2-chloropyridin-4-yl) imidazo
[1, 2-b] pyrida∑in-6-yl] amino } cyclohexanol (39mg) in 6M
HCl/dioxane (3ml) was stirred at 1000C for 48 hours. The reaction mixture was concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform: methanol=20: 1 to 10:1) to give 4-{ 6- [ (trans-4- hydroxycyclohexyl) amino] imidazo [ 1, 2-b] pyridazin-3-yl } -
2 ( IH) -pyridinone (7.3 mg) .
1H-NMR (DMSO-d6)δ: 1.15-1.46 (4H,m) , 1.86-1.91 (2H,m) ,2.09-2.14 (
2H,m) ,3.50 (2H,brs) ,6.74-6.79(3H,m),7.13 (IH, d, J=6.7Hz) , 7.35 ( IH, d, J=7.0hz) ,7.55(lH,s) ,7.77 (IH, d, J=9.6Hz) ,8.08 (IH, s) .
MS.401.
The following compound was obtained in a similar manner to that of Example 269
Example 270 5-{ 6- [ (trans-4-Hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl}-2 (IH) -pyridinone .
1H-NMR(DMSO-O6)O: 1.20-1.46 (4H,m) , 1.83-1.90 (2H,m) ,2.03-2.09 (
2H,m) ,3.51 (2H,brs) , 4.62 ( IH, s) , 6.45 ( IH, d, J=9.6Hz) ,6.62 (IH, d,
J=9.6Hz) ,6.92 (lH,d, J=7.2Hz) ,7.70 (IH, d, J=9.8Hz) ,7.75(lH,s),8 .03(lH,dd, J=2.5, 9.6Hz) ,8.44 (IH, d, J=2.5Hz) , 12.00 ( IH, brs ) .
MS: 326 (M+H)+,348 (M+Na)+.
Example 271
To a mixture of benzenthiol (238mg) and sodium hydride (78mg) in 1, 3-dimethyl-2-imidazolidinone (=DMI , 8.75ml) was added 6-chloro-3- (4-pyridinyl) -imidazo [1, 2-b] pyridazine (lOOmg), the mixture was stirred at rt . The reaction mixture was poured into water and extracted with ethyl acetate. The organic extract was washed with water twice and brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography eluted with chloroform/ methanol (9 : 1) to 6- (phenylthio) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazine (81 mg) .
1H-NMR(DMSO-d6)δ:7.35 (lH,d, J=9.6Hz) , 7.58-7.78 (7H,m) , 8.15 ( IH
,d, J=9.6Hz) ,8.39-8.41 (2H,m) ,8.45 (IH, s) . MS:305 (M+H)+. The following compounds were obtained in a similar manner to that of Example 271
Example 272
6- (Cyclohexyloxy) -3- (4-pyridinyl) imidazo [1, 2-b] pyridazine . 1H-NMR (DMSO-de) δ : 1.21-1.62 (7H,m) , 1.78 (2H,brs) , 2.12 (2H,m) , 1. 17 (lH,brs) ,6.99 (IH, d, J=9.6Hz) , 8.10-8.17 (3H,m) , 8.37 ( IH, s) , 8. 65-8.68 (2H,m) . MS: 295 (M+H)+, 317 (M+Na)+. Example 273 6-Phenoxy-3- (4-pyridinyl) imidazo [1, 2-b] pyridazine .
1H-NMR(DMSO-d6)δ:7.32 (IH, d, J=9.6Hz) ,7.39-7.43 (3H,m) ,7.52-7. 60 (IH, m) ,7.55 ( IH, d, J=6.6Hz) , 7.82-7.85 (2H,m) , 8.32 (lH,d, J=9.6 Hz) /8.41-8.45 (3H,m) . MS:289. Example 274
To a solution of methyl 4-{ 6- [ (trans-4-hydroxycyclohexyl) amino] imidazo [1, 2-b] pyridazin-3-yl }pyridine-2-carboxylate ( 1 7mg) in ethanol (1 mL) was added sodium borohydride (5.2 mg) at ambient temperature. The resulting mixture was stirred at ambient temperature. The reaction mixture was poured into water and extracted with ethyl acetate. The organic extract was washed with water twice and brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography eluted with chloroform/methanol (9:1) to trans-4- ( {3- [2- (hydroxymethyl) -4-pyridinyl] imidazo [ 1, 2-b] pyridazin-6-yl }amino) cyclohexanol (15 mg) . 1H-NMR (DMSO-d6) 5:1.23-1.43 (4H,m) , 1.84-1.90 (2H,m) , 2.08-2.15 ( 2H,m) ,3.67 (2H,brs) ,4.58 (lH,brs) , 4.62 (2H, s) , 5.42 (lH,brs) ,6.7 5 (lH,d, J=9.6Hz) ,7.05 ( IH, d, J=6.6Hz) ,7.78 ( IH, d, J=9.6Hz) ,8.04 ( IH, d, J=4.0Hz) ,8.14 (IH, s) ,8.40(lH,s) ,8.51 (lH,d, J=5.4Hz) . MS: 340 (M+H)+,362 (M+Na)+. Example 275
Aniline (96.2 mg) and lithium 1, 1, 1, 3, 3, 3-hexamethyldisilazan- 2-ide(94.2 μl) were mixed in tetrahydrofuran (1.5mL) under argon atmosphere and were stirred at 00C for 30 minutes. To the reaction mixture, methyl 6- [ (trans-4-hydroxycyclohexyl ) amino] imidazo [1, 2-b] pyridazine-3-carboxylate was added at 0 0C. The temperature was raised to ambient temperature, and the whole mixture was stirred for additional 3 hours at 250C. The mixture was poured into saturated NH4Cl and stirred for 30 minutes. The resulting solution was was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo . The residue was purified by silica gel column chromatography eluting with chloroform/methanol (50:1 to 10:1) to give 6-[(trans-4- hydroxycyclohexyl) amino] -N-phenylimidazo [1, 2-b] pyridazine- 3-carboxamide (17.5 mg) .
1H-NMR (DMSO-de)δ: 1.15-1.42 (4H,m) , 1.76-2.23 (4H,m) , 3.37-3.59 ( IH, m) ,3.60-3.83 (lH,m) , 4.62 (lH,d) , 6.87 (IH, d) , 7.16 (IH, dd) , 7.3 3-7.53 (3H,m) ,7.70 (2H,d) ,7.88 (IH, d) ,8.02 (IH, s) , 10.80 (IH, s) . MS:374 (M+Na)+. Example 276
To a stirred mixture of 2- (3-{ [3- (4-pyridinyl) imidazo [1, 2-b]pyridazin-6-yl] amino} benzyl) -lH-isoindole-1, 3 (2H) - dione (120 mg) and in ethanol/tetrahydrofuran (total 2.4 ml) were added hydrazine hydrate (67.3 mg) at ambient temperature. The reaction mixture was refluxed for 5 hours. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was cooled to ambient temperature. The resulting solution was concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol ( 98 : 2 to 90 : 10) to give N- [3- (aminomethyl) phenyl] -3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-6-amine (23.1 mg) . 1H-NMR(DMSO-d6)δ:3.77 (2H,s) ,7.00-7.08 (2H, m) , 7.33 (IH, dd) , 7.4 0-7.48 (lH,m) ,7.82 (IH, s) ,8.00 (IH, d) , 8.17 (2H,d) ,8.22 (IH, s) , 8. 66(2H,d) ,9.52 (IH, bs) . MS:317 (NRH)+. Example 277 To a stirred mixture of N- ( trans-4-ethoxycyclohexyl) -3-
( 4-pyridinyl ) imidazo [1, 2-b] pyridazin-β-amine (100.0 mg) and NaHCO3 (49.8 mg) in methanol (1.5 ml) were added Br2 (47.4 mg) at ambient temperature. The reaction mixture was stirred for 3 hours at the same temperature. After all starting material had been consumed, as judged by TLC plate, the resulting solution was filtrated. The filtration was was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (50 : 1 to 20:1) to give 2-bromo-N- (trans-4-ethoxycyclohexyl) -3- (4-pyridinyl) imidazo [ 1, 2-b] pyridazin-β-amine (36.4 mg) .
1H-NMR (DMSO-d6)δ: 1.10 (3H, t ) , 1.19-1.39 ( 4H, m) , 1.87-2.17 (4H,m) ,3.16-3.40 (IH, m) ,3.40-3.56 (IH, m) , 3.45(2H,q) , 6.79(lH,d) ,7.17 (IH, d) ,7.75 ( IH, d) ,7.94 (2H,d) ,8.70 (2H,d) . MS:416(M)+, 418(M+2)+. Example 278
To a stirred mixture of 2-bromo-N- (trans-4-ethoxycyclohexyl) - 3- (4-pyridinyl) imidazo [1, 2-b] pyridazin-6-amine (30.0 mg) and Zinc cyanide (16.9 mg) in 1, 3-dimethyl-2-imidazolidinone (=DMI,0.90 ml) were added tetrakis (triphenylphosphine) palladium(O) (25.0 mg) at ambient temperature. The reaction mixture was stirred for 3 hours at 1400C. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was cooled to ambient temperature and diluted with ethyl acetate/water (lOmL/lOmL). The resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (50 : 1 to 10:1) to give 6- [ (trans-4-ethoxycyclohexyl) amino] -3- (4-pyridinyl) imidazo [1, 2-b] pyridazine-2-carbonitrile (13.2 mg) . 1H-NMR(CDCl3) δ:1.23 (3H,t), 1.23-1.59 (4H, m) , 2.03-2.39 (4H, m) ,3 .20-3.42 (lH,m) ,3.54 (2H,q) , 3.60-3.82 (IH, m) , 4.77 ( IH, d) , 6.71 ( 1 H,d) ,7.72 (IH, d) ,8.29 (2H,d) ,8.79 (2H,d) . MS:363 (M+H)+. Example 279
To a stirred mixture of 6- [ (trans-4-ethoxycyclohexyl) amino] -3- (4-pyridinyl) imida∑o [1, 2-b] pyridazine-2-carbonitrile (10.0 mg) and 5M NaOH aqueous solution (49.5 μl) in ethanol/ dimethylsulfoxide (0.4ml/0.4ml) were added 31% H2O2 aqueous solution (27. βμl) at ambient temperature . The reaction mixture was stirred for 3 hours at 500C. After all starting material had been consumed, as judged by TLC plate, the reaction mixture was cooled to ambient temperature and quenched with IM HCl aqueous solution. The resulting mixture was neutralized with 0.1 M NaOH aqueous solution to PH 7. Then, the resulting solution was extracted with ethyl acetate three times, the organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/ ethanol (50:1 to 10:1) to give 6- [ (trans-4-ethoxycyclohexyl) amino] - (4- pyridinyl) imidazo [1, 2-b] pyridazine-2-carboxamide (4.56 mg) . 1H-NMR(CDCl3) δ:1.22 (3H,t) ,1.23-1.45 (4H,m) ,2.02-2.24 (4H,m) ,3 .22-3.36(lH,m) ,3.53 (2H,q) ,3.50-3.70 ( IH, m) , 4.46 (IH, d) , 5.46 (1 H, s) , 6.61(lH,d) ,7.31 (IH, s) ,7.66(lH,d) ,8.15(2H,d) ,8.70 (2H,d)
MS:403(M+Na)+. Example 280 To a stirred mixture of trans-4- ( { 3- [ (E) -2-phenylvinyl] imidazo [1, 2-b] pyridazin-6-yl } amino) cyclohexanol (100.0 mg) and cyclohexene (1.0 ml) in ethanol/tetrahydrofuran (3.0ml/ 3.0ml) were added palladium hydroxide (=Pd (OH) 21 50.0 mg) at ambient temperature. The reaction mixture was stirred at 80 0C for 5 hours. After all starting material had been consumed, as judged by TLC plate, the resulting solution was filtrated. After filtration, the reaction mixture was evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol (98:2 to 90:10) to give trans-4-{ [3- (2-phenylethyl) imidazo [1, 2-b] pyridazin-β-yl] amino } cyclohexanol (45.6 mg) .
1H-NMR(DMSO-d5)δ:1.10-1.42 (4H,m) , 1.81-2.22 (4H,m),2.87-3.28( 4H,m) ,3.32-3.69 (2H,m) , 4.57 (IH, d) , 6.56 ( IH, d) , 6.75 (IH, d) , 7.14 -7.38 (6H,m) ,7.60 (IH, d) . MS:337 (M+H)+. Example 281
To a stirred solution of N, 6- [ (IS) -1-phenylethyl] imidazo [ 1, 2-b] pyridazine-3, 6-diamine (50 mg) in dichloromethane (0.5 ml) was added isocyanatobenzene (0.0214 mL) at O0C. The reaction mixture was stirred at this temperature for 2 hours. The reaction mixture was concentrated in vacuo. The residue was purified by washing with ethyl acetate/n-hexane to give l-phenyl-3- (6-{ [ (IS) -1-phenylethyl] amino} imidazo [1, 2-b] pyridazin-3-yl) urea (55 mg) . MS:395 (M+Na)+. The following compound was obtained in a similar manner to that of Example 281.
Example 282
1- (2-Chlorophenyl) -3- (6-{ [ ( IS) -1-phenylethyl] amino} imidazo [1, 2-b] pyridazin-3-yl) urea .
MS:429 (M+Na)+.
Example 283
To a stirred solution of N-6- [( IS) -1-phenylethyl] imidazo
[1, 2-b] pyridazine-3, 6-diamine (80 mg) in dichloromethane (0.8 ml) were added triethylamine (0.176 mL) and benzenesulfonyl chloride (83.7 mg) at 0 0C. The reaction mixture was stirred at the same temperature for 4 hours. The reaction mixture was quenched with water and extracted with dichloromethane. The organic layers was dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with chloroform/methanol ( 9 : 1) to give N- (6-{ [ (IS) -1-phenylethyl] amino} imidazo [1, 2-b] pyridazin-3-yl) benzenesulfonamide (27 mg) .
MS:394 (M+H)+.
[Table 1] : The following compounds (Example 284 - Example 361) were obtained in a similar manner to that of Example 98. E
Figure imgf000156_0001
[Table 1] (contd. )
Figure imgf000157_0001
[Table 1] (contd.
Figure imgf000158_0001
Figure imgf000159_0001
[Table 1] (contd. )
Figure imgf000160_0001
[Table 1] (contd.
Figure imgf000161_0001
[Table 1] (contd.
Figure imgf000162_0001
[Table 1] (contd.
Figure imgf000163_0001
[Table 2]
Figure imgf000164_0005
Figure imgf000164_0001
Figure imgf000164_0002
Figure imgf000164_0003
Figure imgf000164_0004
The structures of the compounds of the invention are shown in the following Tables. These compounds can be easily prepared by the above preparation methods, methods described in Examples or Preparations, or methods that are well-known to one skilled in the art, or its variations.
Symbols in the Tables have the following meaning. No: compound number
R: substituent group in the general formula Me: methyl, Et: ethyl.
[Table 3]
Figure imgf000166_0001
Figure imgf000166_0002
Figure imgf000167_0001
[Table 4]
Figure imgf000167_0002
Figure imgf000167_0003
[Table 4] (contd. )
[Table 4] (contd.
Figure imgf000169_0001
[Table 4] (contd.
Figure imgf000170_0001
[Table 5;
Figure imgf000170_0002
Figure imgf000170_0003
[Table 5] (contd.
Figure imgf000171_0001
Figure imgf000172_0001
[Table 5] (contd.
Figure imgf000173_0002
[Table 6]
Figure imgf000173_0001
Figure imgf000173_0003
[Table 6] (contd. )
Figure imgf000174_0001
[Table 6] (contd.
Figure imgf000175_0001
[Table β] (contd.
Figure imgf000176_0001
[Table 6] (contd.
Figure imgf000177_0001
[Table 6] (contd.
Figure imgf000178_0001
Figure imgf000179_0001

Claims

1. A fused heterocyclic compound represented by the formula (D :
Figure imgf000180_0001
wherein one of Y and Z is C atom, and the other is N atom,
-X- is bond, -N(R1)-, -0-, -S-, -S(=0)-, -S(=0)2-;
-R1 is hydrogen or lower alkyl; -A- is bond, lower alkylene or lower alkenylene, each of which may be substituted by one or more substituents selected from the group consisting of -OH and -NR11R12, wherein a methylene unit of -A- is optionally replaced by -0- or -C(=O)-; -R11 and -R12 are the same or different, each being hydrogen or lower alkyl;
-R2 is hydrogen, cycloalkyl, aryl, 5- or 6-membered non-aromatic heterocycle or 5- or 6-membered aromatic heterocycle, each of which may be substituted, or alternatively -R1 and "-A-R2" taken with the adjacent nitrogen atom may form 5-, 6- or 7- membered cyclic amino, which may be substituted; -E- represents bond, lower alkylene, lower alkenylene or lower alkynylene, wherein a methylene unit of -E- is optionally replaced by -0-, -(CO)O-, -NH-, -NHCO-, -NHSO2- or -NH(CO)NH-; -R3 is cycloalkyl, aryl, 5- or 6-membered non-aromatic heterocycle or 5- or 6-membered aromatic heterocycle, each of which may be substituted and may be fused with ■ ' benzene; and • '
-R4, -R5 and -R6 are the same or different, each being . hydrogen, halogen, lower alkyl, -0- lower alkyl or aryl; provided that (i) when -A- is bond, -X- is NH, -R2 is 4-tetrahydropyranyl and -R3 is 3-chlorophenyl, then Y is C atom and Z is N atom; (ii) when -X- is NH, -R2 is cyclopropyl,
2-pyridyl, 3-pyridyl, 2-thienyl or 4-fluorophenyl and -R3 is 3-acetylphenyl, 3-chlorophenyl, 4-chlorophenyl, phenyl, 2-furyl or 2-thienyl, then -A- is bond. or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein one of Y and Z is C atom, and the other is N atom; . -X- is -N(R1)-, -O-, or -S-; -R1 is hydrogen or lower alkyl; -A- is bond, lower alkylene or lower alkenylene each of which may be substituted by one or more substituents selected from the group consisting of -OH and -NR11R12, wherein a methylene unit of -A- is optionally replaced by -0- or -C (=0) -;
-R11 and -R12 are the same or different, each being hydrogen or lower alkyl;
-R2 is hydrogen, C5-10 cycloalkyl, aryl, 5- or 6-membered non-aromatic heterocycle which contains one to three heteroatom (s) or 5- or 6-membered aromatic heterocycle which contains one heteroatom; each of which may be substituted with one to three substituent (s) selected from the group consisting of halogen, hydroxy, nitro, lower alkyl, -0-lower alkyl, -0-lower alkyl having halogen, -0- ( 6-membered cyclic amino), -CONH-lower alkyl, -C (0) NH-aryl, -S(O)2- aryl, -C (0) 0-lower alkyl, -C(O)OH, -C (0) NH-0-lower alkyl, -NR11R12, 6-membered non-aromatic heterocycle, and -0- ( 6-membered aromatic heterocycle), or alternatively -R1 and "-A-R2" taken with the adjacent nitrogen atom may form 5-, 6- or 7- membered cyclic amino, which may be substituted;
-E- is bond, lower alkylene, lower alkenylene or lower alkynylene, wherein a methylene unit of -E- is optionally replaced by -NHSO2- or -NH(CO)NH-; -R3 is 5- or 6-membered non-aromatic heterocycle or 5- or β-membered aromatic heterocycle which contains one to two nitrogen atom, which may be fused with benzene; each of which may be substituted with one to three substituent (s) selected from the group consisting of halogen, lower alkyl, lower alkyl having halogen, lower alkyl having hydroxyl, -OH, cyano, -0-lower alkyl, phenyl, -O-phenyl, -S-phenyl, -O-cycloalkyl, -C(0)0-lower alkyl, -C(O)NH2, -NHCO-aryl, -NHC(0)0-lower alkyl and -NR11R1'2; and
-R4, -R5 and -R6 are the same or different, each being hydrogen, halogen, lower alkyl, -0-lower alkyl or aryl; or a pharmaceutically acceptable salt thereof.
3. The compound of claim 2, wherein one of Y and Z is C atom, and the other is N atom; -X- is -N(R1)-, or -0-; -R1 is hydrogen; -A- is bond or lower alkylene;
-R2 is hydrogen, cyclohexyl, phenyl, adamantyl, pyridinyl, piperidinyl, or tetrahydropyranyl; each of which may be substituted with one to two substituent (s) selected from the group consisting of hydroxy, halogen, methyl and lower alkyloxy optionally substituted with halogen; -E- is bond;
-R3 is pyridinyl which may be substituted with halogen; -R4, -R5 and -Rb are the same or different, each being hydrogen, halogen, methyl, or phenyl; or a pharmaceutically acceptable salt thereof.
4. The compound of claim 3 , which is
(1) N-Cyclohexyl-3- (4-pyridinyl) -imidazo [ 1, 2-b] pyridazin-6-amine
(2) 3- (4-Pyridinyl) -N- (tetrahydro-2H-pyran-4-yl) imidazo [1, 2-b] pyridazin-6-amine
(3) N-Phenyl-3- (4-pyridinyl) -imidazo [l,2-b]pyridazin- β-amine (4 ) N, 3-Dipyridin-4-ylimidazo [1, 2-b] pyridazin-6- amine
(5) N-Benzyl-3- (4-pyridinyl) -imidazo [1, 2-b] pyridazin- 6-amine
(6) N-Adamantan-l-yl-3- (4-pyridinyl) -imidazo [1, 2-b] pyridazin-6-amine
(7) trans-4-{ [3- (2-Chloropyridin-4-yl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanol
(8 ) N- (trans-4-Ethoxycyclohexyl) -3-pyridin-4- ylimidazo [1, 2-b] pyridazin-6-amine (9) (1R,2R, 3S,5s)-5-{ [3- (4-Pyridyl) imidazo [ 1, 2-b] pyridazin-6-yl] amino } -2-adamantanol
(10) 4-Methyl~3-[ (3- (4-pyridinyl) -imidazo [1, 2-b] pyridazin-6-yl) amino] phenol
(11) trans-4- [ (8-Methyl-3- (4-pyridinyl) -imidazo [1, 2-b] pyridazin-6-yl) amino] cyclohexanol
(12) trans-4-{ [3- (2-Bromopyridin-4-yl) imidazo [1, 2-b] pyridazin-6-yl] amino} cyclohexanol
(13) N- (2, 5-Dichlorobenzyl) -3- (4-pyridinyl) -imidazo
[1, 2-b] -pyridazin-6-amine (14) N- [2- (Difluoromethoxy) benzyl] -3-pyridin-4- ylimidazo- [1, 2-b] pyridazin-6-amine
(15) N- [3-Chloro-2-fluorobenzyl] -3-pyridin-4- ylimidazo- [1, 2-b] pyridazin-6-amine or a pharmaceutically acceptable salt thereof.
5. A Lck inhibitor comprising the compound of claim 1.
6. A pharmaceutical composition for treating or preventing rejection reaction in organ transplantation, autoimmune diseases, asthma, atopic dermatitis, which comprises the compound of claim 1.
7. A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 1 in admixture with pharmaceutically acceptable and substantially non-toxic carrier or excipient.
8. The compound of any of claim 1 for use as a medicament.
9. A method for inhibiting Lck, comprising using the compound of claim 1.
10. Use of the compound of claim 1 for the manufacture of a medicament for inhibiting Lck.
11. A method for treating or preventing rejection reaction in organ transplantation, autoimmune diseases, asthma, atopic dermatitis, which comprises administering an effective amount of the compound of claim 1 to a human being or an animal.
12. Use of the compound of claim 1 for the manufacture of a medicament for treating or preventing rejection reaction in organ transplantation, autoimmune diseases, asthma, atopic dermatitis.
13. A commercial package comprising the pharmaceutical composition of claim 6 or claim 7 and a written matter associated therewith, the written matter stating that the pharmaceutical composition may or should be used for treating or preventing rejection reaction in organ transplantation, autoimmune diseases, asthma, atopic dermatitis .
PCT/JP2006/315346 2005-07-29 2006-07-27 Fused heterocycles as lck inhibitors WO2007013673A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/993,229 US20100216798A1 (en) 2005-07-29 2006-07-27 Fused heterocycles as lck inhibitors
EP06768412A EP1910369A1 (en) 2005-07-29 2006-07-27 Fused heterocycles as lck inhibitors
JP2008503311A JP2009502734A (en) 2005-07-29 2006-07-27 Fused heterocycles as Lck inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70349705P 2005-07-29 2005-07-29
US60/703,497 2005-07-29

Publications (1)

Publication Number Publication Date
WO2007013673A1 true WO2007013673A1 (en) 2007-02-01

Family

ID=37177853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/315346 WO2007013673A1 (en) 2005-07-29 2006-07-27 Fused heterocycles as lck inhibitors

Country Status (4)

Country Link
US (1) US20100216798A1 (en)
EP (1) EP1910369A1 (en)
JP (1) JP2009502734A (en)
WO (1) WO2007013673A1 (en)

Cited By (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007147646A1 (en) * 2006-06-21 2007-12-27 Bayer Schering Pharma Aktiengesellschaft OXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
WO2008037459A1 (en) * 2006-09-28 2008-04-03 Novartis Ag Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
WO2008016192A3 (en) * 2006-08-04 2008-05-08 Takeda Pharmaceutical Fused heterocyclic derivative and use thereof
WO2008138889A2 (en) * 2007-05-11 2008-11-20 Novartis Ag 3, 6-disubstituted-imidazo [1, 2-b] pyridazines and 3, 5-disubstituted pyrazolo[1, 5-a] pyrimidines as phosphatidylinositol-3-kinase inhibitors
FR2918061A1 (en) * 2007-06-28 2009-01-02 Sanofi Aventis Sa 6-CYCLOAMINO-3- (PYRIDIN-4-YL) IMIDAZO [1,2-B] -PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
FR2918986A1 (en) * 2007-07-19 2009-01-23 Sanofi Aventis Sa New 6-cycloamino-3-(pyridazin-4-yl)imidazo(1,2-b)-pyridazine compounds are casein kinase 1 delta inhibitors useful to treat or prevent e.g. primary insomnia, bipolar disorders, anxiety, depression, Alzheimer's disease and lung cancer
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
WO2009041456A1 (en) * 2007-09-28 2009-04-02 Daiichi Sankyo Company, Limited Imidazopyridazine derivative
EP2049539A1 (en) * 2006-06-21 2009-04-22 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same.
WO2009106577A1 (en) * 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
EP2176266A2 (en) * 2005-09-02 2010-04-21 Bayer Schering Pharma Aktiengesellschaft Substituted imidazo[1,2b]pyridazines as kinase inhibitors, the production thereof, and use of the same as medicaments
WO2010051549A1 (en) 2008-10-31 2010-05-06 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
US7750007B2 (en) 2006-11-06 2010-07-06 Supergen, Inc. Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors
US7767675B2 (en) 2006-11-22 2010-08-03 Incyte Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
WO2011013729A1 (en) 2009-07-30 2011-02-03 オンコセラピー・サイエンス株式会社 Fused imidazole derivative having ttk inhibitory action
WO2011015652A1 (en) 2009-08-07 2011-02-10 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
JP2011520887A (en) * 2008-05-13 2011-07-21 アイアールエム・リミテッド・ライアビリティ・カンパニー Fused nitrogen-containing heterocycles and their compositions as kinase inhibitors
CN102186852A (en) * 2008-08-12 2011-09-14 赛诺菲-安万特 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-ib]-pyridazine derivatives, preparation thereof, and therapeutic application thereof
WO2011101304A3 (en) * 2010-02-17 2011-10-20 F. Hoffmann-La Roche Ag Piperidine derivatives
US8114874B2 (en) 2005-12-23 2012-02-14 Ariad Pharmaceuticals, Inc. Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
US8198450B2 (en) 2006-06-30 2012-06-12 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8212041B2 (en) 2006-07-14 2012-07-03 Amgen Inc. Fused heterocyclic derivatives and methods of use
CN102548995A (en) * 2009-08-12 2012-07-04 诺瓦提斯公司 Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
CN102574853A (en) * 2009-08-20 2012-07-11 诺瓦提斯公司 Heterocyclic oxime compounds
US8278307B2 (en) 2006-05-08 2012-10-02 Ariad Pharmaceuticals, Inc. Monocyclic Heteroaryl compounds
WO2012156367A1 (en) 2011-05-17 2012-11-22 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
WO2012163942A1 (en) 2011-06-01 2012-12-06 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
WO2012175591A1 (en) 2011-06-22 2012-12-27 Bayer Intellectual Property Gmbh Heterocyclyl aminoimidazopyridazines
WO2013009582A1 (en) 2011-07-12 2013-01-17 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US8389527B2 (en) 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
WO2013034570A1 (en) 2011-09-06 2013-03-14 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
WO2013041634A1 (en) 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
US8420645B2 (en) 2008-05-21 2013-04-16 Incyte Corporation Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
US8461167B2 (en) 2006-05-08 2013-06-11 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
US8461163B2 (en) 2008-03-31 2013-06-11 Takeda Pharmaceutical Company Limited Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1
WO2013087581A1 (en) 2011-12-12 2013-06-20 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
US8487096B2 (en) 2010-02-03 2013-07-16 Incyte Corporation Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors
US8513263B2 (en) 2008-10-22 2013-08-20 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
WO2013144189A1 (en) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
WO2013149909A1 (en) 2012-04-04 2013-10-10 Bayer Pharma Aktiengesellschaft Amino-substituted imidazopyridazines
WO2013183578A1 (en) 2012-06-04 2013-12-12 第一三共株式会社 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR
US8609687B2 (en) 2008-06-20 2013-12-17 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US8716282B2 (en) 2009-10-30 2014-05-06 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
EP2734205A1 (en) * 2011-07-21 2014-05-28 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
US8748435B2 (en) 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
US8791123B2 (en) 2009-07-09 2014-07-29 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
WO2014118135A1 (en) 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as mknk-1 kinase inhibitors
WO2014128093A1 (en) 2013-02-20 2014-08-28 Bayer Pharma Aktiengesellschaft Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors
US8846664B2 (en) 2008-11-12 2014-09-30 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
US8859543B2 (en) 2010-03-09 2014-10-14 Janssen Pharmaceutica Nv Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US8889673B2 (en) 2008-06-20 2014-11-18 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
US8962834B2 (en) 2008-02-22 2015-02-24 Hoffmann-La Roche Inc. Modulators of amyloid beta
US8999998B2 (en) 2009-07-02 2015-04-07 Genentech, Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods
WO2015089143A1 (en) * 2013-12-10 2015-06-18 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2015104254A1 (en) 2014-01-09 2015-07-16 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
WO2015118434A1 (en) 2014-02-05 2015-08-13 Celon Pharma S.A. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS KINASE JAK-2 INHIBITORS
WO2015148354A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015148344A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Trka kinase inhibitors, compositions and methods thereof
US9181261B2 (en) 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9346815B2 (en) 2014-05-23 2016-05-24 Genentech, Inc. 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof
US9370515B2 (en) 2013-03-07 2016-06-21 Califia Bio, Inc. Mixed lineage kinase inhibitors and method of treatments
US9493476B2 (en) 2010-05-20 2016-11-15 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
US9493470B2 (en) 2012-12-12 2016-11-15 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
US9550784B2 (en) 2012-07-09 2017-01-24 Beerse Pharmaceutica NV Inhibitors of phosphodiesterase 10 enzyme
US9556169B2 (en) 2012-11-19 2017-01-31 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9669035B2 (en) 2012-06-26 2017-06-06 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
US9718782B2 (en) 2013-09-22 2017-08-01 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9783543B2 (en) 2012-11-19 2017-10-10 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines
US9782414B2 (en) 2014-11-16 2017-10-10 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US9896447B2 (en) 2013-09-22 2018-02-20 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9914736B2 (en) 2014-03-26 2018-03-13 Merck Sharp & Dohme Corp. TrKA kinase inhibitors, compositions and methods thereof
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
US10137127B2 (en) 2016-04-04 2018-11-27 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
WO2019029629A1 (en) 2017-08-11 2019-02-14 Teligene Ltd Substituted pyrazolopyrimidines useful as kinases inhibitors
US10307426B2 (en) 2017-05-22 2019-06-04 Genentech, Inc. Therapeutic compounds and compositions, and methods of use thereof
US10370727B2 (en) 2015-10-26 2019-08-06 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
JP2019163256A (en) * 2014-08-06 2019-09-26 ファイザー・インク Imidazopyridazine compounds
US10544149B2 (en) 2013-10-03 2020-01-28 Agency For Science, Technology And Research Bicyclic alkyne derivatives and uses thereof
CN110734437A (en) * 2018-07-19 2020-01-31 金秋 Pyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof
US10556900B2 (en) 2015-04-08 2020-02-11 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US10604523B2 (en) 2011-06-27 2020-03-31 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
WO2020116662A1 (en) 2018-12-06 2020-06-11 第一三共株式会社 Cycloalkane-1,3-diamine derivative
US10688100B2 (en) 2017-03-16 2020-06-23 Array Biopharma Inc. Macrocylic compounds as ROS1 kinase inhibitors
WO2020187291A1 (en) * 2019-03-19 2020-09-24 华中师范大学 Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor
CN111718351A (en) * 2019-03-19 2020-09-29 华中师范大学 Oxygen-containing substituted pyrazolopyrimidine compound, pharmaceutical composition and application thereof
CN111718350A (en) * 2019-03-19 2020-09-29 华中师范大学 Pyrazole-substituted pyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof
CN111718349A (en) * 2019-03-19 2020-09-29 华中师范大学 Fluorine-containing pyrazolopyrimidine compound, pharmaceutical composition and application thereof
CN112010860A (en) * 2020-08-05 2020-12-01 南京纳丁菲医药科技有限公司 Benzyloxypyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof
US11091486B2 (en) 2016-10-26 2021-08-17 Array Biopharma, Inc Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
US11214571B2 (en) 2016-05-18 2022-01-04 Array Biopharma Inc. Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN115536571A (en) * 2022-11-09 2022-12-30 上海裕兰生物科技有限公司 Preparation method of indole derivative

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006088246A1 (en) * 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Agent for controlling function of gpr34 receptor
AU2012325909B2 (en) 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
WO2013059589A1 (en) * 2011-10-20 2013-04-25 Sirtris Pharmaceuticals, Inc. Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
CN107652289B (en) 2012-06-13 2020-07-21 因塞特控股公司 Substituted tricyclic compounds as FGFR inhibitors
AU2013344716B2 (en) 2012-11-16 2018-03-01 University Health Network Pyrazolopyrimidine compounds
JP6449244B2 (en) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Bicyclic heterocycles as FGFR inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134320A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
JP7076432B2 (en) 2016-09-09 2022-05-27 インサイト・コーポレイション Pyrazolopyridine derivatives as HPK1 regulators and their use for the treatment of cancer
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AR109595A1 (en) 2016-09-09 2018-12-26 Incyte Corp PIRAZOLOPIRIMIDINE COMPOUNDS AND USES OF THESE AS HPK1 INHIBITORS
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-cyano-indazole compounds as hematopoietic progenitor kinase 1 (hpk1) modulators
CN111918651B (en) * 2018-01-29 2024-01-30 默克专利股份有限公司 GCN2 inhibitors and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
PE20210397A1 (en) 2018-02-20 2021-03-02 Incyte Corp DERIVATIVES OF N- (PHENYL) -2- (PHENYL) PYRIMIDINE-4-CARBOXAMIDE AND RELATED COMPOUNDS AS HPKI INHIBITORS TO TREAT CANCER
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
DK3788047T3 (en) 2018-05-04 2024-09-16 Incyte Corp Solid forms of an FGFR inhibitor and methods of making the same
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
ES2973117T3 (en) 2018-09-25 2024-06-18 Incyte Corp Pyrazolo[4,3-d]pyrimidine compounds as modulators of ALK2 and/or FGFR
TW202214648A (en) * 2019-01-07 2022-04-16 美商美國禮來大藥廠 Il-17a inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4010338A1 (en) 2019-08-06 2022-06-15 Incyte Corporation Solid forms of an hpk1 inhibitor
MX2022004513A (en) 2019-10-14 2022-07-19 Incyte Corp Bicyclic heterocycles as fgfr inhibitors.
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2023505258A (en) 2019-12-04 2023-02-08 インサイト・コーポレイション Tricyclic heterocycles as FGFR inhibitors
BR112022010664A2 (en) 2019-12-04 2022-08-16 Incyte Corp DERIVATIVES OF A FGFR INHIBITOR
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN112876482B (en) * 2020-12-31 2023-07-28 中国药科大学 Polysubstituted heterocyclic derivative, preparation method and medical application thereof
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023010102A1 (en) * 2021-07-30 2023-02-02 Sumitomo Pharma Oncology, Inc. Imidazo[1,2-b]pyridazinyl compounds and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003510A1 (en) * 1996-07-24 1998-01-29 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
WO2000017202A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft 4-aminopyrrolopyrimidines as kinase inhibitors
JP2005008581A (en) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd NEW PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME AND APPLICATION THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003510A1 (en) * 1996-07-24 1998-01-29 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
WO2000017202A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft 4-aminopyrrolopyrimidines as kinase inhibitors
JP2005008581A (en) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd NEW PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME AND APPLICATION THEREOF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A.N. BULLOCK ET AL: "Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in Moloney Murine Leukemia Virus (PIM-1) Kinase", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 48, no. 24, 1 December 2005 (2005-12-01), pages 7604 - 7614, XP002405453, ISSN: 0022-2623 *
DATABASE WPI Week 200512, Derwent World Patents Index; AN 2005-104579, XP002405424 *

Cited By (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2176266A2 (en) * 2005-09-02 2010-04-21 Bayer Schering Pharma Aktiengesellschaft Substituted imidazo[1,2b]pyridazines as kinase inhibitors, the production thereof, and use of the same as medicaments
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US9029533B2 (en) 2005-12-23 2015-05-12 Ariad Pharmaceuticals, Inc. Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors
US8470851B2 (en) 2005-12-23 2013-06-25 Ariad Pharmaceuticals, Inc. Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors
US9278971B2 (en) 2005-12-23 2016-03-08 Ariad Pharmaceuticals, Inc. Substituted acetylenic pyrazolo[1,5-a]pyrimidines as kinase inhibitors
US8778942B2 (en) 2005-12-23 2014-07-15 Ariad Pharmaceuticals, Inc. Substituted acetylenic imidazo[1,2-A]pyrazine compounds as kinase inhibitors
US8114874B2 (en) 2005-12-23 2012-02-14 Ariad Pharmaceuticals, Inc. Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
US8461167B2 (en) 2006-05-08 2013-06-11 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
US9090561B2 (en) 2006-05-08 2015-07-28 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
US8278307B2 (en) 2006-05-08 2012-10-02 Ariad Pharmaceuticals, Inc. Monocyclic Heteroaryl compounds
EP2049539A1 (en) * 2006-06-21 2009-04-22 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same.
US20090093475A1 (en) * 2006-06-21 2009-04-09 Olaf Prien Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals
WO2007147646A1 (en) * 2006-06-21 2007-12-27 Bayer Schering Pharma Aktiengesellschaft OXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS
US8653076B2 (en) 2006-06-21 2014-02-18 Bayer Intellectual Property Gmbh Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticals
US8198450B2 (en) 2006-06-30 2012-06-12 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US9066954B2 (en) 2006-07-14 2015-06-30 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8524900B2 (en) 2006-07-14 2013-09-03 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8212041B2 (en) 2006-07-14 2012-07-03 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8044049B2 (en) 2006-08-04 2011-10-25 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
US8273741B2 (en) 2006-08-04 2012-09-25 Takeda Pharmaceutical Company Limited Imidazo-pyridazinyl compounds and uses thereof
WO2008016192A3 (en) * 2006-08-04 2008-05-08 Takeda Pharmaceutical Fused heterocyclic derivative and use thereof
US8034812B2 (en) 2006-08-04 2011-10-11 Takeda Pharmaceutical Company Limited Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof
JP2009545583A (en) * 2006-08-04 2009-12-24 武田薬品工業株式会社 Fused heterocyclic derivatives and uses thereof
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
US8143251B2 (en) 2006-08-07 2012-03-27 Incyte Corporation Triazolotriazines as kinase inhibitors
US7915408B2 (en) 2006-08-07 2011-03-29 Incyte Corporation Triazolotriazines as kinase inhibitors
WO2008037459A1 (en) * 2006-09-28 2008-04-03 Novartis Ag Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
JP2010504933A (en) * 2006-09-29 2010-02-18 ノバルティス アーゲー Pyrazolopyrimidines as PI3K lipid kinase inhibitors
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
JP2010508315A (en) * 2006-10-30 2010-03-18 ノバルティス アーゲー Heterocyclic compounds as anti-inflammatory agents
AU2007316417B2 (en) * 2006-11-06 2013-08-22 Tolero Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US20110281863A1 (en) * 2006-11-06 2011-11-17 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US7750007B2 (en) 2006-11-06 2010-07-06 Supergen, Inc. Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors
US8710057B2 (en) 2006-11-06 2014-04-29 Tolero Pharmaceuticals, Inc. Imidazo[1,2-B]pyridazine and pyrazolo[1 .5-A]pyrimidine derivatives and their use as protein kinase inhibitors
EP2086979B1 (en) * 2006-11-06 2015-06-03 Tolero Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US8461330B2 (en) 2006-11-22 2013-06-11 Incyte Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
US10738052B2 (en) 2006-11-22 2020-08-11 Incyte Holdings Corporation Imidazotriaines and imidazopyrimidines as kinase inhibitors
US11261191B2 (en) 2006-11-22 2022-03-01 Incyte Holdings Corporation Imidazotriaines and imidazopyrimidines as kinase inhibitors
US9944645B2 (en) 2006-11-22 2018-04-17 Incyte Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
US7767675B2 (en) 2006-11-22 2010-08-03 Incyte Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
US12084449B2 (en) 2006-11-22 2024-09-10 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
WO2008138889A3 (en) * 2007-05-11 2009-04-30 Novartis Ag 3, 6-disubstituted-imidazo [1, 2-b] pyridazines and 3, 5-disubstituted pyrazolo[1, 5-a] pyrimidines as phosphatidylinositol-3-kinase inhibitors
WO2008138889A2 (en) * 2007-05-11 2008-11-20 Novartis Ag 3, 6-disubstituted-imidazo [1, 2-b] pyridazines and 3, 5-disubstituted pyrazolo[1, 5-a] pyrimidines as phosphatidylinositol-3-kinase inhibitors
WO2009016286A2 (en) * 2007-06-28 2009-02-05 Sanofi-Aventis 6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof
FR2918061A1 (en) * 2007-06-28 2009-01-02 Sanofi Aventis Sa 6-CYCLOAMINO-3- (PYRIDIN-4-YL) IMIDAZO [1,2-B] -PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
WO2009016286A3 (en) * 2007-06-28 2009-04-09 Sanofi Aventis 6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof
US8354405B2 (en) 2007-06-28 2013-01-15 Sanofi 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof
US8846676B2 (en) 2007-06-28 2014-09-30 Sanofi 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof
FR2918986A1 (en) * 2007-07-19 2009-01-23 Sanofi Aventis Sa New 6-cycloamino-3-(pyridazin-4-yl)imidazo(1,2-b)-pyridazine compounds are casein kinase 1 delta inhibitors useful to treat or prevent e.g. primary insomnia, bipolar disorders, anxiety, depression, Alzheimer's disease and lung cancer
US8455491B2 (en) 2007-07-19 2013-06-04 Sanofi 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same
WO2009037394A2 (en) * 2007-07-19 2009-03-26 Sanofi-Aventis 6-cycloamino-s-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof
EA016376B1 (en) * 2007-07-19 2012-04-30 Санофи-Авентис 6-cycloamino-s-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof
US9108971B2 (en) 2007-07-19 2015-08-18 Sanofi 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof
WO2009037394A3 (en) * 2007-07-19 2009-06-18 Sanofi Aventis 6-cycloamino-s-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
WO2009041456A1 (en) * 2007-09-28 2009-04-02 Daiichi Sankyo Company, Limited Imidazopyridazine derivative
US8389527B2 (en) 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
US8962834B2 (en) 2008-02-22 2015-02-24 Hoffmann-La Roche Inc. Modulators of amyloid beta
WO2009106577A1 (en) * 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
CN102015716B (en) * 2008-02-28 2014-09-17 诺华股份有限公司 Imidazo [1,2-b] pyridazine derivatives for the treatment of C-MET tyrosine kinase mediated disease
US8822468B2 (en) 2008-02-28 2014-09-02 Novartis Ag 3-Methyl-imidazo[1,2-b]pyridazine derivatives
US8921358B2 (en) 2008-03-31 2014-12-30 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
US8461163B2 (en) 2008-03-31 2013-06-11 Takeda Pharmaceutical Company Limited Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1
JP2011520887A (en) * 2008-05-13 2011-07-21 アイアールエム・リミテッド・ライアビリティ・カンパニー Fused nitrogen-containing heterocycles and their compositions as kinase inhibitors
JP2014098010A (en) * 2008-05-13 2014-05-29 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
US10799509B2 (en) 2008-05-21 2020-10-13 Incyte Corporation Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US8901123B2 (en) 2008-05-21 2014-12-02 Incyte Corporation Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US11452726B2 (en) 2008-05-21 2022-09-27 Incyte Corporation Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US8420645B2 (en) 2008-05-21 2013-04-16 Incyte Corporation Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US10245265B2 (en) 2008-05-21 2019-04-02 Incyte Incorporation Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US8609687B2 (en) 2008-06-20 2013-12-17 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
US9434732B2 (en) 2008-06-20 2016-09-06 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
US8889673B2 (en) 2008-06-20 2014-11-18 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
CN102186852A (en) * 2008-08-12 2011-09-14 赛诺菲-安万特 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-ib]-pyridazine derivatives, preparation thereof, and therapeutic application thereof
US10590139B2 (en) 2008-09-22 2020-03-17 Array Biopharma Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US10011604B2 (en) 2008-09-22 2018-07-03 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
US9227975B2 (en) 2008-09-22 2016-01-05 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2B]pyridazine compounds
US9796723B2 (en) 2008-09-22 2017-10-24 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US9795611B2 (en) 2008-09-22 2017-10-24 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US9127013B2 (en) 2008-10-22 2015-09-08 Array Biopharma, Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
US8513263B2 (en) 2008-10-22 2013-08-20 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US11267818B2 (en) 2008-10-22 2022-03-08 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
US8865698B2 (en) 2008-10-22 2014-10-21 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
US9447104B2 (en) 2008-10-22 2016-09-20 Array Biopharma, Inc. Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
US10774085B2 (en) 2008-10-22 2020-09-15 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
US9676783B2 (en) 2008-10-22 2017-06-13 Array Biopharma, Inc. Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
US10005783B2 (en) 2008-10-22 2018-06-26 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
US10047097B2 (en) 2008-10-22 2018-08-14 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
EP2348860A4 (en) * 2008-10-31 2012-10-24 Genentech Inc Pyrazolopyrimidine jak inhibitor compounds and methods
EP2962566A1 (en) * 2008-10-31 2016-01-06 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
US8637526B2 (en) 2008-10-31 2014-01-28 Genentech, Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods
WO2010051549A1 (en) 2008-10-31 2010-05-06 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
EP2348860A1 (en) 2008-10-31 2011-08-03 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
JP2012507569A (en) * 2008-10-31 2012-03-29 ジェネンテック， インコーポレイテッド Pyrazolopyrimidine JAK inhibitor compounds and methods
US8846664B2 (en) 2008-11-12 2014-09-30 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
US8999998B2 (en) 2009-07-02 2015-04-07 Genentech, Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods
US8791123B2 (en) 2009-07-09 2014-07-29 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US10251889B2 (en) 2009-07-09 2019-04-09 Array BioPharm Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US9782415B2 (en) 2009-07-09 2017-10-10 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US9682979B2 (en) 2009-07-09 2017-06-20 Array Biopharma, Inc. Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors
US9796724B2 (en) 2009-07-09 2017-10-24 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US10758542B2 (en) 2009-07-09 2020-09-01 Array Biopharma Inc. Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors
WO2011013729A1 (en) 2009-07-30 2011-02-03 オンコセラピー・サイエンス株式会社 Fused imidazole derivative having ttk inhibitory action
WO2011015652A1 (en) 2009-08-07 2011-02-10 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
CN102548995B (en) * 2009-08-12 2015-01-28 诺华股份有限公司 Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
CN102548995A (en) * 2009-08-12 2012-07-04 诺瓦提斯公司 Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
US8410264B2 (en) 2009-08-20 2013-04-02 Novartis Ag Heterocyclic oxime compounds
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
CN102574853B (en) * 2009-08-20 2015-01-21 诺华股份有限公司 Heterocyclic oxime compounds
CN102574853A (en) * 2009-08-20 2012-07-11 诺瓦提斯公司 Heterocyclic oxime compounds
US8507676B2 (en) 2009-08-20 2013-08-13 Novartis Ag Heterocyclic oxime compounds
US8716282B2 (en) 2009-10-30 2014-05-06 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
US9221824B2 (en) 2010-02-03 2015-12-29 Incyte Holdings Corporation Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
US8487096B2 (en) 2010-02-03 2013-07-16 Incyte Corporation Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors
US9988387B2 (en) 2010-02-03 2018-06-05 Incyte Holdings Corporation Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
US10919901B2 (en) 2010-02-03 2021-02-16 Incyte Holdings Corporation Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
US10472367B2 (en) 2010-02-03 2019-11-12 Incyte Incorporation Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
RU2554353C2 (en) * 2010-02-17 2015-06-27 Ф. Хоффманн-Ля Рош Аг Piperidine derivatives
WO2011101304A3 (en) * 2010-02-17 2011-10-20 F. Hoffmann-La Roche Ag Piperidine derivatives
US8859543B2 (en) 2010-03-09 2014-10-14 Janssen Pharmaceutica Nv Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases
US9750744B2 (en) 2010-05-20 2017-09-05 Array Biopharma, Inc. Macrocyclic compounds as Trk kinase inhibitors
US10647730B2 (en) 2010-05-20 2020-05-12 Array Biopharma Inc. Macrocyclic compounds as TRK kinase inhibitors
US9840519B2 (en) 2010-05-20 2017-12-12 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
US9902741B2 (en) 2010-05-20 2018-02-27 Array Biopharma Inc. Macrocyclic compounds as TRK kinase inhibitors
US9493476B2 (en) 2010-05-20 2016-11-15 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
US9718822B2 (en) 2010-05-20 2017-08-01 Array Biopharma, Inc. Macrocyclic compounds as Trk kinase inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US8748435B2 (en) 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
WO2012156367A1 (en) 2011-05-17 2012-11-22 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
US9730929B2 (en) 2011-06-01 2017-08-15 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
WO2012163942A1 (en) 2011-06-01 2012-12-06 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
JP2014517053A (en) * 2011-06-22 2014-07-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Heterocyclylaminoimidazopyridazine
WO2012175591A1 (en) 2011-06-22 2012-12-27 Bayer Intellectual Property Gmbh Heterocyclyl aminoimidazopyridazines
US9284319B2 (en) 2011-06-22 2016-03-15 Bayer Intellectual Property Gmbh Heterocyclyl aminoimidazopyridazines
CN103764656A (en) * 2011-06-22 2014-04-30 拜耳知识产权有限责任公司 Heterocyclyl aminoimidazopyridazines
US10604523B2 (en) 2011-06-27 2020-03-31 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
US9102673B2 (en) 2011-07-12 2015-08-11 Merck Sharp & Dohme Corp. Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors
WO2013009582A1 (en) 2011-07-12 2013-01-17 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US10047093B2 (en) 2011-07-21 2018-08-14 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors
US10392392B2 (en) 2011-07-21 2019-08-27 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors
EP2734205A4 (en) * 2011-07-21 2014-12-10 Tolero Pharmaceuticals Inc Heterocyclic protein kinase inhibitors
EP2734205A1 (en) * 2011-07-21 2014-05-28 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
US10875864B2 (en) 2011-07-21 2020-12-29 Sumitomo Dainippon Pharma Oncology, Inc. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
WO2013034570A1 (en) 2011-09-06 2013-03-14 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
US9499547B2 (en) 2011-09-06 2016-11-22 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
WO2013041634A1 (en) 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
WO2013087581A1 (en) 2011-12-12 2013-06-20 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
US9643974B2 (en) 2011-12-12 2017-05-09 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
WO2013144189A1 (en) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
US9777004B2 (en) 2012-03-29 2017-10-03 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
WO2013149909A1 (en) 2012-04-04 2013-10-10 Bayer Pharma Aktiengesellschaft Amino-substituted imidazopyridazines
US9409889B2 (en) 2012-04-04 2016-08-09 Bayer Pharma Aktiengesellschaft Amino-substituted imidazopyridazines
US9181261B2 (en) 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9187489B2 (en) 2012-06-04 2015-11-17 Daiichi Sankyo Company, Limited Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
WO2013183578A1 (en) 2012-06-04 2013-12-12 第一三共株式会社 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR
US9751887B2 (en) 2012-06-04 2017-09-05 Daiichi Sankyo Company, Limited Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
US9669035B2 (en) 2012-06-26 2017-06-06 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
US9550784B2 (en) 2012-07-09 2017-01-24 Beerse Pharmaceutica NV Inhibitors of phosphodiesterase 10 enzyme
US9556169B2 (en) 2012-11-19 2017-01-31 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9783543B2 (en) 2012-11-19 2017-10-10 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines
US9926314B2 (en) 2012-11-19 2018-03-27 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US11384086B2 (en) 2012-12-12 2022-07-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
US11192896B2 (en) 2012-12-12 2021-12-07 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
US10662197B2 (en) 2012-12-12 2020-05-26 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b)pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
US9493470B2 (en) 2012-12-12 2016-11-15 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
US11192895B2 (en) 2012-12-12 2021-12-07 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
US11279705B2 (en) 2012-12-12 2022-03-22 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
US10125136B2 (en) 2012-12-12 2018-11-13 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
US11192897B2 (en) 2012-12-12 2021-12-07 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
WO2014118135A1 (en) 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as mknk-1 kinase inhibitors
US9745304B2 (en) 2013-01-30 2017-08-29 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as MKNK-1 kinase inhibitors
WO2014128093A1 (en) 2013-02-20 2014-08-28 Bayer Pharma Aktiengesellschaft Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors
US9370515B2 (en) 2013-03-07 2016-06-21 Califia Bio, Inc. Mixed lineage kinase inhibitors and method of treatments
US9896447B2 (en) 2013-09-22 2018-02-20 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9718782B2 (en) 2013-09-22 2017-08-01 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US10544149B2 (en) 2013-10-03 2020-01-28 Agency For Science, Technology And Research Bicyclic alkyne derivatives and uses thereof
CN105992768A (en) * 2013-12-10 2016-10-05 百时美施贵宝公司 Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
US10273237B2 (en) 2013-12-10 2019-04-30 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses
WO2015089143A1 (en) * 2013-12-10 2015-06-18 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
US10214545B2 (en) 2014-01-09 2019-02-26 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
WO2015104254A1 (en) 2014-01-09 2015-07-16 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
CN105899512A (en) * 2014-01-09 2016-08-24 拜耳医药股份公司 Amide group substituted imidazopyridazines useful in the treatment of hyperproliferative and/or angiogenic diseases
WO2015118434A1 (en) 2014-02-05 2015-08-13 Celon Pharma S.A. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS KINASE JAK-2 INHIBITORS
US9815846B2 (en) 2014-03-26 2017-11-14 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9914736B2 (en) 2014-03-26 2018-03-13 Merck Sharp & Dohme Corp. TrKA kinase inhibitors, compositions and methods thereof
US9862707B2 (en) 2014-03-26 2018-01-09 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
WO2015148354A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015148344A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Trka kinase inhibitors, compositions and methods thereof
WO2015148373A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US9862716B2 (en) 2014-03-26 2018-01-09 Merck Sharp & Dohme Corp. TRKA kinase inhibitors, compositions and methods thereof
US9604984B2 (en) 2014-05-23 2017-03-28 Genentech, Inc. 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof
US9346815B2 (en) 2014-05-23 2016-05-24 Genentech, Inc. 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof
JP7074903B2 (en) 2014-08-06 2022-05-24 ファイザー・インク Imidazopyridazine compound
JP2019163256A (en) * 2014-08-06 2019-09-26 ファイザー・インク Imidazopyridazine compounds
JP2021105002A (en) * 2014-08-06 2021-07-26 ファイザー・インク Imidazopyridazine compound
US9782414B2 (en) 2014-11-16 2017-10-10 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10172861B2 (en) 2014-11-16 2019-01-08 Array Biopharma Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10799505B2 (en) 2014-11-16 2020-10-13 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10813936B2 (en) 2014-11-16 2020-10-27 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10285993B2 (en) 2014-11-16 2019-05-14 Array Biopharma Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10556900B2 (en) 2015-04-08 2020-02-11 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US10370727B2 (en) 2015-10-26 2019-08-06 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10907215B2 (en) 2015-10-26 2021-02-02 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10655186B2 (en) 2015-10-26 2020-05-19 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10724102B2 (en) 2015-10-26 2020-07-28 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10378068B2 (en) 2015-10-26 2019-08-13 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10668072B2 (en) 2016-04-04 2020-06-02 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10137127B2 (en) 2016-04-04 2018-11-27 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10588908B2 (en) 2016-04-04 2020-03-17 Loxo Oncology, Inc. Methods of treating pediatric cancers
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
US11484535B2 (en) 2016-04-04 2022-11-01 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US11191766B2 (en) 2016-04-04 2021-12-07 Loxo Oncology, Inc. Methods of treating pediatric cancers
US11214571B2 (en) 2016-05-18 2022-01-04 Array Biopharma Inc. Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
US11091486B2 (en) 2016-10-26 2021-08-17 Array Biopharma, Inc Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
US10688100B2 (en) 2017-03-16 2020-06-23 Array Biopharma Inc. Macrocylic compounds as ROS1 kinase inhibitors
US10966985B2 (en) 2017-03-16 2021-04-06 Array Biopharma Inc. Macrocyclic compounds as ROS1 kinase inhibitors
US10307426B2 (en) 2017-05-22 2019-06-04 Genentech, Inc. Therapeutic compounds and compositions, and methods of use thereof
WO2019029629A1 (en) 2017-08-11 2019-02-14 Teligene Ltd Substituted pyrazolopyrimidines useful as kinases inhibitors
CN110734437A (en) * 2018-07-19 2020-01-31 金秋 Pyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof
CN110734437B (en) * 2018-07-19 2022-04-08 南京烁慧医药科技有限公司 Pyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof
US12060365B2 (en) 2018-12-06 2024-08-13 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
US11236106B2 (en) 2018-12-06 2022-02-01 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
WO2020116662A1 (en) 2018-12-06 2020-06-11 第一三共株式会社 Cycloalkane-1,3-diamine derivative
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN111718349B (en) * 2019-03-19 2021-11-02 华中师范大学 Fluorine-containing pyrazolopyrimidine compound, pharmaceutical composition and application thereof
CN111718351A (en) * 2019-03-19 2020-09-29 华中师范大学 Oxygen-containing substituted pyrazolopyrimidine compound, pharmaceutical composition and application thereof
CN111718349A (en) * 2019-03-19 2020-09-29 华中师范大学 Fluorine-containing pyrazolopyrimidine compound, pharmaceutical composition and application thereof
CN111718350A (en) * 2019-03-19 2020-09-29 华中师范大学 Pyrazole-substituted pyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof
WO2020187291A1 (en) * 2019-03-19 2020-09-24 华中师范大学 Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor
AU2020242735B2 (en) * 2019-03-19 2022-12-01 Central China Normal University Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor
CN111718351B (en) * 2019-03-19 2021-10-12 华中师范大学 Oxygen-containing substituted pyrazolopyrimidine compound, pharmaceutical composition and application thereof
CN111718350B (en) * 2019-03-19 2021-04-13 华中师范大学 Pyrazole-substituted pyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof
CN112010860A (en) * 2020-08-05 2020-12-01 南京纳丁菲医药科技有限公司 Benzyloxypyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof
CN112010860B (en) * 2020-08-05 2023-03-10 南京纳丁菲医药科技有限公司 Benzyloxypyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof
CN115536571A (en) * 2022-11-09 2022-12-30 上海裕兰生物科技有限公司 Preparation method of indole derivative
CN115536571B (en) * 2022-11-09 2024-03-29 上海裕兰生物科技有限公司 Preparation method of indole derivative

Also Published As

Publication number Publication date
EP1910369A1 (en) 2008-04-16
JP2009502734A (en) 2009-01-29
US20100216798A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
EP1910369A1 (en) Fused heterocycles as lck inhibitors
KR102429419B1 (en) Tyrosine amide derivatives as RHO-kinase inhibitors
JP6666263B2 (en) A novel inhibitor of glutaminase
EP3421464B1 (en) Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
US10022374B2 (en) Certain protein kinase inhibitors
AU2009257712B2 (en) Pyrrolo [2, 3-c] pyridine derivatives as p38 kinase inhibiting agents
IL313281A (en) Mta-cooperative prmt5 inhibitors
TW202122389A (en) Heterocyclic rip1 kinase inhibitors
TW201938158A (en) Amino acid compounds and methods of use
CA3082156C (en) Heterocyclic compound as a protein kinase inhibitor
CA2948587A1 (en) Pyrazolopyridines and pyrazolopyrimidines
CA2615291A1 (en) Heterocyclic janus kinase 3 inhibitors
JP2020525525A (en) RHO-related protein kinase inhibitor, pharmaceutical composition containing RHO-related protein kinase inhibitor, preparation method and use of the pharmaceutical composition
CN101578285A (en) Condensed pyridine compound
JP2017516855A (en) Certain protein kinase inhibitors
KR102111570B1 (en) Novel Imidazopyridazine Compounds and their Use
TW201429967A (en) Compounds and compositions for the treatment of parasitic diseases
CN102131809A (en) Tri-cyclic pyrazolopyridine kinase inhibitors
TW202344504A (en) Lpa receptor antagonists and uses thereof
CA3216163A1 (en) Carboxy-benzimidazole glp-1r modulating compounds
CN117083268B (en) Amino heteroaryl compounds and compositions
WO2015198046A1 (en) 1,3-substituted 2-aminoindole derivatives and analogues useful in the treatment or prevention of diabetes mellitus, obesity and inflammatory bowel disease
JP2021529819A (en) Tyrosine amide derivative as an RHO kinase inhibitor
CA3115472A1 (en) Compounds and compositions for treating conditions associated with apj receptor activity
CN111484479B (en) Azacyclic compounds, pharmaceutical compositions containing the same, and methods of making and using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006768412

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11993229

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008503311

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE